SEC Filing | Arbutus Biopharma Corporation

View:

Download DOC

Download PDF

Download XLS

Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934



Filed by the Registrant x
Filed by a Party other than the Registrant o
Check the appropriate box:
o	Preliminary Proxy Statement
o	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
ý	Definitive Proxy Statement
o	Definitive Additional Materials
o	Soliciting Material Pursuant to §240.14a-12

ARBUTUS BIOPHARMA CORPORATION

(Name of the Registrant as Specified in its Charter)

(Name of Person(s) Filling Proxy Statement, if other than the Registrant)



	Payment of Filing Fee (Check the appropriate box):
ý	No fee required.
	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
	1	Title of each class of securities to which transaction applies:
	2	Aggregate number of securities to which transaction applies:
	3	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
	4	Proposed estimated aggregate value of transaction:
	5	Total Fee Paid:
	Fee paid previously with preliminary materials.
	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
	1	Amount Previously Paid:
	2	Form, Schedule, or Registration Statement No.:
	3	Filing Party:
	4	Date Filed:

https://cdn.kscope.io/998d9cb06cdba04f4495d3f95ccadea6-arbutuslogojpeg.jpg

December 6, 2017

Dear Shareholder:

You are cordially invited to attend the Special Meeting of Shareholders (the “Meeting”) of Arbutus Biopharma Corporation (“Arbutus” or the “Company”) to be held on Thursday January 11, 2018. The Meeting will be held at Arbutus’ headquarters located at 100-8900 Glenlyon Parkway, Burnaby, British Columbia beginning at 2:00 pm (Pacific Time).

The purpose of the Meeting is for shareholders to consider an additional equity investment in the Company by Roivant Sciences Ltd. (“Roivant”) and certain related governance matters requiring amendments to the Company’s Articles of Incorporation.

As previously announced on October 16, 2017, Roivant completed the $50 million first tranche of its proposed $116.4 million strategic investment in the Company (the “Private Placement”) by acquiring 500,000 series A participating convertible preferred shares (the “Preferred Shares”) pursuant to a subscription agreement between the Company and Roivant dated October 2, 2017 (the “Subscription Agreement”).

Under the terms of the Subscription Agreement, Roivant agreed to subscribe for a second tranche of 664,000 Preferred Shares (the “Second Tranche”) from the Company. If the Second Tranche is completed, Roivant will hold a 49.9% equity interest in Arbutus after giving effect to the conversion of all of the 1,164,000 Preferred Shares to be acquired in the Private Placement (assuming no further dilution). Such conversion is mandatory four years after issuance of the Preferred Shares subject to limited circumstances that would permit earlier conversion at Roivant's option.

After careful consideration, the Arbutus Board has unanimously determined that the Private Placement is in the best interests of Arbutus and fair to the disinterested shareholders and recommends that Arbutus shareholders vote “FOR” the proposals set forth in the accompanying Notice and Management Proxy Circular and Proxy Statement for the Meeting.

The recommendation of the Board is based on various factors described more fully in the accompanying Notice and Management Proxy Circular and Proxy Statement for the Meeting, including the unanimous recommendation of the Special Committee of independent directors with respect to the Private Placement, which recommendation was made by the Special Committee after consultation with its financial and legal advisors. The enclosed Notice and Management Proxy Circular and Proxy Statement for the Meeting also describe the Private Placement and the matters to be presented at the Meeting for approval in further detail.

Whether or not you plan to attend the Meeting, please vote as soon as possible to ensure that your shares will be represented and voted at the Meeting. It is important to cast your vote due to voting rules that may prevent your bank or broker from voting your uninstructed shares on a discretionary basis for the proposals to be acted on at the Meeting.

We look forward to seeing you at the Meeting.

Sincerely,

/s/ Richard Henriques

Richard Henriques, Chair of the Special Committee

ARBUTUS BIOPHARMA CORPORATION

100-8900 Glenlyon Parkway

Burnaby, British Columbia V5J 5J8

NOTICE OF SPECIAL MEETING OF SHAREHOLDERS

TO BE HELD THURSDAY, JANUARY 11, 2018

Dear Shareholders of Arbutus Biopharma Corporation:

NOTICE IS HEREBY GIVEN that a Special Meeting (the “Meeting”) of the shareholders (“Shareholders”) of Arbutus Biopharma Corporation, a British Columbia corporation (“Arbutus” or the “Company”) will be held on Thursday, January 11, 2018 at 2:00 pm (Pacific Time) at Arbutus’ headquarters located at 100-8900 Glenlyon Parkway, Burnaby, British Columbia in Vancouver, British Columbia, for the following purposes:

PROPOSAL NO. 1 - APPROVAL OF THE SECOND TRANCHE OF THE PRIVATE PLACEMENT. To approve the issuance by the Company to Roivant Sciences Ltd. (“Roivant”) of a second tranche of 664,000 series A participating convertible preferred shares of the Company (the “Preferred Shares”) at a price of $100 per share for gross proceeds to the Company of $66.4 million (the “Second Tranche”), and common shares, no par value, issuable upon conversion of the Preferred Shares, pursuant to the Subscription Agreement between the Company and Roivant dated October 2, 2017 (the “Subscription Agreement”), as part of a larger subscription by Roivant under the Subscription Agreement for an aggregate of 1,164,000 Preferred Shares for gross proceeds to the Company of $116.4 million (the “Private Placement”).


2.	PROPOSAL NO. 2 - APPROVAL OF AN AMENDMENT TO PART 27 OF ARBUTUS’ ARTICLES. To approve an amendment to Part 27 of Arbutus’ Articles of Incorporation (“Articles”) to extend the period during which certain decisions of the Board of Directors of the Company (the "Board") require approval of at least 70% of the directors from March 4, 2018 to October 16, 2021.

PROPOSAL NO. 3 - APPROVAL OF AN AMENDMENT TO PART 28 OF ARBUTUS’ ARTICLES. To approve an amendment to Part 28 of Arbutus’ Articles pursuant to which: (i) Roivant would have the right until October 16, 2021, subject to certain conditions, to nominate up to three members of the Board (at least one of whom must be "independent" within the meaning of the Articles, if Roivant has three nominees), and (ii) for so long as Roivant has such nomination rights, the total number of directors of Arbutus would not, without the prior written consent of Roivant, be permitted to exceed seven directors, the majority of whom would be required to be "independent".


4.	PROPOSAL NO. 4 - ANY OTHER BUSINESS. To transact such other business as may properly come before the Meeting, or at any adjournments or postponements thereof.

After careful consideration, the Board has unanimously determined that the Private Placement is in the best interests of Arbutus and fair to the disinterested Shareholders and recommends that Shareholders vote “FOR” each of the proposals set forth above. The recommendation of the Board is based on various factors, including the unanimous recommendation of the Special Committee of independent directors with respect to the Private Placement and other foregoing proposals, which recommendation was made by the Special Committee after consultation with its financial and legal advisors.

Proposal No. 1 must be approved by the affirmative vote of at least a majority of the votes cast by Shareholders represented in person or by proxy at the Meeting other than those holders of common shares excluded pursuant to Section 8.1(2) of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions (“MI 61-101” or the “Canadian Related Party Rules”). Accordingly, in determining whether Shareholder approval for Proposal No. 1 has been obtained, the Company will exclude the votes cast by Roivant and its “related parties” and “joint actors” (as defined in MI 61-101). Proposal No. 2 must be approved by the affirmative vote of two thirds of the votes cast by Shareholders represented in person or by proxy at the Meeting. Proposal No. 3 must be approved by the affirmative vote of a majority of the votes cast by Shareholders represented in person or by proxy at the Meeting. The amendments to Part 27 and Part 28 of the Articles contemplated by Proposal No.’s 2 and 3, respectively, are collectively referred to as the “Governance Amendments”.

Under the terms of the Subscription Agreement, completion of the Second Tranche is conditional on the approval of Proposal No.’s 1, 2 and 3. However, if such proposals are not approved, then Arbutus and Roivant may, nonetheless, jointly elect to waive such condition and: (i) close the Second Tranche if Proposal No. 1 is approved, even if one or both of the Governance Amendments comprising Proposal No. 2 and Proposal No. 3 are not approved, or (ii) proceed with one or both of the Governance Amendments if such applicable proposal is approved, even if Proposal No. 1 is not approved. In addition, as permitted by the respective resolutions for each of the Governance Amendments, the Company may determine not to proceed with either or both of the Governance Amendments, even if the relevant resolutions are approved at the Meeting; however, the Company expects that any such determination will be made on or before the date of the Company’s next annual meeting of shareholders currently scheduled to be held in May 2018.

The foregoing matters are more fully described in the accompanying Management Proxy Circular and Proxy Statement.

The record date for the Meeting is November 24, 2017. Only Shareholders of record at the close of business on November 24, 2017 will be entitled to notice of and to vote at the Meeting in person or by proxy or any adjournments or postponements thereof.

Even if you plan to attend the Meeting in person, Arbutus requests that you complete, sign and return the enclosed proxy or otherwise provide your proxy and thus ensure that your shares will be represented at the Meeting if you are unable to attend. If you sign, date and mail your proxy or otherwise provide your proxy without indicating how you wish to vote, your proxy will be counted as a vote in favor of the above proposals.

BY ORDER OF THE BOARD OF DIRECTORS

/s/ Richard Henriques

Richard Henriques, Chair of the Special Committee

Vancouver, British Columbia

December 6, 2017

YOUR VOTE IS VERY IMPORTANT

IN ORDER TO ASSURE YOUR REPRESENTATION AT THE MEETING, PLEASE REVIEW THE PROXY MATERIALS CAREFULLY AND VOTE AS PROMPTLY AS POSSIBLE. PLEASE REFER TO THE SECTION ENTITLED “QUESTIONS ABOUT VOTING” ON PAGE 1 OF THE MANAGEMENT PROXY CIRCULAR AND PROXY STATEMENT FOR A DESCRIPTION OF HOW TO VOTE YOUR SHARES.

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON THURSDAY, JANUARY 11, 2018

This Notice of the Special Meeting of Shareholders and the Management Proxy Circular and Proxy Statement are available at http://investor.arbutusbio.com/financials.cfm

ARBUTUS BIOPHARMA CORPORATION

100-8900 Glenlyon Parkway

Burnaby, British Columbia V5J 5J8

_______________________________

MANAGEMENT PROXY CIRCULAR AND PROXY STATEMENT

_______________________________

SPECIAL MEETING OF SHAREHOLDERS

TO BE HELD ON THURSDAY, JANUARY 11, 2018

This Management Proxy Circular and Proxy Statement (“Proxy Statement/Circular”) is furnished in connection with the solicitation of proxies by the management of Arbutus Biopharma Corporation, a British Columbia corporation, for use at the Special Meeting, or at any adjournments or postponements thereof (the “Meeting”), of its shareholders (“Shareholders”) to be held on Thursday, January 11, 2018 at the time and place and for the purposes set forth in the accompanying Notice of the Meeting.

In this Proxy Statement/Circular, references to “the Company,” “Arbutus,” “we,” “us,” and “our” refer to Arbutus Biopharma Corporation. “Common Shares” means common shares without par value in the capital of the Company. Unless otherwise indicated, the statistical and financial data contained in this Proxy Statement/Circular are as of November 24, 2017.

Effective January 1, 2016, Arbutus’ functional currency is the United States dollar. The information provided in this Proxy Statement/Circular is provided in United States dollars unless otherwise stated.

Whether or not you plan to attend the Meeting, please promptly provide your voting instructions. Your promptness in voting will assist in the expeditious and orderly processing of the proxies and in ensuring that a quorum is present. If you vote your proxy, you may nevertheless attend the Meeting and vote your Common Shares in person if you wish. Please note, however, that if your Common Shares are held of record by an Intermediary or other nominee and you wish to vote in person at the Meeting, you must follow the instructions provided to you by your Intermediary or such other nominee. If you want to revoke your instructions at a later time prior to the vote for any reason, you may do so in the manner described in this Proxy Statement/Circular.

TABLE OF CONTENTS



	Page
QUESTIONS ABOUT VOTING	1

CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS	7

DELIVERY OF PROXY MATERIALS TO HOUSEHOLDS	7

NOTICE TO SHAREHOLDERS IN THE UNITED STATES	8

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT	8

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS	9

THE PRIVATE PLACEMENT	10

RISK FACTORS	17

PROPOSAL NO. 1 - APPROVAL OF THE SECOND TRANCHE OF THE PRIVATE PLACEMENT	19

PROPOSAL NO. 2 - APPROVAL OF AN AMENDMENT TO PART 27 OF ARBUTUS’ ARTICLES	20

PROPOSAL NO. 3 - APPROVAL OF AN AMENDMENT TO PART 28 OF ARBUTUS’ ARTICLES	21

OTHER BUSINESS	23

RELATED PARTY TRANSACTION MATTERS	24

INTEREST OF CERTAIN PERSONS OR COMPANIES IN MATTERS TO BE ACTED UPON	26

INTERESTS OF INFORMED PERSONS IN MATERIAL TRANSACTIONS	27

MANAGEMENT CONTRACTS	27

ADDITIONAL INFORMATION	27

SOLICITATION OF PROXIES	27

AUDITOR OF THE COMPANY AND THEIR ATTENDANCE AT THE MEETING	27

INCORPORATION BY REFERENCE	28

APPROVAL OF MANAGEMENT PROXY CIRCULAR AND PROXY STATEMENT	29

EXHIBIT A - SUBSCRIPTION AGREEMENT AND RELATED DOCUMENTS	A-1



EXHIBIT B - GOVERNANCE AMENDMENTS	B-1

EXHIBIT C - AMENDED AND RESTATED GOVERNANCE AGREEMENT	C-1

EXHIBIT D - AMENDED AND RESTATED LOCKUP AGREEMENT	D-1

EXHIBIT E - AMENDMENT TO REGISTRATION RIGHTS AGREEMENT	E-1

EXHIBIT F - AMENDED AND RESTATED STANDSTILL AGREEMENT	F-1

EXHIBIT G - PREFERRED SHARE ARTICLE AMENDMENT	G-1

QUESTIONS ABOUT VOTING

Why did I receive this Proxy Statement/Circular?

Our management is soliciting your proxy to vote at the Meeting. This Proxy Statement/Circular contains important information about the matters to be voted on at the Meeting and about Arbutus. As many of our Shareholders may be unable to attend the Meeting in person, proxies are solicited to give each Shareholder an opportunity to vote on all matters that will properly come before the Meeting. References in this Proxy Statement/Circular to the Meeting include any adjournments or postponements of the Meeting.

What are the date, time and place of the Meeting?

The Meeting will be held at Arbutus’ headquarters located at 100-8900 Glenlyon Parkway, Burnaby, British Columbia, on Thursday, January 11, 2018, at 2:00 pm (Pacific Time).

Who can vote at the Meeting?

Only Shareholders as of the close of business on the record date Friday, November 24, 2017 are entitled to receive notice of and vote on matters to be presented at the Meeting, or any adjournment or postponement thereof, in the manner and subject to the procedures described in this Proxy Statement/Circular and the accompanying proxy card.

At the close of business on the record date, 55,051,995 Common Shares of Arbutus were issued and outstanding.

Each Shareholder is entitled to one vote per Common Share held on all matters to come before the Meeting. Common Shares of Arbutus are the only securities of Arbutus which will have voting rights at the Meeting.

What is the quorum for the Meeting?

To transact business at the Meeting, a quorum of Shareholders must be present at the commencement of the Meeting, either in person or by proxy. Under Arbutus’ Articles (as defined below), a quorum for the transaction of business at the Meeting is the presence, in person or by proxy, of 33 1/3% of the Common Shares outstanding.

How do I vote?

The voting process is different depending on whether you are a Registered or Beneficial Shareholder:


•	You are a Registered Shareholder if your Common Shares are registered in your name;


•	You are a Beneficial Shareholder if your shares are held on your behalf by an Intermediary. This means the shares are registered in your Intermediary’s name, and you are the beneficial owner. “Intermediaries” refers to brokers, investment firms, clearing houses and similar entities that own securities on behalf of Beneficial Shareholders.

Registered Shareholder: Common Shares Registered in Your Name

If you are a Registered Shareholder, you may vote in person at the Meeting or by proxy whether or not you attend the Meeting in person.


•	To vote over the Internet, go to www.astvotemyproxy.com and follow the online voting instructions and refer to your holder account number and proxy access number provided on the enclosed proxy card. To vote via the Internet, you will need to use the control number appearing on your proxy card. Internet voting is available 24 hours a day.


•	To vote in person at the Meeting, please come to the Meeting with personal identification and proof of ownership and we will give you an attendance card when you arrive.


•	To vote by mail, please promptly complete, sign and return your enclosed proxy card to our transfer agent to ensure that it is received prior to the closing of the polls at the Meeting: AST Trust Company (Canada): PO Box 721, Agincourt, ON M1S 0A1 (mail) or 1600-1066 West Hastings St., Vancouver, BC V6E 3X1.


•	To vote by telephone, call 1-888-489-5760 (toll free in North America) and follow the instructions and refer to your holder account number and proxy access number provided on the enclosed proxy card.


•	To vote by facsimile, fax your completed and signed proxy card to 1-866-781-3111 (toll free in North America) or 1-416-368-2502.


•	To vote by email, send your completed and signed proxy card to proxy@canstockta.com.

In each case, other than voting in person at the Meeting, the vote must be submitted no later than 48 hours (excluding Saturdays, Sundays and holidays) prior to the time of the Meeting, or adjournment thereof. The Chair of the Meeting may waive the proxy cut-off without notice. If the proxy is not dated, it will be deemed to be submitted seven calendar days after the date on which it was mailed to you.

Beneficial Shareholder: Common Shares Registered in the Name of an Intermediary such as a Brokerage Firm, Bank, Dealer or other Similar Organization

The following information is of significant importance to Shareholders who do not hold Common Shares in their own name. Beneficial Shareholders should note that in order to vote in person at the Meeting, you must request in writing that your Intermediary send you a legal proxy which would enable you to attend the Meeting and vote your Common Shares.

If your Common Shares are listed in an account statement provided to you by a broker, then in almost all cases your Common Shares will not be registered in your name on the records of Arbutus. In such circumstances your Common Shares will more likely be registered under the names of your broker or an agent of that broker. In the United States, the vast majority of such Common Shares are registered under the name of Cede & Co., as nominee for The Depository Trust Company (which acts as depositary for many U.S. brokerage firms and custodian banks), and in Canada, under the name of CDS & Co. (the registration name for CDS Clearing and Depository Services Inc., which acts as nominee for many Canadian brokerage firms).

Intermediaries are required to seek voting instructions from Beneficial Shareholders in advance of shareholders’ meetings. Every Intermediary has its own mailing procedures and provides its own return instructions to clients.

The Proxy Statement/Circular is being sent to both Registered Shareholders and Beneficial Shareholders. There are two kinds of Beneficial Shareholders - those who object to their names being made known to the issuers of securities which they own (called OBOs for Objecting Beneficial Owners), and those who do not object (called NOBOs for Non-Objecting Beneficial Owners).

Arbutus is taking advantage of National Instrument 54-101 - Communications with Beneficial Owners of Securities of a Reporting Issuer, which permits it to deliver proxy-related materials indirectly to its NOBOs and OBOs. As a result, if you are a NOBO or OBO you can expect to receive Meeting materials from your Intermediary via Broadridge Financial Solutions Inc. (“Broadridge”), including a voting information form (“VIF”). If you receive a VIF, you should follow the instructions in the VIF to ensure that your Common Shares are voted at the Meeting. The VIF or form of proxy will name the same individuals as Arbutus’ proxy to represent you at the Meeting. You have the right to appoint a person (who need not be a Shareholder) other than the individuals designated in the VIF, to represent you at the Meeting. To exercise this right, you should insert the name of your desired representative in the blank space provided in the VIF. The completed VIF must then be returned in accordance with the instructions in the VIF. Broadridge then tabulates the results of all instructions received and completed in accordance with the instructions provided in the VIF and provides appropriate instructions respecting the voting of Common Shares to be represented at the Meeting. If you receive a VIF from Broadridge, you cannot use it to vote Common Shares directly at the Meeting - the VIF must be completed and returned in accordance with its instructions, and by the deadline prescribed in the instructions, in order to have your Common Shares voted.

Although as a Beneficial Shareholder you may not be recognized directly at the Meeting for the purposes of voting Common Shares registered in the name of your Intermediary, you, or a person designated by you, may attend at the Meeting as proxyholder for your Intermediary and vote your Common Shares in that capacity. If you wish to attend the Meeting and indirectly vote your Common Shares as proxyholder for your Intermediary, or to have a person designated by you do so, you should enter your own name, or the name of the person you wish to designate, in the blank space on the VIF provided to you and return the same in accordance with the deadlines and instructions provided in the VIF, well in advance of the Meeting.

If you are a Beneficial Shareholder, and Arbutus or its agent has sent these materials to you, your name and address and information about your holdings of Common Shares have been obtained in accordance with applicable securities regulatory requirements from the Intermediary holding on your behalf.

Corporate Shareholders

In order to be entitled to vote or to have its Common Shares voted at the Meeting, a Shareholder which is a corporation (a “Corporate Shareholder”) must either (a) attach a certified copy of the directors’ resolution authorizing a representative to attend the Meeting on the Corporate Shareholder’s behalf, or (b) attach a certified copy of the directors’ resolution authorizing the completion and delivery of the proxy.

What am I voting on at the Meeting?

At the Meeting, you will be asked to vote on the following proposals:

Proposal No. 1: To approve the issuance by the Company to Roivant Sciences Ltd. (“Roivant”) of a second tranche of 664,000 series A participating convertible preferred shares of the Company (the “Preferred Shares”) at a price of $100 per share for gross proceeds to the Company of $66.4 million (the “Second Tranche”), and Common Shares issuable upon conversion of the Preferred Shares, pursuant to the Subscription Agreement between the Company and Roivant dated October 2, 2017 (the “Subscription Agreement”), as part of a larger subscription by Roivant under the Subscription Agreement for an aggregate of 1,164,000 Preferred Shares for gross proceeds to the Company of $116.4 million (the “Private Placement”). See “Proposal No. 1 - Approval of the Second Tranche of the Private Placement” below.

Proposal No. 2: To approve an amendment to Part 27 of Arbutus’ Articles of Incorporation ("Articles") to extend the period during which certain decisions of the board of directors of the Company (the “Board of Directors” or the “Board”) require approval of at least 70% of the directors from March 4, 2018 to October 16, 2021. See “Proposal No. 2 - Approval an Amendment to Part 27 of Arbutus’ Articles” below.

Proposal No. 3: To approve an amendment to Part 28 of Arbutus’ Articles pursuant to which: (i) Roivant would have the right until October 16, 2021, subject to certain conditions, to nominate up to three members of the Board (at least one of whom must be "independent" within the meaning of the Articles, if Roivant has three nominees), and (ii) for so long as Roivant has such nomination rights, the total number of directors of Arbutus would not, without the prior written consent of Roivant, be permitted to exceed seven directors, the majority of whom would be required to be "independent". See “Proposal No. 3 - Approval of an Amendment to Part 28 of Arbutus’ Articles” below.


4.	Proposal No. 4: To transact such other business as may properly come before the Meeting, or at any adjournments or postponements thereof. As of the date of this Proxy Statement/Circular, the Board is not aware of any such other matters.

Proposal No.’s 1, 2, and 3 are collectively referred to herein as the “Proposals”. The amendments to the Articles contemplated by Proposal No. 2 and Proposal No. 3 constitute the Governance Amendments (as defined below).

How does the Board recommend that I vote?

Our Board recommends that each Shareholder vote “FOR” each of the Proposals.

What vote is required in order to approve the Proposals?

Proposal No. 2 must be approved by the affirmative vote of two thirds of the votes cast by Shareholders represented in person or by proxy at the Meeting.

Proposal No. 3 must be approved by the affirmative vote of a majority of the votes cast by Shareholders represented in person or by proxy at the Meeting.

Proxies returned by Intermediaries as “broker non-votes” because the Intermediary has not received instructions from the Beneficial Shareholder with respect to the voting of certain of the Common Shares and under applicable stock exchange or other rules, will be treated as not entitled to vote on the Proposals and will not be counted as a vote cast for purposes of such Proposals. Common Shares represented by such broker “non-votes” will, however, be counted in determining whether there is a quorum for the Meeting.

What impact does an “Abstain” vote have?

When a proxy is properly executed and returned, the Common Shares it represents will be voted at the Meeting as directed. With respect to each of the Proposals, you may either vote “For” such Proposal, “Against” such Proposal, or “Abstain”. If you vote “For” or “Against” a Proposal, your Common Shares will be voted accordingly. If you select “Abstain” with respect to a Proposal, your vote will not be counted as a vote cast for the purposes of such Proposal.

What is the effect if I do not cast my vote?

If a Registered Shareholder does not cast its vote by proxy or in any other permitted fashion, no votes will be cast on its behalf on any of the items of business at the Meeting. If a Beneficial Shareholder does not instruct its Intermediary on how to vote on a Proposal or any unusual item, the Intermediary does not have discretionary authority to vote the Beneficial Shareholder’s Common Shares on such Proposal or any unusual item, so no votes will be cast on behalf of such Beneficial Shareholder with respect to such item. If you have further questions on this issue, please contact your Intermediary or Arbutus (as provided below).

What happens if Proposal No. 1, Proposal No. 2 or Proposal No. 3 is not approved?

If Proposal No. 1 is not approved, the Second Tranche will not be completed. If the Second Tranche is not completed, the market price of the Common Shares may be impacted to the extent that the market price reflects a market assumption that the Second Tranche will be completed. Moreover, if the Subscription Agreement is terminated, there is no assurance that the Company will be able to find an alternative financing transaction. Certain costs relating to the Second Tranche, such as legal, accounting and certain financial advisor fees must be paid by the Company even if the Second Tranche is not completed. This may have a material adverse effect upon the business, financial condition and results of operations of the Company and may cause the value of the Common Shares to decline. See “Risk Factors” below. Notwithstanding the failure of Proposal No.’s 1, 2

or 3, Roivant will have contractual board nomination rights under the terms of the Amended and Restated Governance Agreement (as defined below). See “The Private Placement - Amended and Restated Governance Agreement” below.

How will proxies be exercised?

The Common Shares represented by proxy will be voted or withheld from voting in accordance with your instructions. With respect to any amendments or variations in the Proposals, or any other matters which may properly come before the Meeting, the Common Shares will be voted by a proxyholder in their sole discretion.

Where you submit a proxy card but do not specify a vote on the Proposals shown in the Proxy Statement/Circular, a nominee of management acting as proxyholder will vote the Common Shares as if you had specified a vote “For” the Proposals.

What does it mean if I receive more than one set of proxy materials?

This means that you own Common Shares that are registered under different accounts. For example, you may own some Common Shares directly as a Registered Shareholder and other Common Shares as a Beneficial Shareholder through an Intermediary, or you may own Common Shares through more than one such organization. In these situations, you will receive multiple sets of proxy materials. It is necessary for you to complete and return all proxy cards and VIFs in order to vote all of the Common Shares you own. Please make sure you return each proxy card or VIF in the accompanying return envelope. You may also vote by Internet, telephone, facsimile or email by following the instructions on your proxy materials.

How do I appoint a proxyholder?

The individuals named in the proxy card are directors or officers of Arbutus. If you are a Shareholder entitled to vote at the Meeting, you have the right to appoint a person or company other than the designees of management named in the proxy card, who need not be a Shareholder of the Company, to vote according to your instructions. To appoint someone other than the designees of management named, please insert your appointed proxyholder’s name in the space provided in the proxy card, sign and date and return the proxy card in accordance with the instructions set out in the proxy card.

The only methods by which you may appoint a person as proxyholder are by submitting a proxy card by mail, hand delivery or fax.

Can I revoke my proxy?

In addition to revocation in any other manner permitted by law, if you are a Registered Shareholder and you wish to revoke your proxy, you may do so by depositing a written instrument to that effect and delivering it to AST Trust Company (Canada) PO Box 721, Agincourt, ON M1S 0A1, or by hand to 1600-1066 West Hastings St., Vancouver, BC V6E 3X1 (hand delivery) or to the address of the registered office of Arbutus at Farris, Vaughan, Wills & Murphy LLP, 25th Floor, 700 West Georgia Street, Vancouver, British Columbia, V7Y 1B3, attention R. Hector MacKay-Dunn, Q.C., at any time up to and including the last business day preceding the day of the Meeting, or any adjournment thereof, or to the Chairman of the Meeting on the day of the Meeting before any vote in respect of which the proxy has been given has been taken.

If you are a Registered Shareholder and you wish to revoke your proxy by providing a written instrument to such effect, such written instrument must be executed in writing by you or your legal personal representative or trustee in bankruptcy, or, if you are a corporation that is a Registered Shareholder, by the corporation or a representative of the corporation appointed in accordance with Arbutus’ Articles.

Beneficial Shareholders who wish to change their vote must, in sufficient time in advance of the Meeting, arrange for their Intermediaries to change the vote and, if necessary, revoke their proxy.

How will proxies be solicited and who will pay the cost of the proxy solicitation?

The solicitation of proxies will be primarily by mail, but Arbutus’ directors, officers and regular employees may also solicit proxies personally or by telephone. Arbutus will bear all costs of the solicitation, including the printing, handling and mailing of the Meeting materials. Arbutus has arranged for Intermediaries to forward the Meeting materials to Beneficial Shareholders of Arbutus held of record by those Intermediaries and Arbutus may reimburse the Intermediaries for their reasonable fees and disbursements in that regard.

Are Meeting materials being provided by way of notice-and-access?

Arbutus is not sending meeting materials for the Meeting to Shareholders using the “notice and access” provisions of National Instrument 54-101 - Communication with Beneficial Owners of Securities of a Reporting Issuer. However, the meeting materials for the Meeting are available at http://investor.arbutusbio.com/financials.cfm.

What if amendments are made to the Proposals or if other matters are brought before the Meeting?

With respect to any amendments or variations in the Proposals shown in the Proxy Statement/Circular, or any other matters which may properly come before the Meeting, the Common Shares will be voted by the appointed proxyholder as he or she in their sole discretion sees fit.

As of the date of this Proxy Statement/Circular, the Board is not aware of any such amendments, variations or other matters to come before the Meeting. However, if any such changes that are not currently known to the Board should properly come before the Meeting, the Common Shares represented by your proxyholders will be voted in accordance with the best judgment of the proxyholders.

How can I find out the results of the voting at the Meeting?

Preliminary voting results will be announced at the Meeting. Final voting results will be filed with the Canadian provincial securities regulatory authorities on SEDAR at www.sedar.com, and will also be published in a Current Report on Form 8-K filed with the United States Securities and Exchange Commission (“SEC”) on EDGAR at https://www.sec.gov/edgar/searchedgar/legacy/companysearch.html within four business days of the Meeting.

Whom should I contact if I have questions concerning the Proxy Statement/Circular or voting?

If you have questions concerning the information contained in this Proxy Statement/Circular or require assistance in voting, you may contact Arbutus by letter, phone, fax or through our website as follows:

Arbutus Biopharma Corporation

Attn: Bruce Cousins

Executive Vice President and Chief Financial Officer

100-9800 Glenlyon Parkway

Burnaby, British Columbia, Canada

V5J 5J8

Phone: 604-419-3200

Fax: 604-419-3201

Website: http://www.arbutusbio.com/

CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS

This Proxy Statement/Circular contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and forward looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”).

Forward-looking statements in this Proxy Statement/Circular include statements about Arbutus’ strategy, future operations, prospects and the plans; the date, time and other details of the Meeting; the expected timing of the closing of the Second Tranche; the Company’s intended use of proceeds of the Private Placement, including the ability to further develop the Company’s HBV Pipeline (as defined below); the potential impact on the Company if the Second Tranche or the Governance Amendments are not approved at the Meeting; the possibility that the Company and Roivant may jointly elect to waive the condition under the Subscription Agreement that each of Proposal No’s. 1, 2 and 3 be approved at the Meeting, and: (i) close the Second Tranche if Proposal No. 1 is approved, even if one or both of the Governance Amendments comprising Proposal No. 2 and Proposal No. 3 are not approved, or (ii) proceed with one or both of the Governance Amendments if such applicable proposal is approved, even if Proposal No. 1 is not approved; the expectation that the Company will make a determination of whether or not to proceed with the Governance Amendments (if approved at the Meeting) on or before the date of the Company’s next annual meeting of shareholders currently scheduled to be held in May 2018; the expected equity ownership that Roivant will have in the Company following closing of the Second Tranche and following conversion of the Preferred Shares into Common Shares; the belief of the Special Committee (as defined below) that the Second Tranche should lead to an even stronger commitment from Roivant to the long-term success of the Company; and future potential strategic opportunities that the Company may explore with Roivant and the possibility that MTS Securities, LLC may be appointed to assist the Company or a special committee with respect thereto.

With respect to the forward-looking statements contained in this Proxy Statement/Circular, Arbutus has made numerous assumptions, including without limitation, that each of the Proposals will be approved at the Meeting and that the Second Tranche will be completed in accordance with the terms of the Subscription Agreement. While Arbutus considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive and market uncertainties and contingencies.

Our actual results could differ materially from those discussed in the forward-looking statements as a result of a number of important factors, including the factors discussed in this Proxy Statement/Circular, including those discussed below under the heading “Risk Factors”, and the risks discussed in our other filings with the SEC and Canadian securities regulators. Specific risk factors include, without limitation, that the Subscription Agreement may, in accordance with its terms or with the mutual consent of the Company and Roivant, be terminated prior to the closing of the Second Tranche; that Shareholders may not approve the Second Tranche or the Governance Amendments; the expected additional dilution that will be realized by Shareholders as a result of the Second Tranche; the uncertainty as to the expected impact on the market price for the Common Shares should the Second Tranche not be approved or completed; Roivant’s increased influence over the Board if the Second Tranche and/or Governance Amendments are approved; that the Company may not pursue any additional strategic opportunities with Roivant; and that each such opportunity may be subject to review and approval under one or more of the Canadian Related Party Rules, the Company’s Related Persons Transaction Policy, and the “supermajority” approval provisions of the Articles. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis, judgment, belief or expectation only as of the date hereof. We explicitly disclaim any obligation to update these forward-looking statements to reflect events or circumstances that arise after the date hereof, except as required by law.

DELIVERY OF PROXY MATERIALS TO HOUSEHOLDS

SEC rules allow us to deliver a single copy of proxy materials to any household at which two or more Shareholders reside. We believe this rule benefits everyone. It eliminates duplicate mailings that Shareholders living at the same address receive, and it reduces our printing and mailing costs. This rule applies to any annual reports, proxy statement/circulars, proxy statements combined with a prospectus and information statements.

If your household would like to receive single rather than duplicate mailings in the future, and you are a Registered Shareholder, please write to AST Trust Company (Canada), PO Box 700, Station B, Montreal, PQ, H3B 3K3, call 800-387-0825 (in North America); 416-682-3860 (outside of North America), or email inquiries@astfinancial.com. Each Shareholder will continue to receive a separate proxy card. If a broker or other nominee holds your shares, you may continue to

receive some duplicate mailings. Certain brokers will eliminate duplicate account mailings by allowing Shareholders to consent to such elimination, or through implied consent if a Shareholder does not request continuation of duplicate mailings. Since not all brokers and nominees offer Shareholders the opportunity to eliminate duplicate mailings, you may need to contact your broker or nominee directly to discontinue duplicate mailings from your broker to your household.

Your household may have received a single set of proxy materials for the Meeting. If you would like to receive another copy of the proxy materials for the Meeting, please contact AST Trust Company (Canada) as specified above.

NOTICE TO SHAREHOLDERS IN THE UNITED STATES

The solicitation of proxies involve securities of an issuer located in Canada and are being effected in accordance with the corporate laws of the Province of British Columbia, Canada and securities laws of the provinces of Canada.

The enforcement by Shareholders of civil liabilities under United States federal securities laws may be affected adversely by the fact that Arbutus is incorporated under the Business Corporations Act (British Columbia), as amended, certain of its executive officers are residents of Canada and a substantial portion of its assets and the assets of such persons are located outside the United States. Shareholders may not be able to sue a foreign company or its officers in a foreign court for violations of United States federal securities laws. It may be difficult to compel a foreign company and its officers to subject themselves to a judgment by a United States court.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table shows information regarding the beneficial ownership of our Common Shares as of November 24, 2017 by (a) each Shareholder, or group of affiliated Shareholders, that we know owns more than 5% of our outstanding Common Shares; (b) each of our “Named Executive Officers,” as that term is defined in Item 402 of Regulation S-K of the Exchange Act; (c) each of our current directors; and (d) all of our current directors and executive officers as a group. The table is based upon information supplied by directors, executive officers and principal Shareholders, and Schedules 13D and 13G filed with the SEC.

Percentage ownership in the table below is based on 55,051,995 Common Shares outstanding as of November 24, 2017. Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission, and generally includes voting power and/or investment power with respect to the securities held. Any securities not outstanding but which are subject to options exercisable within 60 days of November 24, 2017 are deemed outstanding and beneficially owned for the purpose of computing the percentage of outstanding Common Shares beneficially owned by the Shareholder holding such options, but are not deemed outstanding for the purpose of computing the percentage of Common Shares beneficially owned by any other Shareholder.

Unless otherwise indicated, each of the Shareholders listed below has sole voting and investment power with respect to the Common Shares beneficially owned.



Name of Beneficial Owner	Amount and Nature of Beneficial Ownership (1)	Percent of Class
Officers and Directors
Mark Murray	872,729	1.6	%
Bruce Cousins	301,667	*
Elizabeth Howard	81,667	*
Michael Sofia	1,758,148	3.2	%
Peter Lutwyche	143,785	*
William Symonds	264,660	*
Vivek Ramaswamy (2)	91,915	*
Frank Karbe	79,500	*
Herbert Conrad	52,000	*
Richard Henriques	53,000	*
Keith Manchester	91,915	*
Daniel Burgess	22,000	*
All current directors and executive officers as a group (12 persons)	3,812,986	6.9	%
5% Shareholders Not Listed Above
Roivant Sciences Ltd. (3)	16,013,540	29.1	%
PRIMECAP Management Company (4)	3,935,000	7.2	%
RTW Investments, LP (5)	2,770,284	5.0	%

_________________

* Less than 1.0%.

Notes:

(1) Includes outstanding Common Shares and options exercisable within 60 days of November 24, 2017.

(2) Does not include 16,013,540 Common Shares held by Roivant over which the Roivant board of directors, including Mr. Ramaswamy, hold voting and investment power. Amount also does not include the Underlying Common Shares (as defined below) issuable upon conversion of the 500,000 Preferred Shares issued to Roivant upon closing of the First Tranche (as defined below) on October 16, 2017.

(3) Based on information contained in Schedule 13D/A filed by Roivant on October 17, 2017. The filing indicated that as of October 16, 2017, Roivant had sole investment and voting power over all of these Common Shares. Voting and investment decisions of Roivant are made collectively by Roivant’s board of directors, which consists of Vivek Ramaswamy, Ilan Oren, Keith Manchester, M.D., Andrew Lo and Patrick Machado. Roivant’s address is: 20-22 Bedford Row, London, United Kingdom, WC1R 4JS. Amount does not include the Underlying Common Shares issuable upon conversion of the 500,000 Preferred Shares issued to Roivant upon closing of the First Tranche on October 16, 2017.

(4) Based on information contained in Schedule 13G/A filed by PRIMECAP Management Company ("PRIMECAP") on February 9, 2017. The filing indicated that as of December 31, 2016, PRIMECAP had sole investment and voting power over all of these Common Shares. PRIMECAP’s address is: 225 South Lake Ave., #400, Pasadena, CA 91101.

(5) Based on information contained in Schedule 13G filed by RTW Investment, LP ("RTW") on May 10, 2017. The filing indicated that as of May 10, 2017, RTW had shared dispositive and voting power over all of these Common Shares. RTW's address is 250 West 55th Street, 16th Floor Suite A, New York, New York 10019

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS

Except as disclosed below, to the knowledge of the directors and executive officers of the Company, no person or corporation owned, directly or indirectly, or exercised control or direction over, Common Shares carrying more than 10% of the voting rights attached to all outstanding Common Shares as at November 24, 2017.



Name	Number of Common Shares Beneficially Owned	Percentage of Outstanding Common Shares
Roivant Sciences Ltd.	16,013,540	29.1% (1)

Note:

(1) See Form 13D/A filed on October 17, 2017 for further details on the ownership of these Common Shares. Amount does not include the Underlying Common Shares issuable upon conversion of the 500,000 Preferred Shares issued to Roivant upon closing of the First Tranche on October 16, 2017.

THE PRIVATE PLACEMENT

Overview

On October 2, 2017, Arbutus entered into the Subscription Agreement with Roivant for the Private Placement, pursuant to which Roivant agreed to purchase from Arbutus an aggregate of 1,164,000 Preferred Shares, for an aggregate purchase price of $116.4 million representing a price per Preferred Share of $100.00 (the “Purchase Price”). The Preferred Shares plus an amount equal to 8.75% of the Purchase Price per annum, compounded annually, will initially be convertible into 22,833,922 underlying Common Shares of Arbutus, no par value, at a conversion price of $7.13 (a 15% premium to the closing price of the Common Shares on September 29, 2017), which conversion will occur mandatorily on October 16, 2021 (subject to limited exceptions in the event of certain fundamental corporate transactions relating to Arbutus’ capital structure or assets, as described below under the heading “The Private Placement - Preferred Share Rights and Restrictions - Optional Conversion” which would permit earlier conversion at Roivant’s option). The 22,833,922 Common Shares are referred to collectively as the “Underlying Common Shares.”

Pursuant to the Subscription Agreement, the Preferred Shares to be issued in the Private Placement are to be issued in two tranches: (i) 500,000 Preferred Shares were issued to Roivant in consideration for an aggregate purchase price of $50.0 million on October 16, 2017 upon closing of the first tranche of the Private Placement (the “First Tranche”), and (ii) following the requisite approval of the Shareholders at the Meeting and the satisfaction of a limited number of other conditions for the closing of the Second Tranche, 664,000 Preferred Shares (the “Second Tranche Preferred Shares”) will be issued to Roivant in exchange for an aggregate purchase price of $66.4 million.

Pursuant to the Subscription Agreement:

(1)

upon closing of the First Tranche, the Company: (i) amended its Articles to add a new Part 26A to provide for the special rights and restrictions attaching to the Preferred Shares (see “The Private Placement - Preferred Share Rights and Restrictions”); (ii) entered into an Amended and Restated Governance Agreement (as defined below) pursuant to which the Company provided certain board nomination rights to Roivant (see “The Private Placement - Amended and Restated Governance Agreement”); (iii) entered into the Amended Registration Rights Agreement (as defined below) pursuant to which the Company provided registration rights to Roivant with respect to the Underlying Common Shares (see “The Private Placement - Amendment to Registration Rights Agreement”); (iv) entered into the Amended and Restated Standstill Agreement (as defined below) pursuant to which Roivant has agreed, subject to certain limitations, not to acquire Common Shares if such acquisition, taken together with the Underlying Common Shares, would cause it to own more than 49.99% of the Company’s outstanding Common Shares (see “The Private Placement - Amended and Restated Standstill Agreement and Amended and Restated Lock-Up Agreement”); and (v) entered into the Amended and Restated Lock-Up Agreement (as defined below), pursuant to which Roivant agreed, subject to certain exceptions, to not sell, pledge, or otherwise transfer or dispose of Common Shares or the Preferred Shares or enter into, sell or otherwise dispose of any swap, option, future forward or similar agreement with respect to Common Shares, the Preferred Shares or the Underlying Common Shares (see “The Private Placement - Amended and Restated Standstill Agreement and Amended and Restated Lock-Up Agreement”); and

(2)

the Company agreed to use commercially reasonable efforts to cause: (i) an amendment to Part 27 of the Company’s Articles, pursuant to which the period during which certain decisions of the Board require the approval of at least 70% of the members of the Board would be extended from its current expiry date of March 4, 2018 to October 16, 2021 (being four years from the closing of the First Tranche); and (ii) the Board Nomination Articles Amendment (as defined below) pursuant to which: (A) Roivant would have the right until October 16, 2021, subject to certain conditions, to nominate up to three members of the Board (at least one of whom must be "independent" within the meaning of the Articles, if Roivant has three nominees), and (B) for so long as Roivant

has such nomination rights, the total number of directors of Arbutus would not, without the prior written consent of Roivant, be permitted to exceed seven directors, the majority of whom would be required to be "independent" (see “The Private Placement - Board Nomination Articles Amendment”) (collectively, the “Governance Amendments”).

Excluding the Preferred Shares, Roivant is the beneficial owner of 29.1% of the Company’s issued and outstanding Common Shares. Following the conversion of the 500,000 Preferred Shares issued in connection with the First Tranche of the Private Placement into Underlying Common Shares, Roivant would own 39.8% of the Company’s issued and outstanding Common Shares (assuming no further dilution). Chairman Vivek Ramaswamy and directors Keith Manchester and William Symonds were nominated by Roivant to serve on the Board pursuant to the Governance Agreement dated January 11, 2015, between the Company and Roivant. In September 2016, director Frank Karbe was appointed CFO at Myovant Sciences Ltd., which is an affiliate of Roivant.

The Board established a Special Committee of independent directors to review and consider the Private Placement, as well as other alternative equity financing structures. For further details, see “The Private Placement - Background to the Private Placement” and “The Private Placement - Special Committee Review”.

The descriptions in this Proxy Statement/Circular, the Subscription Agreement, and the related Preferred Share Articles Amendment, the Board Nomination Article Amendment, the Amended and Restated Governance Agreement, the Amended Registration Rights Agreement, the Amended and Restated Standstill Agreement and the Amended and Restated Lock-Up Agreement (each as defined below, and, together, the “Documents”) are summaries of the material terms of those Documents, and are qualified in their entirety by the terms of the Documents, which are set forth in Exhibits A - G of this Proxy Statement/Circular.

The representations, warranties and covenants set forth in the Documents attached to this Proxy Statement/Circular have been made only for the purposes of the Documents and solely for the benefit of the parties to the Documents, may be subject to limitations agreed upon by the contracting parties, may have been made for the purposes of allocating contractual risk between the parties to the Documents instead of establishing these matters as facts, and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors. Accordingly, the Documents have been attached only to provide investors with information regarding the terms of the Documents, and not to provide investors with any other factual information regarding the parties or their respective businesses, and should be read in conjunction with the disclosures in periodic reports and other filings made by Arbutus or Roivant with the SEC. Matters may change from the state of affairs contemplated by the representations and warranties. Arbutus does not undertake any obligation to publicly release any revisions to these representations and warranties, except as required under U.S. federal or other applicable securities laws.

Background to the Private Placement

The Company’s relationship with Roivant dates back to January 2015 when the Company and OnCore Biopharma, Inc. (“OnCore”) agreed to merge (the “Merger”). At that time, Roivant owned a majority of the issued and outstanding shares of OnCore. On March 4, 2015, the Merger was completed and, as a result, OnCore became a wholly-owned subsidiary of the Company, Roivant became the Company’s single largest shareholder (with ownership and control over 16,013,540 Common Shares, representing approximately 34% of the then outstanding Common Shares), and three nominees of OnCore were appointed to the Board (Vivek Ramaswamy, Keith Manchester and William Symonds).

Subsequent to the Merger, the Company’s management team and Board have, as a regular part of the Company’s business, reviewed and considered various opportunities to strengthen the Company’s research and development capabilities, including potential strategic financings, licenses, development agreements, joint ventures and other potential strategic transactions.

In early September 2017, representatives of the Company and Roivant had preliminary discussions about exploring possible transactions that the parties could pursue, including a potential strategic investment by Roivant in the Company (a “Potential Strategic Investment”). It was acknowledged at this time that any Potential Strategic Investment would, under the Canadian Related Party Rules, constitute a “related party transaction” and, under the Company’s Related Persons Transaction Policy adopted by the Board on December 7, 2016, constitute a “Covered Transaction” (being certain “transactions with related persons” as that term is defined in Item 404 of Regulation S-K of the Exchange Act). Accordingly, the Board approved the formation of a Special Committee of independent directors, comprised of Richard Henriques (Chair), Daniel Burgess, and Herbert Conrad (the “Special Committee”), so that, if and when a Potential Strategic Investment was proposed for Board consideration, the Special Committee could ascertain whether it would be in the best interests of the Company to pursue a Potential Strategic Investment with Roivant, and to provide a recommendation to the Board in that regard.

Special Committee Review

The Special Committee first met on September 6, 2017, and appointed Richard Henriques as its Chair. Farris, Vaughan, Wills & Murphy LLP, the Company’s corporate counsel, was appointed legal counsel to the Special Committee. MTS Securities, LLC was subsequently appointed by the Special Committee to serve as its independent financial advisor. MTS Securities, LLC had not been previously engaged by the Company, the Board or Roivant. MTS Securities, LLC may, however, be appointed in the future to assist the Company or a special committee of the Board in exploring with Roivant, or other third parties, various additional potential strategic opportunities.

The Special Committee’s mandate and responsibilities were to investigate, analyze, consider, solicit, negotiate and provide advice and recommendations to the Board with respect to the merits of a Potential Strategic Investment, in conjunction with management and any financial and legal advisors that the Special Committee may determine to appoint and, to that end:


•	consider and respond to all aspects of any Potential Strategic Investment, including reviewing the terms of such Potential Strategic Investment, and proposing any amendments thereto, if deemed appropriate;


•	consider other potential alternative equity financing structures;


•	deal with or authorize or direct management of the Company, and the financial, legal and other advisors of the Company in dealing with all matters relating to any Potential Strategic Investment;


•	provide advice and guidance to the Board as to:


◦	whether a Potential Strategic Investment is in the best interest of the Company, taken as a whole, and fair to Shareholders, having regard to all relevant stakeholders and considerations;


◦	the content of resolutions and other actions reasonably desirable to give effect to any Potential Strategic Investment; and


◦	matters considered by the Special Committee to be reasonably ancillary to any Potential Strategic Investment;

•

make such recommendations to the Board and Shareholders as the Special Committee considered advisable, including, without limitation, ensuring, if applicable, that Shareholders are provided with sufficient information with respect to a Potential Strategic Investment, and the business and affairs of the Company, so as to enable them to make an informed decision with respect to a Potential Strategic Investment;

•

review and comment upon, in the course of preparation thereof, (i) all relevant and related subscription agreements and other related agreements and ancillary documents in connection with any Potential Strategic Investment, and (ii) if applicable, all circulars or documents to be mailed or delivered to Shareholders in connection with a Potential Strategic Investment, and, in particular, to approve those portions of such circulars and documents which pertain to the Special Committee, including the recommendations of the Special Committee to the Board and of the Board to the Shareholders; and


•	if a Potential Strategic Investment is approved, to maintain on behalf of the Board a review of its implementation.

Following the September 6, 2017 Special Committee meeting, senior management of the Company, at the request and under the direction of the Special Committee, commenced initial, exploratory discussions with representatives of Roivant with respect to a Potential Strategic Investment.

The Special Committee formally met, together with its legal advisors on September 13^th, 18^th, 20^th, 22^ndand 27^th, 2017, including meetings with its financial advisors and management of the Company, as well as in closed sessions without management present, to discuss the potential terms of, and the structure for, a Potential Strategic Investment. During this time, the Chair of the Special Committee and other members of the Special Committee, as well as the Special Committee as a whole (with its legal and financial advisors), had periodic communications with management of the Company and representatives of Roivant regarding the key terms of such a Potential Strategic Investment. The Special Committee received progress reports from time to time from management on the status of management's discussions with representatives of Roivant and provided guidance and direction to members of management in that regard. The Special Committee also received reports from MTS Securities, LLC with respect to various financial aspects that could affect the desirability of a Potential Strategic Investment and other alternative equity financing structures, including a review of the terms of comparable convertible preferred share

offerings, the status of the public markets and the potential terms, including indicative price, size and discount ranges, of a traditional public equity offering, that MTS Securities, LLC and the Special Committee considered relevant to any Potential Strategic Investment.

To facilitate further exploratory discussions regarding a Potential Strategic Investment, on September 28, 2017, Roivant provided the Company with a draft of a non-binding term sheet for the Private Placement.

On September 29, 2017, the Company, though counsel for the Special Committee, provided Roivant with high-level comments on the draft term sheet, including comments related to pricing. Later that evening, Roivant, through its counsel, formalized a proposal for a Potential Strategic Investment and provided a mark-up of the non-binding draft term sheet (the “Roivant Proposal”), followed by a form of Subscription Agreement incorporating the terms and conditions of the Roivant Proposal.

Following receipt of the form of Subscription Agreement on September 29, 2017 and through the early evening of October 1, 2017, the Company and Roivant negotiated and exchanged drafts of the Subscription Agreement and related agreements and ancillary documents, on terms and conditions consistent with those set out in the non-binding draft term sheet.

In the early evening of October 1, 2017, the Special Committee met to review and consider the proposed terms of the Potential Strategic Investment as set out in the Roivant Proposal, and to receive the views of management and the advice of its legal and financial advisors in a closed session without management present. The Special Committee reviewed and considered the terms and conditions of the Private Placement and, based on the proposed terms and conditions of the Potential Strategic Investment as set out in the Roivant Proposal and the legal and financial advice provided by its legal and financial advisors, including a review of certain potential alternative equity financing structures that might be available to the Company, determined: (a) that the Private Placement was in the best interests of the Company and fair to the disinterested Shareholders, (b) to recommend to the Board that the Company undertake the Private Placement, and (c) to authorize management of the Company, together with legal counsel for the Special Committee, to negotiate and settle the forms of the Subscription Agreement and related agreements and ancillary documents, on terms and conditions consistent with those set out in the Roivant Proposal, subject to final Board approval of the Subscription Agreement.

Throughout the evening and early into the morning of October 2, 2017, management of the Company and representatives of Roivant, together with legal counsel for the Special Committee and Roivant, respectively, further negotiated and finalized the Subscription Agreement and the related agreements and ancillary documents, and the Board (other than Messrs. Ramaswamy, Manchester, Symonds and Karbe, each of whom declared his interest in the Private Placement by virtue of his relationship with Roivant and abstained from voting) subsequently unanimously accepted the recommendation of the Special Committee and determined to undertake the Private Placement, enter into the Subscription Agreement and related agreements and ancillary documents, and recommend that Shareholders vote to approve the Second Tranche and the Governance Amendments.

Reasons for the Private Placement

In evaluating and approving the Private Placement, and in making their recommendation that Shareholders vote to approve the Second Tranche and the Governance Amendments, the Special Committee and the Board carefully considered a number of factors, including those listed below.

•

Second Tranche is Part of a Larger Financing With Attractive Terms - The Second Tranche is part of a larger Private Placement, which includes both the $50 million in gross proceeds received from the First Tranche and the $66.4 million in gross proceeds to be received from the Second Tranche. The Private Placement of $116.4 million, including the Second Tranche, was undertaken following an assessment of certain potential alternative equity financing structures that might be available to the Company. In particular, with the assistance of its financial advisors, the Special Committee reviewed the terms of comparable convertible preferred share offerings against the terms of the Private Placement and the potential terms, including indicative price, size and discount ranges, of a traditional public equity offering or PIPE (private investment in a public entity) transaction. The Special Committee concluded, following the receipt of advice from its legal and financial advisors that the Private Placement offered the best opportunity to expeditiously complete a much larger equity financing, on more attractive terms, and with greater closing and pricing certainty, in each case than would likely otherwise be obtained in a public offering or PIPE transaction.


•	Development of HBV Pipeline - If completed, the net proceeds from the Second Tranche will provide the Company with significant additional resources to continue the development of the Company’s clinical and pre-clinical HBV pipeline programs (the “HBV Pipeline”).


•	Certainty of Closing - The First Tranche has already been completed. The obligation of Roivant to complete the Second Tranche is subject only to a limited number of closing conditions, as provided for in the Subscription Agreement. In particular, there is no right to terminate the Subscription Agreement due to a “material adverse effect” occurring with respect to the Company.


•	Shareholder Approval - The Second Tranche must receive minority Shareholder approval in accordance with the Canadian Related Party Rules. See “Proposal No. 1 - Approval of the Second Tranche”.

•

Private Placement Further Establishes Roivant as a Committed Long-Term Strategic Investor - Although Roivant currently holds a 39.8% equity interest in the Company (on a partially-diluted basis assuming conversion of the 500,000 Preferred Shares issued to Roivant in connection with the First Tranche), following the closing of the Second Tranche, Roivant would hold a significantly larger equity interest of approximately 49.9% (on a partially diluted basis assuming conversion of the 1,164,000 Preferred Shares that would then be held by Roivant). The Special Committee believes that this level of ownership will lead to an even stronger commitment from Roivant to the long-term success of the Company, particularly given that, until October 16, 2021:


◦	subject to the occurrence of certain limited events set forth in the Preferred Share Articles Amendment, the Preferred Shares will not convert into Common Shares;

◦

pursuant to the terms of the Amended and Restated Standstill Agreement, Roivant has agreed, until the earlier of (i) 48 months following the First Closing, and (ii) when Roivant no longer has the right to nominate one or more directors under the Board Nomination Articles Amendment (together, the "Outside Date"), other than pursuant to certain customary exceptions, not to acquire additional Common Shares if such acquisition would result in Roivant owning an amount of Common Shares that, taken together with the Underlying Common Shares, would exceed 49.99% of the outstanding Common Shares , or take certain other actions related to the calling of meetings, proxies, proposals and other actions of the Shareholders; and


◦	pursuant to the terms of the Amended and Restated Lock-Up Agreement, Roivant has agreed, until the Outside Date, other than pursuant to certain customary exceptions, not to sell, pledge, or otherwise transfer or dispose of any Common Shares or the Preferred Shares.

•

Potential Strategic Opportunities with Roivant - The opportunity to explore with Roivant various potential strategic opportunities, including the potential to: (i) leverage Roivant’s infrastructure to more efficiently develop the Company’s HBV Pipeline; (ii) expand the Company’s geographic footprint in HBV drug development; and (iii) to maximize the value of the Company’s non-HBV assets, including the Company’s LNP and GalNAc platforms for the delivery of novel therapeutic modalities, such as RNA interference, mRNA, and gene editing technologies. For further information on these platforms, see the Company's current Annual Report on Form 10-K for the fiscal year ended December 31, 2016.


•	Independent Financial Advisors - The Special Committee received and considered financial advice provided by MTS Securities, LLC with respect to the Private Placement, including a review of certain potential alternative equity financing structures that might be available to the Company, as discussed above.


•	Management Input - The Special Committee received and considered input from the Company’s management on the benefits and risks associated with the Private Placement, as well as with respect to other potential alternative equity financing structures that might be available to the Company, as discussed above.

The Special Committee and the Board weighed the factors described above, which the Special Committee and the Board viewed generally as supporting their respective decisions to approve the Private Placement and to recommend that Shareholders approve the Second Tranche and the Governance Amendments, against a number of other factors identified in their respective deliberations weighing negatively against the Private Placement including, without limitation, Roivant’s increased influence on the Board, Roivant’s increased voting power following the conversion of the Preferred Shares into Underlying Common Shares, the dilutive effect on existing Shareholders following the conversion of the Preferred Shares into Underlying Common Shares, the Preferred Shares ranking in preference to the Common Shares upon liquidation or dissolution of the Company, and the

concern that the agreements entered into with Roivant and Roivant's equity holdings could discourage takeover, merger or other transactions in which Shareholders could receive a premium over the then current market price of the Common Shares.

The foregoing discussion of the information and factors considered by the Special Committee and the Board is not meant to be exhaustive, but includes the material information, factors and analyses considered by the Special Committee and the Board in reaching their respective conclusions and recommendations in relation to the Private Placement. The members of the Special Committee and the Board evaluated the various factors listed above in light of their knowledge of the business, financial condition and prospects of the Company, taking into account the advice of the financial and legal advisors to the Special Committee. In light of the variety of factors and amount of information that the Special Committee and the Board considered, the members of the Special Committee and the Board did not find it practicable to provide a specific assessment of, quantify or otherwise assign any relative weights to, the factors considered in determining their recommendations. Rather, the respective recommendations of the Special Committee and the Board were made after considering the totality of the information and factors involved. Individual members of the Special Committee and the Board may have ascribed different weight to different factors.

Events Subsequent to the Special Committee Review

On October 2, 2017, the Company and Roivant entered into the Subscription Agreement.

On October 16, 2017, the Company completed the First Tranche and issued 500,000 Preferred Shares to Roivant, raising gross proceeds of $50 million.

On November 14, 2017, the Board approved the formation of a special committee of independent directors, comprised of Daniel Burgess (Chair), Richard Henriques and Herbert Conrad, to review and consider potential opportunities to accelerate the development of the Company’s LNP and GalNAc platforms.

Preferred Share Rights and Restrictions

Pursuant to the Subscription Agreement, Arbutus filed an amendment to the Notice of Articles and the Articles of Arbutus (the “Preferred Share Articles Amendment”) on October 16, 2017 on closing of the First Tranche. The terms, rights, obligations and preferences of the Preferred Shares are set forth in the Preferred Share Articles Amendment.

Dividends

In the event Arbutus distributes to all or substantially all holders of Common Shares any cash, shares, evidences of Arbutus’ indebtedness or other assets, securities or property, including rights to acquire assets, securities or property, the holders of a Preferred Share will be entitled to receive such dividend in cash (the “Participating Cash Dividend”) or such other distributed items (a “Participating In-Kind Dividend”) at the same time and in the same manner as holders of Common Shares would have received if such Preferred Share had been converted into Common Shares upon the Mandatory Conversion Date (as defined below).

Mandatory Conversion

On the fourth anniversary of the closing of the First Tranche (the “Mandatory Conversion Date”), any Preferred Shares not yet converted will be automatically converted into (i) a number of Common Shares equal to the amount determined by dividing (A) the Purchase Price plus an amount equal to 8.75% of the Purchase Price per annum, compounded annually (the “Liquidation Preference”) by (B) the conversion price in effect at the time of conversion, being $7.13 (a 15% premium to the closing price of the Common Shares on September 29, 2017), subject to adjustment for certain distributions, recapitalizations, reclassifications and other transactions by Arbutus on or with respect to the Common Shares; (ii) cash for any accrued but unpaid Participating Cash Dividends (to the extent not included in the Purchase Price) on the Preferred Shares being converted; and (iii) any accrued and unpaid Participating In-Kind Dividends.

Optional Conversion

In the event of a transaction that involves (i) a fundamental transfer of value to the Common Shares in which the Preferred Shares do not have the right to participate or (ii) a Fundamental Change (as defined in the Preferred Share Articles Amendment, which is included as Exhibit G hereto), each Preferred Share may be converted prior to such transaction at the option of its holder into (A) a number of Common Shares equal to the amount determined by dividing (x) the Liquidation Preference

(calculated giving effect to the four-year period set forth in “Mandatory Conversion” above, irrespective of the date of conversion) by (y) the conversion price in effect at the time of conversion, being $7.13 (a 15% premium to the closing price of the Common Shares on September 29, 2017), subject to adjustment for certain distributions, recapitalizations, reclassifications and other transactions by Arbutus on or with respect to the Common Shares; (B) cash for any accrued but unpaid Participating Cash Dividends (to the extent not included in the Purchase Price) on the Preferred Shares being converted; and (C) any accrued and unpaid Participating In-Kind Dividends.

Liquidation Preference; Ranking

In the event of any liquidation, dissolution or winding up of Arbutus, the holders of the Preferred Shares will be entitled to receive an amount in cash equal to the amount that the holder of a Preferred Share would have been entitled to receive if such Preferred Share had been converted into Common Shares upon the Mandatory Conversion Date. Neither the voluntary sale, conveyance, exchange or transfer of all or substantially all of the assets of Arbutus nor the consolidation or merger of Arbutus with or into another entity will be deemed a liquidation, dissolution or winding up of Arbutus.

The Preferred Shares will rank senior to the Common Shares with respect to any distributions or rights upon liquidation, dissolution or winding up of Arbutus.

Voting Rights

The Preferred Shares will not have the right to vote on any matters except as required by law, including under the Business Corporations Act (British Columbia).

Board Nomination Articles Amendment

Pursuant to the Subscription Agreement, Arbutus and Roivant must use commercially reasonable efforts to cause the amendment of Arbutus’ Articles (the “Board Nomination Articles Amendment”) by the closing of the Second Tranche. Pursuant to the Board Nomination Articles Amendment, Roivant will have the right to nominate a certain number of directors to Arbutus’ Board, which right will terminate upon the earlier of (i) 48 months following the closing of the First Tranche and (ii) when Roivant no longer meets certain beneficial ownership thresholds. With respect to the beneficial ownership thresholds, for so long as Roivant has beneficial ownership or exercises control or direction over not less than (i) 30% of the issued and outstanding Common Shares, Roivant has the right to nominate three individuals for election to the Board, one of whom must be “independent” within the meaning of applicable law and the rules and regulations of The Nasdaq Stock Market LLC, not including the rules related to the independence of audit committee members; (ii) 20% of the issued and outstanding Common Shares, Roivant has the right to nominate two individuals for election to the Board; and (iii) 10% of the issued and outstanding Common Shares, Roivant has the right to nominate one individual for election to the Board. For so long as Roivant has the right to nominate one or more directors to the Board, the Board Nomination Articles Amendment requires that the total number of directors of Arbutus will not, without the prior written consent of Roivant, be permitted to exceed seven directors, the majority of whom must be “independent” within the meaning of the Articles as set forth in (i) above.

Amended and Restated Governance Agreement

Pursuant to the Subscription Agreement, at the closing of the First Tranche, Roivant entered into an Amended and Restated Governance Agreement with Arbutus (the “Amended and Restated Governance Agreement”), which replaced and superseded the existing Governance Agreement dated as of January 11, 2015 between Roivant and Arbutus. Pursuant to the terms of the Amended and Restated Governance Agreement, Arbutus must cause that number of individuals designated by Roivant to be appointed to the Board in accordance with the Board Nomination Articles Amendment either concurrently with the closing of the Second Tranche, or, if for any reason the closing of the Second Tranche does not occur, by resolution of the Board to add a director, and otherwise in accordance with the Board Nomination Articles Amendment. Consistent with the Board Nomination Articles Amendment, the Amended and Restated Governance Agreement was effective upon the closing of the First Tranche and will terminate upon the earlier of (i) 48 months following the closing of the First Tranche and (ii) when Roivant no longer has a right to nominate one or more directors under the Board Nomination Articles Amendment.

Amendment to Registration Rights Agreement

The Preferred Shares and Underlying Common Shares will not be registered under the U.S. Securities Act, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Pursuant to the Subscription Agreement, Arbutus and Roivant entered into a second amendment to the Registration Rights Agreement (the

“Amended Registration Rights Agreement”) at the closing of the First Tranche pursuant to which the definition of Registrable Securities was expanded to include the Underlying Common Shares (and Common Shares issued upon conversion of Participating In-Kind Dividends, if any). The details of the original Registration Rights Agreement are summarized in the Company’s Current Report on Form 8-K filed with the SEC on EDGAR on January 11, 2015.

Amended and Restated Standstill Agreement and Amended and Restated Lock-Up Agreement

Pursuant to the Subscription Agreement, at the closing of the First Tranche, Roivant entered into (i) an Amended and Restated Standstill Agreement with Arbutus (the “Amended and Restated Standstill Agreement”), which replaced and superseded the Standstill Agreement dated as of January 11, 2015 between Roivant and Arbutus, and (ii) an Amended and Restated Lock-Up Agreement with Arbutus (the “Amended and Restated Lock-Up Agreement”), which replaced and superseded the Lock-Up Agreement dated as of January 11, 2015 between Roivant and Arbutus.

Pursuant to the terms of the Amended and Restated Standstill Agreement, Roivant agreed not to acquire, offer to acquire, or agree to acquire, ownership of any additional Common Shares if such acquisitions would result in Roivant owning an amount of Common Shares that, taken together with the Underlying Common Shares, would exceed 49.99% of the outstanding Common Shares, or take certain other actions related to the calling of meetings, proxies, proposals and other actions of the shareholders of Arbutus.

Pursuant to the terms of the Amended and Restated Lock-Up Agreement, Roivant agreed, subject to certain customary exceptions, not to (i) sell, pledge, or otherwise transfer or dispose of Common Shares or the Preferred Shares; or (ii) enter into, sell or otherwise dispose of any swap, option, future, forward or other similar agreement with respect to Common Shares, the Preferred Shares and the Underlying Common Shares. Roivant is permitted pursuant to the Amended and Restated Lock-Up Agreement to pledge its Common Shares in connection with a bona fide loan from a financial institution and to transfer such shares in connection with the exercise of any remedies by such financial institution.

The Amended and Restated Standstill Agreement and the Amended and Restated Lock-Up Agreement were effective upon the closing of the First Tranche and will terminate upon the earlier of (i) 48 months following the closing of the First Tranche and (ii) when Roivant no longer has a right to nominate one or more directors under the Board Nomination Articles Amendment. The restrictions under the two agreements will also cease to apply if Arbutus enters into a sale transaction, a third party seeks to acquire Arbutus by way of a bona fide tender offer or Arbutus enters into a sale process under circumstances specified in the Amended and Restated Standstill Agreement.

Unregistered Securities

The securities to be issued pursuant to the Subscription Agreement as described above, including the Underlying Common Shares, have not been registered under the Securities Act, and will be issued pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act. Roivant represented, pursuant to the terms of the Subscription Agreement, that it is an accredited investor, and will not offer, sell or otherwise dispose of the securities of Arbutus, except pursuant to offers, sales or dispositions registered under, or exempted from, the registration requirements of the Securities Act.

RISK FACTORS

Shareholders voting in favour of the Proposals will be choosing to approve, among other things, the Second Tranche and the Board Nomination Article Amendment. The completion of the transactions contemplated by the Proposals involves risks. In addition to the risk factors described under the heading “Risk Factors” in the Company’s comparative annual report on Form 10-K for year ended December 31, 2016, which risk factors are specifically incorporated by reference into this Proxy Statement/Circular, the following are additional and supplemental risk factors which Shareholders should carefully consider before making a decision regarding approving the Proposals. Readers are cautioned that such risk factors are not exhaustive and additional risks and uncertainties, including those currently unknown or considered immaterial to the Company, may also adversely affect the Common Shares and/or the business of the Company before and following completion of the transactions contemplated herein.

The Subscription Agreement may be terminated and alternative financing on similar terms may not be available, which could have a material adverse effect on the business, financial condition and results of operations of the Company and the market value of the Common Shares.

The Subscription Agreement may be terminated by the Company or Roivant in certain circumstances. Accordingly, there is no certainty, nor can the Company provide any assurance, that the Subscription Agreement will not be terminated by either the Company or Roivant before the completion of the Second Tranche. If the Second Tranche is not completed, the Company will have significantly less available capital to fund its operations and the further research and development of its product candidates. Moreover, if the Subscription Agreement is terminated, there is no assurance that the Company will be able to find

an alternative financing transaction. Certain costs relating to the Second Tranche, such as legal, accounting and certain financial advisor fees must be paid by the Company even if the Second Tranche is not completed. This may have a material adverse effect upon the business, financial condition and results of operations of the Company and may cause the value of the Common Shares to decline. In addition, if the Second Tranche is not completed, the market price of the Common Shares may be impacted to the extent that the market price reflects a market assumption that the Second Tranche will be completed.

If the required Shareholder approvals are not obtained, the Second Tranche may not be completed and, if the alternative financing on similar terms is not available, the Company will have significantly less available capital to fund its operations.

In order for the Proposals to pass, Proposal No. 1 regarding the Second Tranche must be approved by the affirmative vote of at least a simple majority of minority Shareholders represented in person or by proxy at the Meeting in accordance with the Canadian Related Party Rules (see “Related Party Transaction Matters”), Proposal No. 2 must be approved by the affirmative vote of two thirds of the votes cast by Shareholders represented in person or by proxy at the Meeting and Proposal No. 3 must be approved by a simple majority of votes cast by Shareholders represented in person or by proxy at the Meeting. There can be no assurance that the required Shareholder approval for the Proposals will be obtained. If such approval is not obtained and the Second Tranche is not completed, the Company will have significantly less available capital to fund its operations and the further research and development of its product candidates. If the Second Tranche is not completed, the market price of the Common Shares may be impacted to the extent that the market price reflects a market assumption that the Second Tranche will be completed. Moreover, if the Subscription Agreement is terminated, there is no assurance that the Company will be able to find an alternative financing transaction. Certain costs relating to the Second Tranche, such as legal, accounting and certain financial advisor fees must be paid by the Company even if the Second Tranche is not completed. This may have a material adverse effect upon the business, financial condition and results of operations of the Company and may cause the value of the Common Shares to decline.

The Underlying Common Shares issuable upon conversion of the Preferred Shares will have a dilutive effect on outstanding shareholders.

The Underlying Common Shares issuable pursuant to the terms of the Preferred Shares will upon issuance have an immediate dilutive effect on the ownership interest of the other Shareholders in the Company.

The market price of the Common Shares may decline if the Second Tranche is not completed on a timely basis.

If, for any reason, the Second Tranche is not completed or its completion is materially delayed and/or the Subscription Agreement is terminated, the market price of the Common Shares may be materially adversely affected.

The Preferred Shares rank ahead of the Common Shares in the event of any liquidation, dissolution or winding up of the Company.

In the event of any liquidation, dissolution or winding up of the Company or any other distribution of assets of the Company among its shareholders for the purpose of winding up its affairs, subject to the prior satisfaction of the claims of all creditors of the Company and of holders of shares of the Company ranking prior to the Preferred Shares, each Preferred Shareholder will be entitled to be paid an amount equal to the Liquidation Preference (less any tax required to be deducted and withheld by the Company), before any amount is paid or any assets of the Company are distributed to holders of the Common Shares.

If the Second Tranche is completed, Roivant will have significant influence over the Company.

Roivant currently holds 29.1% of the Company’s issued and outstanding Common Shares. Assuming no changes to the capital structure of the Company, following conversion into Common Shares of the Preferred Shares to be issued in connection with: (i) the First Tranche, Roivant would own 39.8% of the Company’s issued and outstanding Common Shares (assuming no further dilution); and (ii) the Second Tranche, Roivant would own 49.9% of the Company’s issued and outstanding Common Shares (assuming no further dilution). For so long as Roivant has the right to vote at least 33-1/3% of the outstanding Common Shares represented at a meeting of Shareholders, it will be in a position to exercise significant influence over matters requiring Shareholder approval, including the election of directors and the determination of significant corporate actions. In addition, for so long as Roivant has the right to vote 33-1/3% of the outstanding Common Shares represented at a meeting of Shareholders, it will have the ability to veto any fundamental transactions that would require the vote of Shareholders. Accordingly, upon the conversion of the Preferred Shares, presuming no intervening change in capital structure of the Company, Roivant will have

significant influence over the Company and there can be no assurance that Roivant’s interests will align with the interests of the Company or other Shareholders.

The Governance Amendments will also give Roivant significant influence on the Board of Directors of the Company.

As described above under the headings “The Private Placement - Board Nomination Articles of Amendment” and “The Private Placement - Amended and Restated Governance Agreement”, Roivant will have a right to nominate up to three of seven members of the Board for a period of up to 48 months following the closing of the First Tranche, subject to certain ownership thresholds being met. Notwithstanding that the proposed amendments to Part 28 of the Articles comprising Proposal No. 3 would, for so long as Roivant has the right to nominate one or more directors to the Board, require a majority of the members of the Board to be "independent" within the meaning of the Articles (including one of Roivant’s nominees, if Roivant has three nominees), Roivant may still have significant influence on the composition of the Board pursuant to its rights under the Company’s Articles, as amended by the Board Nomination Articles of Amendment, and/or the Amended and Restated Governance Agreement, and it may therefore exert influence on the decisions of the Board.

The use of proceeds from the Private Placement will be allocated as determined by the Board without shareholder approval.

The proposed use of proceeds from the Private Placement described above under the heading “The Private Placement - Reasons for the Private Placement” is based on the current expectations of the Company; however, there may be circumstances where, for business reasons, a reallocation of funds may be necessary as determined at the discretion of the Board, and there can be no assurance as to how those funds may be reallocated. Accordingly, Shareholders will have to rely upon the judgment of the Board with respect to the use of the proceeds, with only limited information concerning the Board’s specific intentions.

The Company’s Agreements with Roivant and Roivant’s shareholdings in the Company may discourage takeover or merger attempts that Shareholders may consider to be favourable.

The Company’s agreements with Roivant described herein and Roivant’s significant equity holdings may make it more difficult for a third party to acquire 100% of the share capital of the Company and could delay, defer or prevent the Company from experiencing a change of control. Any delay or prevention of a change of control transaction could deter potential acquirors or prevent the completion of a transaction in which Shareholders could receive a premium over the then current market price of the Common Shares.

PROPOSAL NO. 1 - APPROVAL OF THE SECOND TRANCHE OF THE PRIVATE PLACEMENT

As described below under the heading “Related Party Transaction Matters” and under the heading “The Private Placement” above, the completion of the Second Tranche requires minority approval under MI 61-101. Accordingly, Shareholders will be asked to approve the Second Tranche as Proposal No. 1. For further details with respect to the Private Placement, see “The Private Placement” above.

Resolution

The text of the resolution in respect of Proposal No. 1 that Shareholders will be asked to approve at the Meeting is as follows:

“BE IT RESOLVED, as an ordinary resolution, THAT:

(a)

the Company be and is hereby authorized and directed to issue pursuant to the terms of the Subscription Agreement (i) the Second Tranche Preferred Shares, (ii) up to 13,025,536 Underlying Common Shares upon conversion of the Second Tranche Preferred Shares and (iii) such additional Common Shares as may become issuable upon conversion of the Second Tranche Preferred Shares pursuant to the rights attached thereto, all as more particularly described in the Company’s Management Proxy Statement/Circular dated December 6, 2017, and such resolution is hereby confirmed, approved and adopted in all respects;

(b)

any officer or director of the Company is hereby authorized, acting for, in the name of and on behalf of the Company, to execute, under the seal of the Company or otherwise, and to deliver or cause to be delivered, all such documents, agreements and instruments, and to do or cause to be done all such other acts and things, as such officer or director determines to be necessary or desirable in order to carry out the intent of the foregoing paragraph of this resolution and

the matters authorized hereby, such determination to be conclusively evidenced by the execution and delivery of such document, agreement or instrument or the doing of any such act or thing;

(c)

notwithstanding that the foregoing resolution has been duly passed by the Shareholders, the directors of the Company be and are hereby authorized and empowered, without further notice to, or approval of, the Shareholders, to (a) decide on the timing of closing of the Second Tranche; or (b) decide not to proceed with all or any part of the Second Tranche and revoke the whole or part of these resolutions before they are acted on; and


(d)	these approvals are given for all purposes under the rules of The Nasdaq Stock Market LLC and under Multilateral Instrument 61-101.”

Required Vote

Proposal No. 1 must be approved by the affirmative vote of at least a majority of the votes cast by Shareholders represented in person or by proxy at the Meeting other than those holders of Common shares excluded pursuant to Section 8.1(2) of MI 61-101. Accordingly, in determining whether Shareholder approval of the Proposal No. 1 has been obtained, the Company will exclude the votes cast by Roivant and its “related parties” and “joint actors” (as defined in MI 61-101).

Recommendation

The Board recommends that the Shareholders vote “FOR” Proposal No. 1.

PROPOSAL NO. 2 - APPROVAL OF AN AMENDMENT TO PART 27 OF ARBUTUS’ ARTICLES

Overview

The following is a summary of the proposed amendment to Part 27 of the Company’s Articles. The description of the following proposed amendment is only a summary and is qualified entirely by reference to the complete text of the proposed amendment, which is attached to this Proxy Statement/Circular as Exhibit B. We urge you to read Exhibit B in its entirety before casting your vote.

At the time of the Merger with OnCore, Arbutus’ Articles were amended to require certain decisions by the Board to be subject to the approval of 70% of the members of the Board. This “supermajority” approval requirement was set to expire on March 4, 2018, being 36 months following the closing of the Merger. Pursuant to the Subscription Agreement, Arbutus agreed to use commercially reasonable efforts to cause Part 27 of the Articles to be amended to extend the expiry date of such provisions from March 4, 2018 to October 16, 2021 (being four years from the closing of the First Tranche). In addition, if the proposed amendments to Part 28 of the Articles comprising Proposal No. 3 are approved at the Meeting: (i) Roivant would have the right until October 16, 2021, subject to certain conditions, to nominate up to three members of the Board (at least one of whom must be "independent" within the meaning of the Articles, if Roivant has three nominees), and (ii) for so long as Roivant has such nomination rights, the total number of directors of Arbutus would not, without the prior written consent of Roivant, be permitted to exceed seven directors, the majority of whom would be required to be "independent".

At the Meeting, Shareholders will be asked to approve an amendment to Part 27 of the Articles to approve the aforementioned extension of the supermajority voting requirement as Proposal No. 2.

Resolution

The text of the resolution in respect of Proposal No. 2 that Shareholders will be asked to approve at the Meeting is as follows:

“BE IT RESOLVED, as a special resolution, THAT:

(a)

the existing Articles of the Company be amended to extend the period during which certain decisions of the Board require approval of at least 70% of the directors from March 4, 2018 to October 16, 2021 by deleting Part 27 thereof in its entirety and replacing it with the amended text of Part 27 substantially in the form attached as Exhibit B to the Company’s Management Proxy Statement/Circular dated December 6, 2017, and such resolution is hereby confirmed, approved and adopted in all respects;

(b)

pursuant to Section 259 of the Business Corporations Act (British Columbia), the alteration of Part 27 of the Articles of the Company approved by the foregoing resolution shall not take effect until a copy of these resolutions are received for deposit at the Company’s records office and a Notice of Alteration identifying the date of this resolution has been filed with the British Columbia Registrar of Companies;

(c)

(d)

notwithstanding that the foregoing resolution has been duly passed by the Shareholders, the directors of the Company be and are hereby authorized and empowered, without further notice to, or approval of, the Shareholders, to (a) decide on the timing of the implementation of all or any part of the amendment to Part 27 of the Articles, or (b) decide not to proceed with the foregoing amendment to Part 27 of the Articles of the Company and revoke the whole or part of these resolutions before they are acted on.”

Required Vote

Proposal No. 2 must be approved by the affirmative vote of two thirds of the votes cast by Shareholders represented in person or by proxy at the Meeting.

Recommendation

The Board recommends that the Shareholders vote “FOR” Proposal No. 2.

PROPOSAL NO. 3 - APPROVAL OF AN AMENDMENT TO PART 28 OF ARBUTUS’ ARTICLES

The following is a summary of the proposed amendment to Part 28 of the Company’s Articles. The description of the following proposed amendment is only a summary and is qualified entirely by reference to the complete text of the proposed amendment, which is attached to this Proxy Statement/Circular as Exhibit B. We urge you to read Exhibit B in its entirety before casting your vote.

As described above under the heading “The Private Placement - Board Nomination Articles of Amendment”, pursuant to the Subscription Agreement, Arbutus and Roivant must use commercially reasonable efforts to cause the Board Nomination Articles of Amendment to take effect by the closing of the Second Tranche. Pursuant to the Board Nomination Articles Amendment, Roivant has the right to nominate a certain number of directors to the Board, which right will terminate upon the earlier of (i) 48 months following the closing of the First Tranche and (ii) when Roivant no longer meets certain beneficial ownership thresholds. With respect to the beneficial ownership thresholds, for so long as Roivant has beneficial ownership or exercises control or direction over not less than (i) 30% of the issued and outstanding Common Shares, Roivant has the right to nominate three individuals for election to the Board, one of whom must be “independent” within the meaning of applicable law and the rules and regulations of The Nasdaq Stock Market LLC, not including the rules related to the independence of audit committee members; (ii) 20% of the issued and outstanding Common Shares, Roivant has the right to nominate two individuals for election to the Board; and (iii) 10% of the issued and outstanding Common Shares, Roivant has the right to nominate one individual for election to the Board. For so long as Roivant has the right to nominate one or more directors to the Board, the Board Nomination Articles Amendment requires that the total number of directors of Arbutus will not, without the prior written consent of Roivant, be permitted to exceed seven directors, the majority of whom must be “independent” within the meaning of the Articles as described in (i) above.

At the Meeting, Shareholders will be asked to approve the Board Nomination Articles of Amendment as Proposal No. 3.

Resolution

The text of the resolution in respect of Proposal No. 3 that Shareholders will be asked to approve at the Meeting is as follows:

“BE IT RESOLVED, as an ordinary resolution, THAT:

(a)

the existing Articles of the Company be amended by deleting Part 28 thereof in its entirety and replacing it with the amended text of Part 28 substantially in the form attached as Exhibit B to the Company’s Management Proxy Statement/Circular dated December 6, 2017 pursuant to which: (i) Roivant would have the right until October 16, 2021, subject to certain conditions, to nominate up to three members of the Board (at least one of whom must be "independent" within the meaning of the Articles, if Roivant has three nominees), and (ii) for so long as Roivant has such nomination rights, the total number of directors of the Company would not, without the prior written consent of Roivant, be permitted to exceed seven directors, the majority of whom would be required to be "independent", and such resolution is hereby confirmed, approved and adopted in all respects;

(b)

pursuant to Section 259 of the Business Corporations Act (British Columbia), the alteration of Part 28 of the Articles of the Company approved by the foregoing resolution shall not take effect until a copy of these resolutions are received for deposit at the Company’s records office and a Notice of Alteration identifying the date of this resolution has been filed with the British Columbia Registrar of Companies;

(c)

(d)

notwithstanding that the foregoing resolution has been duly passed by the Shareholders, the directors of the Company be and are hereby authorized and empowered, without further notice to, or approval of, the Shareholders, to (a) decide on the timing of the implementation of all or any part of the amendment to Part 28 of the Articles, or (b) decide not to proceed with the foregoing amendment to Part 28 of the Articles of the Company and revoke the whole or part of these resolutions before they are acted on.”

Required Vote

Proposal No. 3 must be approved by the affirmative vote of a majority of the votes cast by Shareholders represented in person or by proxy at the Meeting.

Recommendation

The Board recommends that the Shareholders vote “FOR” Proposal No. 3.

OTHER BUSINESS

If any other matters are properly presented for consideration at the Meeting, including, among other things, consideration of a motion to adjourn the Meeting to another time or place in order to solicit additional proxies in favor of the recommendations of the Board, the designated proxyholders intend to vote the Common Shares represented by the proxies appointing them on such matters in accordance with the recommendations of the Board, and the authority to do so is included in the proxy.

As of the date of this Proxy Statement/Circular, the Board knows of no other matters which are likely to come before the Meeting.

RELATED PARTY TRANSACTION MATTERS

Overview

MI 61-101 is intended to regulate certain transactions to ensure equality of treatment among shareholders, requiring enhanced disclosure, approval by a majority of shareholders excluding interested or related parties, independent valuations and, in certain instances, approval and oversight of the transaction by a special committee of independent directors. The protections of MI 61-101 generally apply to “related party transactions” (as such term is defined in MI 61-101).

The Related Party Transaction

The Private Placement constitutes a related party transaction as (i) Roivant is a “related party” (as such term is defined in MI 61-101) of the Company by having beneficial ownership or control of more than 10% of the voting rights attached to all of the Company’s outstanding securities; and (ii) the Private Placement involves the issuance of the Company’s securities to a related party, being Roivant.

As disclosed in the Company’s material change report dated October 5, 2017 and filed on SEDAR, the Company relied on the exemption from the minority approval requirement of MI 61-101 provided by subsection 5.5(a) thereof (the “25% Market Capitalization Exemption”) for the First Tranche. Neither the 25% Market Capitalization nor any other exemption from the minority approval requirement in MI 61-101 is available for purposes of the Second Tranche.

In light of the foregoing, Proposal No. 1 to approve the Second Tranche is subject to “minority approval” (as such term is defined in MI 61-101). Accordingly, the Company is seeking approval of Proposal No. 1 from a simple majority of the votes cast at the Meeting in person or by proxy, excluding the votes cast by Roivant and its “related parties” and “joint actors” (as such terms are defined in MI 61-101). The aggregate of 16,329,782 Common Shares representing approximately 29.7% of the issued and outstanding Common Shares owned and controlled by Roivant and Messrs. Ramaswamy, Manchester, Symonds and Karbe will be excluded in determining whether minority approval is obtained for Proposal No. 1. The number of Common Shares beneficially owned or under the control or direction of such persons are set out above under the heading “Security Ownership of Certain Beneficial Owners and Management”.

Bona Fide Prior Offers

Apart from the offer from Roivant which resulted in the Company entering into the Subscription Agreement, there have been no bona fide prior offers that relate to the subject matter of, or are otherwise relevant to, the Private Placement during the 24 months prior to the date the Subscription Agreement was agreed to. The background of the Subscription Agreement and its material terms are discussed under the heading “The Private Placement”.

Prior Valuations

To the knowledge of the Company and its directors and senior officers, after reasonable inquiry, there have been no “prior valuations” (as such term is defined in MI 61-101) in respect of the Company that relate to the subject matter of or are otherwise relevant to the Private Placement during the 24 months prior to the date hereof.

Exemption from the Formal Valuation Requirement

The Company is relying on the exemption from the formal valuation requirement of MI 61-101 provided by subsection 5.5(c) thereof (the “Distribution of Securities for Cash Exemption”). The facts supporting reliance on the Distribution of Securities for Cash Exemption are as follows:


(i)	the Private Placement is a distribution of securities of the Company to Roivant for cash consideration;


(ii)	neither the Company, nor, to the knowledge of the Company after reasonable inquiry, Roivant had knowledge of any material information concerning the Company or its securities that had not been generally disclosed at the time the Subscription Agreement was agreed to; and


(iii)	a description of the effect of the issuance of Preferred Shares on the direct or indirect voting interest of Roivant in the Company are set forth above under the heading “The Private Placement - Reasons for the Private Placement”.

Arrangements Between the Company and Shareholders

Other than the Subscription Agreement and the related agreements to be entered into pursuant thereto described under the heading “The Private Placement”, there is no agreement, commitment or understanding made by the Company, or, to the Company’s knowledge, made by a Shareholder of the Company, relating to the Private Placement.

Material Changes

Other than the closing of the Private Placement and the other matters disclosed in this Proxy Statement/Circular, the Company is not aware of any plans or proposals for material changes in the affairs of the Company.

INTEREST OF CERTAIN PERSONS OR COMPANIES IN MATTERS TO BE ACTED UPON

Excluding the Preferred Shares, Roivant is the beneficial owner of 29.1% of Arbutus’ issued and outstanding Common Shares. Assuming no changes to the capital structure of the Company, following the conversion of the 500,000 Preferred Shares issued in connection with the First Tranche into Underlying Common Shares, Roivant would own 39.8% of the Company’s issued and outstanding Common Shares. Chairman Vivek Ramaswamy and directors Keith Manchester and William Symonds were nominated by Roivant to serve on the Board pursuant to the Governance Agreement dated January 11, 2015, between Arbutus and Roivant. As of the date hereof, Mr. Ramaswamy is the Chief Executive Officer and a director of Roivant, Mr. Manchester is a director of Roivant and Mr. Symonds is Roivant's Chief Development Officer. In September 2016, director Frank Karbe was appointed CFO at Myovant Sciences Ltd., which is an affiliate of Roivant. In addition, Messrs. Ramaswamy and Symonds own shares of Roivant. The foregoing disclosure in this paragraph is based upon information supplied by the named directors and executive officers. For further details see “The Private Placement”.

The Board established the Special Committee, comprised of Richard Henriques (Chair), Daniel Burgess, and Herbert Conrad, each of whom is an independent director, to review the Private Placement and provide a recommendation to the full Board. For further details see “The Private Placement - Special Committee Review”.

INTERESTS OF INFORMED PERSONS IN MATERIAL TRANSACTIONS

Roivant is an “informed person” (as defined in National Instrument 51-102 - Continuous Disclosure Obligations) as a result of beneficially owning more than 10% of the voting rights attached to Arbutus’ issued and outstanding Common Shares. Chairman Vivek Ramaswamy and directors Keith Manchester and William Symonds were nominated by Roivant to serve on the Board pursuant to the Governance Agreement dated January 11, 2015, between Arbutus and Roivant. As of the date hereof, Mr. Ramaswamy is the Chief Executive Officer and a director of Roivant, Mr. Manchester is a director of Roivant and Mr. Symonds is Roivant's Chief Development Officer. In September 2016, director Frank Karbe was appointed CFO at Myovant Sciences Ltd., which is an affiliate of Roivant. In addition, Messrs. Ramaswamy and Symonds own shares of Roivant. Each of Messrs. Ramaswamy, Manchester, Symonds and Karbe is an “informed person” (as defined in National Instrument 51-102 - Continuous Disclosure Obligations) of the Company by virtue of being a director of the Company. Roivant and Mr. Ramaswamy have a material interest in the Private Placement and the Private Placement would materially affect the Company. The material terms of the Private Placement and Roivant’s and Mr. Ramaswamy’s interests therein are described under the heading “The Private Placement”. The address of Roivant and Mr. Ramaswamy is Suite 1, 3rd Floor, 11-12 St. James Square, London, SW1Y 4LB, United Kingdom. The foregoing disclosure in this paragraph is based upon information supplied by the named directors and executive officers.

To the Company’s knowledge, no “informed person” (as defined in National Instrument 51-102 - Continuous Disclosure Obligations) or any associate or affiliate of any such informed person had any material interest, direct or indirect, in any transaction or proposed transaction which has materially affected or would materially affect the Company or any of its subsidiaries since the beginning of the most recently completed financial year, other than as set out herein.

MANAGEMENT CONTRACTS

There are no management functions of the Company which are performed by an individual or company other than the directors or executive officers of the Company or a subsidiary.

ADDITIONAL INFORMATION

Additional information relating to Arbutus, including Arbutus’ most current Annual Report on Form 10-K for the fiscal year ended December 31, 2016, the comparative consolidated financial statements of Arbutus for the fiscal year ended December 31, 2016, together with the report of the independent auditor thereon and management’s discussion and analysis of Arbutus’ financial condition and results of operations for fiscal 2016 which provide financial information concerning Arbutus can be found on the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com or on the website of the SEC at www.sec.gov. Copies of those documents, as well as any additional copies of this Proxy Statement/Circular, are available at no cost upon written request to the Corporate Secretary, 100-8900 Glenlyon Parkway Burnaby, British Columbia V5J 5J8. Additionally, the reports and other information filed by us with the SEC can be inspected on the SEC’s website at www.sec.gov and such information can also be inspected and copies ordered at the public reference facilities maintained by the SEC at the following location: 100 F Street NE, Washington, D.C. 20549.

SOLICITATION OF PROXIES

We pay for preparing, printing and mailing this Proxy Statement/Circular. Our directors, executive officers and employees may, without additional compensation, solicit proxies in person or by e-mail, telephone, fax or special letter. We will reimburse banks, brokers and other custodians, nominees and fiduciaries for their costs of sending the proxy materials to our Beneficial Shareholders.

AUDITOR OF THE COMPANY AND THEIR ATTENDANCE AT THE MEETING

Representatives from KPMG, our independent auditor for the current fiscal year and the most recently completed fiscal year, are not expected to be present at the Meeting, and consequently, they will not have the opportunity to make a statement if they desire to do so, and they are not expected to be available to respond to appropriate questions.

INCORPORATION BY REFERENCE

The SEC allows us to “incorporate by reference” information we file with the SEC. This means that we can disclose important information to you by referring you to those documents.

Pursuant to Item 13(a) of Schedule 14A of the Exchange Act, we incorporate by reference into this Proxy Statement/Circular the financial statements meeting the requirements of Regulation S-X of the Exchange Act (including all notes and related schedules), supplementary financial information, management's discussion and analysis of financial condition and results of operations, and quantitative and qualitative disclosures about market risk, included in the documents listed below:



	(a)	our Annual Report on Form 10-K for the year ended December 31, 2016, filed with the SEC on March 22, 2017, as amended on Form 10-K/A on May 17, 2017; and



	(b)	our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2017, filed on May 4, 2017; June 30, 2017, filed on August 3, 2017; and September 30, 2017, filed on November 2, 2017.

In addition, to the extent that they include information required under Item 13(a), all registration statements filed by us under the Securities Act, annual or other reports filed under Sections 13(a) or 15(d) of the Exchange Act, and proxy and information statements filed under Section 14 of the Exchange Act, after the date of this Proxy Statement/Circular but before the Meeting, are hereby incorporated by reference into this Proxy Statement/Circular.

We have not authorized anyone to provide you with any different or additional information other than that contained in or incorporated by reference into this Proxy Statement/Circular. We take no responsibility for, and can provide no assurance as to the reliability of, any information that others may provide.

Any statement contained in a document incorporated or deemed to be incorporated by reference into this Proxy Statement/Circular will be deemed to be modified or superseded for purposes of this Proxy Statement/Circular to the extent that a statement contained in this Proxy Statement/Circular or any other subsequently filed document that is deemed to be incorporated by reference into this Proxy Statement/Circular modifies or supersedes the statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this Proxy Statement/Circular.

The documents incorporated by reference into this Proxy Statement/Circular are available from us. We will provide a copy of any and all of the information that is incorporated by reference into this Proxy Statement/Circular to any person, including a beneficial owner, to whom a Proxy Statement/Circular is delivered, without charge, upon written or oral request, and by first class mail or other equally prompt means, within one business day of receipt of such request. If exhibits to the documents incorporated by reference into this Proxy Statement/Circular are not themselves specifically incorporated by reference in this Proxy Statement/Circular, then the exhibits will not be provided.

You may read and copy any document we file at the SEC’s public reference room at 100 F Street, N.E., Washington D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on its public reference room. Our SEC filings are also available to the public from the SEC’s web site at http://www.sec.gov.

Requests for any of these documents should be directed to:

Investor Relations

Arbutus Biopharma Corporation

100-8900 Glenlyon Parkway,

Burnaby, BC V5J 5J8

(604) 419-3200

APPROVAL OF MANAGEMENT PROXY CIRCULAR AND PROXY STATEMENT

The contents and mailing to Shareholders of this Proxy Statement/Circular have been approved by the Board.

/s/ Richard Henriques

Richard Henriques, Chair of the Special Committee

Vancouver, British Columbia

December 6, 2017

EXHIBIT A

ARBUTUS BIOPHARMA CORPORATION

SUBSCRIPTION AGREEMENT FOR PREFERRED SHARES

TO: ARBUTUS BIOPHARMA CORPORATION

The undersigned (the Subscriber) hereby irrevocably subscribes for and agrees to purchase from Arbutus Biopharma Corporation (the Company) that number of preferred shares in the capital of the Company (the Preferred Shares) set out below for the aggregate subscription amount set out below, representing a subscription price per Preferred Share of $100.00 (the Subscription Price), on the terms and subject to the conditions set out in this Subscription Agreement (as defined below). The Subscriber agrees to be bound by the terms and conditions set forth in the attached “Terms and Conditions of Subscription for Preferred Shares”.

SUBSCRIPTION AND SUBSCRIBER INFORMATION

Please print all information (other than signatures), as applicable, in the space provided below



Roivant Sciences Ltd.		Number of Tier 1 Preferred Shares: 500,000
(Name of Subscriber)
		Tier 1 Subscription Amount: $50,000,000 (calculated as number of Tier 1 Preferred Shares divided by Subscription Price)

		Number of Tier 2 Preferred Shares: 664,000
Account Reference (if applicable):
By: /s/Marianne L. Romeo		Tier 2 Subscription Amount: $66,400,000 (calculated as number of Tier 2 Preferred Shares divided by Subscription Price)
Authorized Signature

Head, Global Transactions & Risk Management (Official Capacity or Title - if the Subscriber is not an individual) (Name of individual whose signature appears above if different than the name of the subscriber printed above.) Suite 1, 3rd Floor, 11-12 St. James Square (Subscriber’s Address, including Municipality and State) London, SW1Y 4LB, United Kingdom info@roivant.com (Telephone Number)(Email Address)

Account Registration Information: (Name) (Account Reference, if applicable) (Address, including Postal Code)		Delivery Instructions as set forth below: (Name) (Account Reference, if applicable) (Address) (Contact Name)(Telephone Number)
		Number and kind of securities of the Company held, directly or indirectly, if any: 16,013,540 Common Shares

A-1

TERMS AND CONDITIONS OF SUBSCRIPTION

FOR PREFERRED SHARES

ARTICLE 1 - INTERPRETATION

1.1 Definitions

Whenever used in this Subscription Agreement, unless there is something in the subject matter or context inconsistent therewith, the following words and phrases shall have the respective meanings ascribed to them as follows:

Amending Agreements means, collectively, the Governance Agreement Amending Agreement, the Lock-Up Amending Agreement, the Registration Rights Amending Agreement and the Standstill Amending Agreement.

Arbutus Inc. means Arbutus Biopharma, Inc., a company incorporated pursuant to the laws of Delaware.

Articles of Amendment means the amendment of the articles of the Company to reflect, inter alia, the Subscriber Board Designation Right.

Business Day means a day other than a Saturday, Sunday or any other day on which the principal chartered banks located in Vancouver, British Columbia are not open for business.

Code means the Internal Revenue Code of 1986, as amended.

Common Shares means the common shares in the capital of the Company.

Company shall have the meaning ascribed to such term on the face page of this Subscription Agreement and includes any successor corporation to or of the Company.

Company Board means the board of directors of the Company as the same is constituted from time to time.

Company Circular means the notice of the Company Meeting to be sent to Shareholders and the management information circular to be prepared in connection with the Company Meeting together with any amendments thereto or supplements thereof, and any other information circular or proxy statement which may be prepared in connection with the Company Meeting.

Company IP means the Proprietary Rights owned by the Company disclosed by the Company in writing to the Subscriber concurrently herewith and identified as "Company IP".

Company Meeting means the special meeting of Shareholders to be held as soon as reasonably practicable to consider and seek, among other things, the Company Shareholder Approval, and any adjournment or postponements thereof held in accordance with the Company’s constating documents and Securities Laws.

Company Options means, at any time, stock options to acquire Common Shares granted under the Company’s Share and Omnibus Incentive Plans and similar plans, or otherwise, which are, at such time, outstanding and unexercised, whether or not vested.

Company Shareholder Approval means: (i) a special resolution of Shareholders approving the Articles of Amendment; (ii) the “minority approval” of the MI 61-101 Resolution, in accordance with MI 61-101; and (iii) if required by NASDAQ, the approval by the holders of Common Shares to the issuance by the Company of the Tier 2 Preferred Shares under the applicable NASDAQ rules, in each case to be sought at the Company Meeting.

Employee Benefit Plan has the meaning ascribed thereto in Section 5.1(iii).

Environmental Approvals means all permits, certificates, authorizations, approvals, orders, consents, instructions, registrations, directions, decisions, decrees, conditions, notifications, demands, filings, licenses or permits whether or not having the force of Law, issued by any Governmental Entity pursuant to any Environmental Laws.

Environmental Laws means all applicable Laws whether foreign or domestic, including applicable common law, relating to the protection of the environment and employee and public health and safety, and for the regulation of contaminants, pollutants, waste, toxic and hazardous substances and includes Environmental Approvals.

A-2

ERISA has the meaning ascribed thereto in Section 5.1(iii).

ERISA Affiliate has the meaning ascribed thereto in Section 5.1(iii).

Evaluation Date has the meaning ascribed thereto in Section 5.1(w).

Fundamental Company Representations and Warranties means those representations and warranties of the Company in Sections 5.1(a), 5.1(b), 5.1(c), 5.1(d), 5.1(e), 5.1(f), 5.1(g), 5.1(h), 5.1(j), 5.1(q), 5.1(z), 5.1(aa), 5.1(dd), 5.1(oo), 5.1(qq), 5.1(ss), 5.1(xx), 5.1(yy) and 5.1(ccc).

Fundamental Subscriber Representations and Warranties means those representations and warranties of the Purchaser in Sections 6.1(a), 6.1(b), 6.1(e), 6.1(g), 6.1(h) and 6.1(k).

GAAP has the meaning ascribed thereto in Section 5.1(r).

Governance Agreement means that certain Governance Agreement, dated as of January 11, 2015, by and between the Company and the Subscriber.

Governance Agreement Amendment has the meaning ascribed thereto in Section 5.4(g)(ii), as affected by the Governance Agreement Amending Agreement.

Governance Agreement Amending Agreement means the amending agreement dated effective as of the Tier 1 Closing Date, in substantially the form attached hereto as Schedule “D”.

Governmental Entity means any applicable: (i) multinational, federal, provincial, state, regional, municipal, local or other government, governmental or public department, central bank, court, tribunal, arbitral body, commission, board, bureau, stock exchange or agency, whether domestic or foreign, (ii) any subdivision, agency, commission, board or authority of any of the foregoing, or (iii) any quasi governmental or private body exercising any regulatory, expropriation or taxing authority under or for the account of any of the foregoing.

Independence Standards means the standards set forth in NASDAQ Marketplace Rule 4200(a)(15) or any successor rule thereto, but not including the requirements for audit committee members set forth in NASDAQ Marketplace Rule 4350(d).

Laws means all laws, by-laws, rules, regulations, orders, ordinances, protocols, codes, guidelines, instruments, policies, notices, directions and judgments or other requirements of any Governmental Entity whether foreign or domestic.

Licensed IP means the Proprietary Rights wholly-owned or co-owned by any person other than the Company as disclosed by the Company in writing to the Subscriber concurrently herewith and identified as "Licensed IP".

Licenses has the meaning ascribed thereto in Section 5.1(gg).

Lien means any encumbrance or title defect of whatever kind or nature, regardless of form, whether or not registered or registerable and whether or not consensual or arising by law (statutory or otherwise), including any mortgage, lien, charge, pledge or security interest, whether fixed or floating, or any assignment, lease, option, right of pre-emption, privilege, encumbrance, easement, servitude, right of way, restrictive covenant, right of use or any other right or claim of any kind or nature whatever which affects ownership or possession of, or title to, any interest in, or the right to use or occupy such property or assets.

Lock-Up Amending Agreement means amended and restated lock-up agreement dated effective as of the Tier 1 Closing Date, in substantially the form attached hereto as Schedule “E”.

Material Adverse Effect means, with respect to any entity, any event, circumstance, development, change or effect on the business, operations or capital of such entity that would reasonably expected to be materially adverse to the condition (financial or otherwise), assets, properties, capital, liabilities (contingent or otherwise), business or operations of such entity and its subsidiaries, on a consolidated basis, except to the extent that such event, circumstance, development, change or effect results from or is caused by: (i) worldwide, national or local conditions or circumstances whether they are economic, political, regulatory or otherwise, including war, armed hostilities, acts of terrorism, emergencies, crises and natural disasters, (ii) changes affecting the worldwide biopharmaceutical industry in general and which does not have a disproportionate effect on such entity as compared to other industry participants, (iii) the announcement of this Subscription Agreement and the Offering contemplated by it, or (iv) any act or omission of such entity taken with the prior consent or at the request of the Subscriber.

A-3

MI 61-101 means Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions.

MI 61-101 Resolution means the resolution in respect of (i) the issuance by the Company of the Tier 2 Preferred Shares to be considered at the Company Meeting and (ii) the Articles of Amendment, in substantially the form attached hereto as Schedule “A”.

NASDAQ means the NASDAQ Global Market (or its successor); provided, that if the Company moves the principal listing of its Common Shares to the NASDAQ Global Select Market, NASDAQ Capital Market or The New York Stock Exchange (or any of their respective successors), “NASDAQ” shall be deemed to refer to such exchange.

Offered Shares means the Preferred Shares offered to the Subscriber under the Offering pursuant to this Subscription Agreement.

Offering means the private placement of the Offered Shares.

Order means any order, decision, judgment, writ, injunction, decree, award or other determination of any Governmental Entity whether foreign or domestic.

Parties mean the Company and the Subscriber, and Party means either of them, as the context requires.

person means any individual (whether acting as an executor, trustee administrator, legal representative or otherwise), corporation, firm, partnership, sole proprietorship, syndicate, joint venture, trustee, trust, unincorporated organization or association, and pronouns have a similar extended meaning.

Preferred Shares shall have the meaning ascribed to such term on the face page of this Subscription Agreement, having such rights and restrictions substantially as set out in Schedule “B” hereto.

Proprietary Rights means any intellectual property and the technology used in the course of the Company’s business and which is material to the Company’s business, taken as a whole, including; (i) all inventions·(whether patentable or unpatentable and whether or not reduced to practice), all improvements thereto, and all patents and published patent applications, together with all reissue, divisional, continuation or continuation-in-part applications, revisions, extensions and re-examinations thereof, (ii) all trademarks, trade dress, logos, trade-names, business names, corporate names and domain names together with all translations, adaptions, derivations and combinations thereof and including all goodwill associated therewith; (iii) all copyrightable works, all copyrights, and all applications, registrations and renewals associated therewith; (iv) all proprietary or confidential information and trade-secrets and know-how, (v) all software; (vi) any copies and tangible embodiments of the foregoing (in whatever form or medium);(vii) all registrations, applications and renewals for any of the intellectual property and the technology referred to above; and (viii) all common law statutory and contractual rights to the intellectual property and the technology referred to above.

Protiva means Protiva Biotherapeutics Inc., a company incorporated pursuant to the laws of British Columbia.

Public Record means all press releases, forms, reports, schedules, financial statements, management’s discussions and analysis of financial conditions and operations, certifications, annual information forms, management information circulars, material change reports and other documents required to be filed by the Company since December 31, 2016 (such forms, reports, schedules, statements, certifications and other documents to include any financial statements or other documents, including any schedules included therein).

Registration Rights Agreement means that certain Registration Rights Agreement, dated as of January 11, 2015, by and among the Company and the Shareholders party thereto, as amended on November 2, 2015.

Registration Rights Amending Agreement means the amending agreement dated effective as of the Tier 1 Closing Date, in substantially the form attached hereto as Schedule “F”.

Registration Rights Amendment has the meaning ascribed thereto in Section 5.4(g)(i), as affected by the Registration Rights Amending Agreement.

Regulation D means Regulation D promulgated under the U.S. Securities Act.

SEC means the United States Securities and Exchange Commission.

SEC Reports has the meaning ascribed thereto in Section 5.1(eee).

A-4

Securities Laws means, as applicable, the securities Laws, regulations, rules, rulings and Orders in each of the provinces of Canada and the federal and state securities laws of the United States, all written instruments, rules, regulations and Orders and applicable policy statements having the force of law of the applicable securities regulatory authorities including, without limitation, the SEC, as well as the policies and rules of NASDAQ.

Shareholders means the holders from time to time of Common Shares or Preferred Shares, collectively or individually, as the context requires.

Standstill Agreement means the standstill agreement between the Company and the Subscriber dated January 11, 2015.

Standstill Amending Agreement means the amending agreement dated effective as of the Tier 1 Closing Date, in substantially the form attached hereto as Schedule “G”.

Subscriber means the subscriber for the Offered Shares as set out on the face page of this Subscription Agreement.

Subscriber Board Designation Right means the right of the Subscriber to nominate (and nominate any replacement should any of its nominees not be able to serve as a director for any reason) (i) three (3) out of seven (7) individuals for election to the Company Board, one (1) of whom shall satisfy the Independence Standards, at each meeting of Shareholders for so long as the Subscriber has a beneficial ownership equal to at least 30% of the outstanding Common Shares; (ii) two (2) out of seven (7) individuals for election to the Company Board at each meeting of Shareholders for so long as the Subscriber has a beneficial ownership equal to at least 20% of the outstanding Common Shares; and (iii) one (1) out of seven (7) individuals for election to the Company Board at each meeting of Shareholders for so long as the Subscriber has a beneficial ownership equal to at least 10% of the outstanding Common Shares; provided that the Subscriber’s percentage beneficial ownership of Common Shares shall be determined based on the sum of (i) the total number of Common Shares beneficially owned by the Subscriber in the form of Common Shares and (ii) the total number of Common Shares into which the Preferred Shares beneficially owned by the Purchaser are convertible, and outstanding Common Shares shall be determined based on the sum of (x) the number of outstanding Common Shares as of the date of determination and (y) the Underlying Common Shares.

Subscription Agreement means this subscription agreement (including any schedules hereto) and any instrument amending this Subscription Agreement.

Subscription Price shall have the meaning ascribed to such term on the face page of this Subscription Agreement, being $100.00 per Preferred Share.

Subsidiaries means the Company's wholly-owned subsidiaries as of the date hereof, being Arbutus Inc. and Protiva.

Tax and Taxes means all taxes, assessments, charges, dues, duties, rates, fees, imposts, levies and similar charges of any kind lawfully levied, assessed or imposed by any Governmental Entity, including any estimated taxes, deficiency assessments, additions to tax, penalties and interest.

Tax Returns means all returns, schedules, elections, declarations, reports, information returns, notices, forms, statements and other documents made, prepared or filed with any taxing authority or required to be made, prepared or filed with any taxing authority relating to Taxes, including any amendments, attachments and schedules with respect to any of the foregoing.

Tier 1 Closing shall have the meaning ascribed to such term in Section 4.1.

Tier 2 Closing shall have the meaning ascribed to such term in Section 4.4.

Tier 1 Closing Date shall have the meaning ascribed to such term in Section 4.1.

Tier 2 Closing Date shall have the meaning ascribed to such term in Section 4.4.

Tier 1 Closing Time shall have the meaning ascribed to such term in Section 4.1.

Tier 2 Closing Time shall have the meaning ascribed to such term in Section 4.4.

Tier 1 Preferred Shares has the meaning ascribed to such term on the face page of this Subscription Agreement, being 500,000 Preferred Shares.

A-5

Tier 2 Preferred Shares has the meaning ascribed to such term on the face page of this Subscription Agreement, being up to a maximum in the aggregate of 664,000 Preferred Shares.

Tier 1 Subscription Amount has the meaning ascribed to such term on the face page of this Subscription Agreement.

Tier 2 Subscription Amount has the meaning ascribed to such term on the face page of this Subscription Agreement.

Underlying Common Shares means the Common Shares that are issuable upon conversion of the Offered Shares.

United States means the United States of America, its territories and possessions, any State of the United States and the District of Columbia.

U.S. Exchange Act means the United States Securities Exchange Act of 1934, as amended.

U.S. Securities Act means the United States Securities Act of 1933, as amended.

1.2 Gender and Number

Words importing the singular number only shall include the plural and vice versa, words importing the masculine gender shall include the feminine gender and words importing persons shall include firms and corporations and vice versa.

1.3 Currency

The symbol “$” is expressed in United States dollars.

1.4 Subdivisions and Headings

The division of this Subscription Agreement into Articles, Sections, Schedules and other subdivisions and the inclusion of headings are for convenience of reference only and shall not affect the construction or interpretation of this Subscription Agreement. The headings in this Subscription Agreement are not intended to be full or precise descriptions of the text to which they refer. Unless something in the subject matter or context is inconsistent therewith, references herein to an Article, Section, Subsection, paragraph, clause or Schedule are to the applicable article, section, subsection, paragraph, clause or schedule of this Subscription Agreement.

ARTICLE 2 - SCHEDULES

2.1 Description of Schedules

The following are the Schedules attached to and incorporated in this Subscription Agreement by reference and deemed to be a part hereof:

Schedule “A” - Form of MI 61-101 Resolution

Schedule “B” - Preferred Share Rights and Restrictions

Schedule “C” - Opinions of Company’s Counsel

Schedule “D” - Governance Agreement Amending Agreement

Schedule “E” - Lock-Up Amending Agreement

Schedule “F” - Registration Rights Amending Agreement

Schedule “G” - Standstill Amending Agreement

ARTICLE 3 - SUBSCRIPTION

3.1 Subscription for Tier 1 Preferred Shares

(a)

The Subscriber hereby commits, subject only to the satisfaction or written waiver by the Subscriber of the conditions precedent set forth in Section 4.2, to subscribe for and purchase the Tier 1 Preferred Shares from the Company for the Tier 1 Subscription Amount payable as described in Section 3.3(a), which, upon acceptance by the Company, will constitute a binding commitment by the Company, subject only to the satisfaction or written waiver by the Company of the conditions precedent set forth in Section 4.3, to issue to the Subscriber the Tier 1 Preferred Shares, all on the terms and subject to the conditions set out in this Subscription Agreement.

A-6


(b)	The Tier 1 Preferred Shares will be issued and registered in the name of the Subscriber as per the instructions on page 1 of this Subscription Agreement without registration of the Tier 1 Preferred Shares under the U.S. Securities Act or qualified by prospectus under any Securities Law.

3.2 Subscription for Tier 2 Preferred Shares

(a)

The Subscriber hereby commits, subject only to the satisfaction or written waiver by the Subscriber of the conditions precedent set forth in Section 4.5, to subscribe for and purchase the Tier 2 Preferred Shares from the Company for the Tier 2 Subscription Amount payable as described in Section 3.3(b), which, upon acceptance by the Company, will constitute a binding commitment by the Company, subject only to the satisfaction or written waiver by the Company of the conditions precedent set forth in Section 4.6, to issue to the Subscriber the Tier 2 Preferred Shares, all on the terms and subject to the conditions set out in this Subscription Agreement.

(b)

If the conditions for the purchase and sale of the Tier 2 Preferred Shares are satisfied (or waived by the Party entitled to do so), the Tier 2 Preferred Shares will be issued and registered in the name of the Subscriber as per the instructions on page 1 of this Subscription Agreement without registration of the Tier 1 Preferred Shares under the U.S. Securities Act or qualified by prospectus under any Securities Law.

3.3 Payment for Preferred Shares


(a)	The Tier 1 Subscription Amount shall be paid at the Tier 1 Closing Time by a direct funds transfer or a wire transfer to the Company arranged with the Company in advance.


(b)	The Tier 2 Subscription Amount shall be paid at the Tier 2 Closing Time by a direct funds transfer or a wire transfer to the Company arranged with the Company in advance.

ARTICLE 4 - CLOSINGS

4.1 Tier 1 Closing

Subject to the receipt of all completed documentation in accordance with Sections 4.2 and 4.3, the delivery and sale of the Tier 1 Preferred Shares will be completed (the Tier 1 Closing) at the offices of the Company’s counsel, Farris, Vaughn, Wills & Murphy LLP, in Vancouver, British Columbia at 6:30 a.m. (Vancouver time) (the Tier 1 Closing Time) on the second (2^nd) Business Day following the performance and satisfaction of the terms and conditions contained in Sections 4.2 and 4.3 of this Subscription Agreement (the date of such closing, the Tier 1 Closing Date), or such other place, date or time as the Company and the Subscriber may agree.

If, prior to or at the Tier 1 Closing Time, the terms and conditions contained in Sections 4.2 and 4.3 of this Subscription Agreement have been complied with to the satisfaction of the Subscriber and the Company, respectively, each acting reasonably, or waived by the Subscriber and the Company, as the case may be, the Subscriber shall deliver to the Company at the Tier 1 Closing Time (i) a direct funds transfer or wire transfer in satisfaction of the Tier 1 Subscription Amount for the Tier 1 Preferred Shares, against delivery by the Company of one or more certificates representing the Tier 1 Preferred Shares registered in the name of the Subscriber and bearing an appropriate legend (as set forth herein) referring to the fact that the Tier 1 Preferred Shares were sold in reliance upon an exemption from (x) registration under the U.S. Securities Act and (y) the prospectus requirement of applicable Securities Law in British Columbia, but otherwise free and clear of all restrictive or other legends or statements or, if the Tier 1 Preferred Shares are entered in a direct registration system, the written notice of such entry; (ii) executed counterparts to the Amending Agreements; and (iv) such other documentation as may be required pursuant to this Subscription Agreement. For certainty, any certificate or notice of entry into a direct registration system shall bear any legends required by the U.S. Securities Act or other Securities Laws, including the legend set forth in Section 6.2(g) hereof.

4.2 Subscriber’s Conditions to Tier 1 Closing

The Company acknowledges and agrees that the obligations of the Subscriber hereunder are conditional on the accuracy in all material respects of the representations and warranties of the Company contained in this Subscription Agreement as of the date of this Subscription Agreement, and as of the Tier 1 Closing Time as if made at and as of the Tier 1 Closing Time (except with respect to representations and warranties which relate to a specific date, in which case such representations and warranties shall be materially accurate as of such date), and the fulfillment of the following additional conditions as soon as reasonably practicable and in any event not later than the Tier 1 Closing Time:

A-7


(a)	the Subscriber shall have received a written waiver from the Company of the provisions of the Standstill Agreement that would otherwise prohibit the execution of this Subscription Agreement or the consummation of the transactions contemplated hereby, including the Subscriber’s acquisition of the Tier 1 Preferred Shares;


(b)	the Subscriber having received evidence, in a form satisfactory to the Subscriber and its legal counsel, acting reasonably, of the alteration to the Company’s constating documents to reflect the Preferred Shares rights and restrictions substantially as set out in Schedule “B”;


(c)	the Subscriber having received an opinion from the Company’s counsel as to the matters set out in Schedule “C”;


(d)	the Subscriber and its legal counsel receiving a certificate from the Company, in form and substance acceptable to the Subscriber and its legal counsel, acting reasonably, dated the Tier 1 Closing Date signed by the Chief Executive Officer or Chief Financial Officer (or such other officer(s) acceptable to the Subscriber) certifying:


i.	the constating documents of the Company;

ii.

the resolutions of the Company Board and the ad hoc independent committee of the Company Board (comprised of all of the members of the Audit Committee of the Company) and any other corporation authorization related to the Offering, the allotment and sale of the Tier 1 Preferred Shares, the reservation of the Underlying Common Shares, the authorization of this Subscription Agreement, the Amending Agreements and the other agreements and transactions contemplated by this Subscription Agreement; and


iii.	the incumbency and signatures of signing officers of the Company;


(e)	the Subscriber and its legal counsel receiving certificates of good standing and/or compliance (or the equivalent) from the Company with respect to the Company and each Subsidiary, in each case dated no earlier than two (2) Business Days prior to the Tier 1 Closing Date;


(f)	the Subscriber and its legal counsel receiving confirmation from the Company's duly appointed registrar and transfer agent for the Common Shares dated no earlier than two (2) Business Days prior to the Tier 1 Closing Date as to the issued and outstanding Common Shares;

(g)

all covenants, agreements and conditions contained in this Subscription Agreement to be performed by the Company on or prior to the Tier 1 Closing Date shall have been performed or complied with in all material respects, and the Subscriber and its legal counsel shall have received a certificate from the Company in form and substance acceptable to the Subscriber and its legal counsel, acting reasonably, dated the applicable date signed by the Chief Executive Officer and the Chief Financial Officer of the Company in each case certifying for and on behalf of the Company, as the case may be, and not in their personal capacities, after having made due inquiries, with respect to the following matters:


i.	the Company having complied with all the covenants in all material respects (or, if qualified by materiality, in all respects) and satisfied all the terms and conditions of this Subscription Agreement on its part to be complied with and satisfied at or prior to the Tier 1 Closing Time;


ii.	there being no Order having the effect of prohibiting the sale of the Tier 1 Preferred Shares or any of the Company’s issued securities, and no proceeding for such purpose being pending or, to the Company’s knowledge, threatened under any applicable Securities Laws; and

iii.

the representations and warranties of the Company contained in this Subscription Agreement and in any certificates of the Company delivered pursuant to or in connection with this Subscription Agreement being true and correct in all material respects (or, if qualified by materiality, in all respects) at the Tier 1 Closing Time, with the force and effect as if made on and as at such Tier 1 Closing Time, except for such representations and warranties which are in respect of a specific date in which case such representations and warranties shall be true and correct, in all material respects (or, if qualified by materiality, in all respects), as of such date;


(h)	the Subscriber not having exercised any rights of termination set forth in Sections 8.1 or 8.3 hereof;


(i)	there being no Order having the effect of prohibiting the sale of the Tier 1 Preferred Shares or any of the Company’s issued securities, and no proceeding for such purpose being pending or, to the Company’s knowledge, threatened under any applicable Securities Laws; and

A-8


(j)	the Company having obtained all necessary approvals and consents required for the Company to consummate the transactions contemplated herein to be consummated at the Tier 1 Closing, including from NASDAQ with respect to the listing of the Underlying Common Shares on such exchange, all of which shall be and remain so long as necessary in full force and effect.

4.3 Company’s Conditions to Tier 1 Closing

The Subscriber acknowledges and agrees that the obligations of the Company hereunder are conditional on the accuracy in all material respects of the representations and warranties of the Subscriber contained in this Subscription Agreement as of the date of this Subscription Agreement, and as of the Tier 1 Closing Time as if made at and as of the Tier 1 Closing Time (except with respect to representations and warranties which relate to a specific date, in which case such representations and warranties shall be materially accurate as of such date), and the fulfillment of the following additional conditions as soon as reasonably practicable and in any event not later than the Tier 1 Closing Time:

(a)

the (i) sale of the Tier 1 Preferred Shares by the Company to the Subscriber being exempt from the requirements as to the filing of a prospectus and as to the preparation of an offering memorandum or similar document contained in any applicable Securities Laws or upon the issuance of such Orders, consents or approvals as may be required to permit such sale without the requirement of filing a prospectus or delivering an offering memorandum or similar document and (ii) offer and sale of the Tier 1 Preferred Shares being exempt from the registration requirements of the U.S. Securities Act and applicable Securities Laws;


(b)	the sale of the Tier 1 Preferred Shares by the Company to the Subscriber being exempt from the formal valuation and minority approval requirements set out in MI 61-101;


(c)	there being no Order having the effect of prohibiting the sale of the Tier 1 Preferred Shares or any of the Company’s issued securities, and no proceeding for such purpose being pending or, to the Company’s knowledge, threatened under any applicable Securities Laws;


(d)	all covenants, agreements and conditions contained in this Subscription Agreement to be performed by the Subscriber on or prior to the Tier 1 Closing Date shall have been performed or complied with in all material respects;


(e)	the Company not having exercised any rights of termination set forth in Sections 8.2 or 8.3 hereof;

(f)

the Subscriber having delivered to the Company payment by direct funds transfer or wire transfer in satisfaction of the Tier 1 Subscription Amount for the Tier 1 Preferred Shares and having properly completed, signed and delivered any further documentation as required under the Securities Laws, which the Subscriber covenants and agrees to do on or prior to the Tier 1 Closing Time on the Tier 1 Closing Date upon the prior written request by the Company; and


(g)	the Company having obtained all necessary approvals and consents required for the Company to consummate the transactions contemplated herein to be consummated at the Tier 1 Closing, including from NASDAQ to the extent required with respect to the listing of the Underlying Common Shares on such exchange, all of which shall be and remain so long as necessary in full force and effect.

4.4 Tier 2 Closing

Subject to the receipt of all completed documentation in accordance with Sections 4.5 and 4.6, the delivery and sale of the Tier 2 Preferred Shares will be completed (the Tier 2 Closing) at the offices of the Company’s counsel, Farris, Vaughn, Wills & Murphy LLP, in Vancouver, British Columbia at 6:30 a.m. (Vancouver time) (the Tier 2 Closing Time) on the second (2^nd) Business Day following the performance and satisfaction of the terms and conditions contained in Sections 4.5 and 4.6 of this Subscription Agreement (the date of such closing, the Tier 2 Closing Date), or such other place, date or time as the Company and the Subscriber may agree.

If, prior to or at the Tier 2 Closing Time, the terms and conditions contained in Sections 4.5 and 4.6 of this Subscription Agreement have been complied with to the satisfaction of the Subscriber and the Company, respectively, each acting reasonably, or waived by the Subscriber and the Company, as the case may be, the Subscriber shall deliver to the Company at the Tier 2 Closing Time (i) a direct funds transfer or wire transfer in satisfaction of the Tier 2 Subscription Amount for the Tier 2 Preferred Shares against delivery by the Company of one or more certificates representing the Tier 2 Preferred Shares registered in the name of the Subscriber and bearing an appropriate legend (as set forth herein) referring to the fact that the Tier 2 Preferred Shares were sold in reliance upon an exemption from (x) registration under the U.S. Securities Act and (y) the prospectus requirement of applicable Securities

A-9

Law in British Columbia, but otherwise free and clear of all restrictive or other legends or statements or, if the Tier 2 Preferred Shares are entered in a direct registration system, the written notice of such entry; and (ii) such other documentation as may be required pursuant to the Subscription Agreement. For certainty, any certificate or notice of entry into a direct registration system shall bear any legends required by the U.S. Securities Act or other Securities Laws, including the legend set forth in Section 6.2(g) hereof.

4.5 Subscriber’s Conditions to Tier 2 Closing

The Company acknowledges and agrees that the obligations of the Subscriber hereunder are conditional on the accuracy in all material respects of the Fundamental Company Representations and Warranties as of the date of this Subscription Agreement, and as of the Tier 2 Closing Time as if made at and as of the Tier 2 Closing Time (except with respect to such representations and warranties which relate to a specific date, in which case such representations and warranties shall be materially accurate as of such date), except for any inaccuracy, individually or in the aggregate, that would not result in a Material Adverse Effect on the Company, and the fulfillment of the following additional conditions as soon as reasonably practicable and in any event not later than the Tier 2 Closing Time:


(a)	the Subscriber receiving a written waiver from the Company of the provisions of the Standstill Agreement that would otherwise prohibit the execution of this Subscription Agreement or the consummation of the transactions contemplated hereby, including the Subscriber’s acquisition of the Tier 2 Preferred Shares;


(b)	the Company obtaining the Company Shareholder Approval at the Company Meeting;


(c)	the Company adopting and filing the Articles of Amendment with the applicable Governmental Entity;


(d)	the Subscriber receiving an opinion from the Company’s counsel as to the matters set out in Schedule “C”;


(e)	the Subscriber and its legal counsel receiving a certificate from the Company, in form and substance acceptable to the Subscriber and its legal counsel, acting reasonably, dated the Tier 2 Closing Date signed by the Chief Executive Officer or Chief Financial Officer (or such other officer(s) acceptable to the Subscriber) certifying:


(i)	the constating documents of the Company;

(ii)

the resolutions of the Company Board and the ad hoc independent committee of the Company Board (comprised of all of the members of the Audit Committee of the Company) and any other corporation authorization related to the Offering, the allotment and sale of the Tier 2 Preferred Shares, the reservation of the Underlying Common Shares, the authorization of this Subscription Agreement, and the other agreements and transactions contemplated by this Subscription Agreement; and


(iii)	the incumbency and signatures of signing officers of the Company;


(f)	the Subscriber and its legal counsel receiving certificates of good standing and/or compliance (or the equivalent) from the Company with respect to the Company and each Subsidiary, in each case dated no earlier than two (2) Business Days prior to the Tier 2 Closing Date;


(g)	the Subscriber and its legal counsel receiving confirmation from the Company's duly appointed registrar and transfer agent for the Common Shares and Preferred Shares dated no earlier than two (2) Business Days prior to the Tier 2 Closing Date as to the issued and outstanding Common Shares and Preferred Shares;

(h)

all covenants, agreements and conditions contained in this Subscription Agreement to be performed by the Company on or prior to the Tier 2 Closing Date shall have been performed or complied with in all material respects, and the Subscriber and its legal counsel shall have received a certificate from the Company in form and substance acceptable to the Subscriber and its legal counsel, acting reasonably, dated the applicable date signed by the Chief Executive Officer and the Chief Financial Officer of the Company in each case certifying for and on behalf of the Company, as the case may be, and not in their personal capacities, after having made due inquiries, with respect to the following matters:


(i)	the Company having complied with all the covenants in all material respects (or, if qualified by materiality, in all respects) and satisfied all the terms and conditions of this Subscription Agreement on its part to be complied with and satisfied at or prior to the Tier 2 Closing Time;

A-10


(ii)	there being no Order having the effect of prohibiting the sale of the Tier 2 Preferred Shares or any of the Company’s issued securities, and no proceeding for such purpose being pending or, to the Company’s knowledge, threatened under any applicable Securities Laws; and

(iii)

the Fundamental Company Representations and Warranties contained in this Subscription Agreement and in any certificates of the Company delivered pursuant to or in connection with this Subscription Agreement being true and correct in all material respects (or, if qualified by materiality, in all respects) at the Tier 2 Closing Time, with the force and effect as if made on and as at such Tier 2 Closing Time, except for such representations and warranties which are in respect of a specific date in which case such representations and warrantied shall be true and correct, in all material respects (or, if qualified by materiality, in all respects), as of such date, except for any inaccuracy, individually or in the aggregate, that would not result in a Material Adverse Effect on the Company;


(i)	the Subscriber not having exercised any rights of termination set forth in Sections 8.1 or 8.3 hereof;


(j)	there being no Order having the effect of prohibiting the sale of the Tier 2 Preferred Shares or any of the Company’s issued securities, and no proceeding for such purpose being pending or, to the Company’s knowledge, threatened under any applicable Securities Laws; and


(k)	the Company having obtained all necessary approvals and consents required for the Company to consummate the transactions contemplated herein to be consummated at the Tier 2 Closing, including from NASDAQ to the extent required with respect to the listing of the Underlying Common Shares on such exchange.

4.6 Company’s Conditions to Tier 2 Closing

The Subscriber acknowledges and agrees that the obligations of the Company hereunder are conditional on the accuracy in all material respects of the Fundamental Subscriber Representations and Warranties as of the date of this Subscription Agreement, and as of the Tier 2 Closing Time as if made at and as of the Tier 2 Closing Time (except with respect to such representations and warranties which relate to a specific date, in which case such representations and warranties shall be materially accurate as of such date), and the fulfillment of the following additional conditions as soon as reasonably practicable and in any event not later than the Tier 2 Closing Time:


(a)	the Company obtaining the Company Shareholder Approval at the Company Meeting;

(b)

the (i) sale of the Tier 2 Preferred Shares by the Company to the Subscriber being exempt from the requirements as to the filing of a prospectus and as to the preparation of an offering memorandum or similar document contained in any applicable Securities Laws or upon the issuance of such Orders, consents or approvals as may be required to permit such sale without the requirement of filing a prospectus or delivering an offering memorandum or similar document and (ii) offer and sale of the Tier 2 Preferred Shares being exempt from the registration requirements of the U.S. Securities Act and applicable Securities Laws;


(c)	the Company having obtained all necessary approvals and consents required for the Company to consummate the transactions contemplated herein to be consummated at the Tier 2 Closing, including from NASDAQ to the extent required with respect to the listing of the Underlying Common Shares on such exchange;


(d)	there being no Order having the effect of prohibiting the sale of the Tier 2 Preferred Shares or any of the Company’s issued securities, and no proceeding for such purpose being pending or, to the Company’s knowledge, threatened under any applicable Securities Laws


(e)	all covenants, agreements and conditions contained in this Subscription Agreement to be performed by the Parties on or prior to the Tier 2 Closing Date shall have been performed or complied with in all material respects;


(f)	the Company not having exercised any rights of termination set forth in Sections 8.2 or 8.3 hereof; and

(g)

the Subscriber having delivered to the Company payment by direct funds transfer or wire transfer in satisfaction of the Tier 2 Subscription Amount for the Tier 2 Preferred Shares and having properly completed, signed and delivered any further documentation as required under the Securities Laws, which the Subscriber covenants and agrees to do on or prior to the Tier 2 Closing Time on the Tier 2 Closing Date upon the prior written request by the Company.

A-11

ARTICLE 5 - ACKNOWLEDGEMENTS, REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY

5.1 Representations and Warranties of the Company

The Company hereby represents and warrants to the Subscriber as follows, with effect as of the date hereof and as of the Tier 1 Closing Time and, if applicable and only with respect to the Fundamental Company Representations and Warranties, the Tier 2 Closing, and acknowledges that the Subscriber is relying on such representations and warranties in connection with the transactions contemplated herein:

(a)

the Company and each Subsidiary is duly organized and validly existing under the Laws of their respective jurisdictions of incorporation, amalgamation, arrangement or continuance, and the Company and the Subsidiaries are in good standing with the corporate governmental authorities of such jurisdictions with respect to the filing of annual returns and such other filings as are necessary to maintain their corporate existence and that each of the Company and the Subsidiaries has full corporate power to conduct its business as such business is now being conducted;

(b)

the securities of the Subsidiaries are held directly by the Company as set out in the Company’s Public Record, free and clear of all Liens and the Company is entitled to the full beneficial ownership of all such shares in the Subsidiaries. All of such shares in the capital of the Subsidiaries have been duly authorized and validly issued and are outstanding as fully paid shares and no person, other than the Company has any right, agreement or option, present or future, contingent or absolute, or any right capable of becoming a right, agreement or option, for the purchase from the Company of any interest in any of such shares or for the issue or allotment of any unissued shares in the capital of the Subsidiaries or any other security convertible into or exchangeable for any such shares;

(c)

the Company and each of the Subsidiaries is, in all material respects, conducting its business in compliance with all applicable Laws, rules and regulations of each jurisdiction in which its business is carried on and each is licensed, registered or qualified in all jurisdictions in which it is required to be licensed, registered or qualified and all such licenses, registrations and qualifications are valid, subsisting and in good standing and neither the Company nor any of the Subsidiaries has received a notice of non-compliance, or knows of, or has reasonable grounds to know of, any facts that could give rise to a notice of non-compliance with any such Laws, rules, regulations, licenses, registrations and qualifications which could have a Material Adverse Effect on the Company or any of the Subsidiaries;

(d)

the Company has the requisite power and authority to enter into and perform its obligations under the Subscription Agreement and to issue the Offered Shares in accordance with the terms hereof, and the execution and delivery of this Subscription Agreement and the performance by the Company of its obligations hereunder and the transactions contemplated hereby, including the issuance of the Offered Shares, have been duly authorized by all necessary corporate action of the Company (except that the consummation of the Tier 2 Closing requires receipt of the Company Shareholder Approval at the Company Meeting) and this Subscription Agreement has been duly executed and delivered by the Company and constitutes a valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, provided that enforcement thereof may be limited by Laws affecting creditors’ rights generally;


(e)	other than the Company Shareholder Approval, no vote or consent of the holders of any class or series of capital stock of the Company or any of its affiliates is necessary to approve this Subscription Agreement or the transactions contemplated hereby and shareholder approval is not required under NASDAQ Listing Rule 5635;

(f)

the execution and delivery of this Subscription Agreement and the fulfillment of the terms hereof by the Company and the issuance, sale and delivery of the Offered Shares do not and will not require the consent, approval, authorization, registration or qualification of or with any Governmental Entity, stock exchange, securities regulatory authority, or other third party, except: (i) such as will have been timely obtained prior to the Tier 1 Closing Time or, if applicable, the Tier 2 Closing Time; or (ii) in the case of post-closing filings, as will be made or obtained within the times prescribed by applicable Securities Laws;

(g)

neither the Company nor any of the Subsidiaries is in default or breach of, and the execution and delivery of this Subscription Agreement, the fulfillment of the terms hereof by the Company and the issuance, sale and delivery of the Offered Shares, do not and will not result in a breach of or constitute a default under, and do not and will not create a state of facts which, after notice or lapse of time or both, will result in a breach of or constitute a default under, and do not and will not conflict with the notice of articles or articles (or equivalent documents) of the Company or its Subsidiaries, any resolutions of the shareholders or directors of the Company or its Subsidiaries, the terms of any material agreement, or any Order, statute, rule or regulation applicable to any of them including applicable Securities Laws, which breach or default has had or would reasonably be expected to have a Material Adverse Effect on the Company;

A-12

(h)

all necessary corporate action will have been taken to validly create, authorize, reserve and issue the Offered Shares and, upon payment by the Subscriber of the aggregate Subscription Amount, will, when issued, be validly issued as fully paid and non-assessable Preferred Shares in the capital of the Company and free of any Liens, rights of first refusal or any kind of transfer restrictions other than as required by applicable Securities Laws and the holder of such Offered Shares shall be entitled to all rights afforded to a holder of Preferred Shares;


(i)	the authorized capital of the Company consists of an unlimited number of Common Shares and an unlimited number of Preferred Shares, of which, as of the close of business on September 29, 2017, 55,026,995 Common Shares and no Preferred Shares were outstanding as fully paid and non-assessable shares of the Company;

(j)

other than as disclosed in the Company’s Public Record, there are no outstanding options, warrants, rights (including conversion or pre-emptive rights and rights of first refusal or similar rights) or agreements, orally or in writing, to purchase or acquire from the Company any Common Shares or Preferred Shares, or any securities convertible into or exchangeable for Common Shares, Preferred Shares or any other equity interests;


(k)	CST Trust Company, at its principal office in Vancouver, British Columbia, is the duly appointed registrar and transfer agent for the Common Shares and Preferred Shares of the Company;

(l)

the Common Shares are registered pursuant to Section 12(b) of the U.S. Exchange Act and listed for trading on NASDAQ, and, except for such listing, no securities of the Company are listed on any other stock or securities exchange or market or registered under any Securities Laws. No delisting, suspension of trading or cease trading order with respect to any securities of the Company is pending or, to the knowledge of the Company, threatened in writing;


(m)	to the knowledge of the Company, as of the date of this Subscription Agreement, no inquiry, review or investigation (formal or informal) of the Company by any securities commission or similar regulatory authority under applicable Securities Laws, or NASDAQ is in effect or ongoing or reasonably expected to be implemented or undertaken;


(n)	the Company is a “reporting issuer” in each of the provinces of Canada;


(o)	no order ceasing or suspending trading in the securities of the Company or prohibiting the sale of the Offered Shares has been issued by any regulatory authority and is continuing in effect and no proceedings for that purpose have been instituted or are pending or, to the knowledge of Company, contemplated or threatened by any regulatory authority;


(p)	other than as disclosed in the Company’s Public Record, no person now has any agreement or option or right or privilege (whether at Law, pre-emptive or contractual) capable of becoming an agreement for the purchase, subscription or issuance of, or conversion into, any unissued shares, securities, warrants or convertible obligations of any nature of the Company or any of the Subsidiaries;


(q)	since December 31, 2016, other than as disclosed in the Public Record or by the Company in writing to the Subscriber:


i.	there has not been any material change in the assets, liabilities, obligations (absolute, accrued, contingent or otherwise), business, condition (financial or otherwise) or results of operations of the Company and the Subsidiaries, on a consolidated basis;


ii.	there has not been any material change in the capital stock or long-term debt of the Company and the Subsidiaries, on a consolidated basis; and


iii.	the Company and the Subsidiaries have carried on their respective businesses in the ordinary course;

(r)

as of their respective dates, the financial statements of the Company included in the SEC Reports (as defined below) complied in all material respects with applicable accounting requirements and the published rules and regulations of the SEC or other applicable rules and regulations with respect thereto. Such financial statements have been prepared in accordance with United States generally accepted accounting principles (GAAP) applied on a consistent basis during the periods involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto or (ii) in the case of unaudited interim statements, to the extent they may not include footnotes or may be condensed or summary statements), and fairly present in all material respects the consolidated financial position of the Company as of the dates thereof and the results of operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments);

A-13


(s)	there are no material off-balance sheet transactions, arrangements or obligations (including contingent obligations) of the Company or the Subsidiaries with unconsolidated entities or other persons that have had or would reasonably be expected to have a Material Adverse Effect on the Company;

(t)

the Company and each Subsidiary maintains a system of internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the U.S. Exchange Act) which is designed to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences;

(u)

to the knowledge of the Company, neither the Company nor any of the Subsidiaries nor the Company’s independent registered accountant has identified or been made aware of: (i) any significant deficiency or material weakness in the design or operation of internal control over financial reporting utilized by the Company; (ii) any material illegal act or fraud related to the business of the Company that involves the Company’s management or other employees; or (iii) any material claim or allegation regarding any of the foregoing;

(v)

the Company has established disclosure controls and procedures (as such term is defined in Rule 13a-15(e) and 15d-15(e) under the U.S. Exchange Act) for the Company and designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the U.S. Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC rules and forms;


(w)	the Company’s certifying officers have evaluated the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered by the Company’s most recently filed periodic report under the U.S. Exchange Act (such date, the Evaluation Date);


(x)	the Company presented in its most recently filed annual report on Form 10-K or quarterly report on Form 10-Q, as applicable, under the U.S. Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date;


(y)	since the Evaluation Date, there have been no changes in the Company’s internal control over financial reporting (as such term is defined in the U.S. Exchange Act) that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting;

(z)

neither the Company nor any Subsidiary is insolvent and is able to meet all of its financial liabilities as they become due and no winding-up, liquidation, dissolution or bankruptcy proceedings have been commenced or are being commenced or contemplated by the Company or any Subsidiary, and no merger, consolidation, amalgamation, sale of all or substantially all of the assets or sale of the business of the Company or any of its Subsidiaries have been commenced or are being commenced or contemplated by the Company or any of its Subsidiaries and neither the Company nor any Subsidiary has knowledge of any such proceedings or transactions having been commenced or being contemplated in respect of the Company or any of its Subsidiaries by any other party;

(aa)

other than as disclosed in the Company's Public Record, there are no actions, suits, proceedings, inquiries or investigations existing, or to the best of the Company’s knowledge, pending or threatened against or adversely affecting the Company or its Subsidiaries or any predecessor company or to which any of the property or assets thereof is subject, at Law or equity, or before or by any court, federal, provincial, state, municipal or other governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, which may in any way materially adversely affect the condition (financial or otherwise), property, assets, operations or business of the Company or its Subsidiaries or their ability to perform the obligations thereof and neither the Company nor any of its Subsidiaries is subject to any Order, rule, policy or regulation of any Governmental Entity, which, either separately or in the aggregate, have had or would reasonably be expected to have a Material Adverse Effect on the Company, or the ability of the Company to perform its obligations pursuant hereto;

(bb) neither the Company nor any of the Subsidiaries, nor to the best of the Company’s knowledge, any other

person, is in default in the observance or performance of any term, covenant or obligation to be performed by the Company or the Subsidiaries or such other person, as applicable, under any material agreement to which the Company or a Subsidiary is a party or otherwise bound, and all such material agreements are in good standing, and no event has occurred which with notice or lapse of time or both would constitute such a default thereunder by the Company, any Subsidiary or any other party;

A-14

(cc) there is no person acting or purporting to act at the request of the Company who is entitled to any brokerage,

agency or other fiscal advisory or similar fee in connection with the Offering, other than as disclosed concurrently herewith by the Company in writing to the Subscriber;

(dd)

the information and statements set forth in the Company’s Public Record were, as of the date filed, in compliance in all material respects with the Securities Laws and did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading;

(ee)

there is no “material change” (as defined in applicable Securities Laws) relating to the Company which has occurred and with respect to which the requisite material change report has not been filed with the applicable securities regulatory authority, nor has the Company filed any confidential material change reports with any securities regulatory authority that are still maintained on a confidential basis;

(ff)

except as qualified in the Company's Public Record, the Company and the Subsidiaries are the absolute legal and beneficial owners of and have good and marketable title to, all of the material property or assets thereof as described in the Company’s Public Record, such material properties and assets are free of all Liens and no other property rights are necessary for the conduct of the business of the Company and the Subsidiaries as currently conducted or currently contemplated to be conducted; the Company knows of no claim or basis for any claim that might or could materially adversely affect the right of the Company or the Subsidiaries to use, transfer or otherwise exploit such property rights; and, except as disclosed in the Company’s Public Record, neither the Company nor any Subsidiary has any responsibility or obligation to pay any commission, royalty, license fee or similar payment to any person with respect to the property rights thereof;

(gg)

the Company holds all requisite licences, registrations, qualifications, permits and consents necessary or appropriate for carrying on its respective business as currently carried on (col1ectively, the Licenses), except where the failure to hold such Licenses would not be reasonably expected to have a Material Adverse Effect on the Company, and (A) all such Licenses are valid and subsisting and in good standing in all material respects and (B) each of the Company and the Subsidiaries are in compliance with all terms of such Licenses and have not received a notice of non-compliance, or know of, or have reasonable grounds to know of, any facts that would give rise to a notice of non- compliance with any such Licenses, other than as disclosed by the Company in writing to the Subscriber concurrently herewith;

(hh)

neither the Company nor any Subsidiary is a party to or bound by any non-competition agreement or any other agreement, obligation or Order that purports to (A) limit the manner or the localities in which all or any material portion of the business of the Company or such Subsidiary is conducted, (B) limit any business practice of the Company or the Subsidiary in any material respect, or (C) restrict any acquisition or disposition of any property by the Company or the Subsidiary in any material respect;


(ii)	to the knowledge of the Company, it is not aware of any legislation, or proposed legislation published by a Governmental Entity, which it anticipates will materially and adversely affect the business, affairs, operations, assets, liabilities (contingent otherwise) or prospects of the Company or any Subsidiary;


(jj)	except as would not reasonably be expected to have a Material Adverse Effect on the Company or a Subsidiary, all rentals, payments and obligations, and other payments due or payable on or prior to the date hereof under or with respect to the assets of the Company and the Subsidiary have been properly and timely paid;

(kk)

the Company's disclosure concurrently herewith of Proprietary Rights identified as "Company IP" contains a true and complete list of all the patents owned by the Company, to the Company's knowledge. The Company has the right to use and exploit the Company IP, except as disclosed by the Company in writing to the Subscriber concurrently herewith, as such Company IP is used as of the Tier 1 Closing Time or, if applicable, the Tier 2 Closing Time or will be used in the conduct of Company’s business, and each contract with respect to the Company IP is valid and subsisting and in good standing and there is no default thereunder by the Company, or to the Company's knowledge by any seller or grantor;


(ll)	the Company is the sole legal and beneficial owner of, has good and marketable title to, and owns all right, title and interest in all the Company IP free and clear of all Liens. The Company has not assigned, licensed or otherwise conveyed any of the Company IP to any third party, except as disclosed by the Company in writing to the Subscriber concurrently herewith;


(mm)	the Company's disclosure concurrently herewith of Proprietary Rights identified "Licensed IP" contains a true and complete list of all Licensed IP licensed to the Company. The Company has the right to use and exploit the Licensed IP,

A-15

as such Licensed IP is used in the conduct of the Company's business as of the Tier 1 Closing Time or, if applicable, the Tier 2 Closing Time, and each contract with respect to the Licensed IP is valid and subsisting and in good standing and there is no default thereunder by the Company or, to the Company’s knowledge, by any licensor;

(nn)

the Proprietary Rights used by the Company in its business are in full force and effect and have not been used, enforced or not enforced in a manner that would result in their abandonment, cancellation or unenforceability. There is no claim existing or, to the Company’s knowledge threatened alleging adverse ownership, invalidity or other opposition to, or any conflict with, any of the Proprietary Rights;

(oo)

to the Company’s knowledge, (A) the Company has not received any notice or claim (whether written, oral or otherwise) challenging the Company’s ownership of or right to use any Proprietary Rights or suggesting that any other person has any claim of legal or beneficial ownership or other claim or interest with respect thereto and (B) there is no reasonable basis for any claim that any person other than the Company has any claim of legal or beneficial ownership or other claim or interest in any of the Proprietary Rights;

(pp)

other than as disclosed by the Company in writing to the Subscriber concurrently herewith, the Proprietary Rights of the Company and the Subsidiaries and the Proprietary Rights used by the Company are sufficient to conduct its business as presently conducted or anticipated to be conducted. No consent of any person is necessary to make, use, reproduce, license, sell, modify, update, enhance or otherwise exploit any Company IP, other than Company IP licensed on a non-exclusive basis, and none of the Company IP comprises an improvement to any Licensed IP that would give any person any rights to the Company IP, including, without limitation, rights to license the Company IP;


(qq)	to the Company’s knowledge, no third party has misappropriated, or is misappropriating, or is threatening to misappropriate, any rights of the Company in or to any Proprietary Rights and no third party’s commercialized product infringes any rights of the Company in or to any Proprietary Rights;

(rr)

the Company and each of its Subsidiaries has used commercially reasonably efforts (including measures to protect secrecy and confidentiality, where appropriate) to protect its Proprietary Rights and confidential information. Without limiting the generality of the foregoing, to the extent that any of the Company IP is licensed or disclosed to a third party or any third party has access to such the Company IP (including but not limited to any employee, officer, shareholder, consultant, systems-integrator, distributor or other customer of the Company), the Company has entered into a valid and enforceable written agreement which contains terms and conditions prohibiting the unauthorized use, disclosure, reverse engineering or transfer of such the Company IP by such third party. All such agreements are in full force and effect and no such third party, to the Company’s knowledge, is in default of its obligations thereunder;

(ss)

the Company has taken or will take all commercially reasonable steps to obtain the approval of NASDAQ to the extent required to list the Offered Shares and has complied with all other requirements of NASDAQ and requirements of the Securities Laws applicable to the offer and sale of the Offered Shares as contemplated herein required to be taken or complied with by it prior to the Tier 1 Closing Date and, if applicable, the Tier 2 Closing Date, as the case may be;

(tt)

the Company has not received any notice of or been prosecuted for an offence alleging violation of or non-compliance with any Environmental Law, and has not settled any allegation of violation or non-compliance short of prosecution. The Company is not aware of any Orders relating to environmental matters requiring any work, repairs, construction or capital expenditures to be made with respect to the business or any property, facilities or assets (whether currently owned, leased, occupied, controlled or licensed or owned, leased, occupied, controlled or licensed at any time prior to the date hereof) of the Company;

(uu)

the Company, its Subsidiaries and, to the knowledge of the Company, if applicable, any predecessor company to the Company or its Subsidiaries, have not received any notice from a Governmental Entity relating to environmental matters that the Company’s business or that the operation of any of the Company’s property, facilities or other assets is in violation of any Environmental Law or any Environmental Approval or that the Company is responsible (or potentially responsible) for the clean up of any hazardous substances at, on or beneath any of its property, facilities or other assets (whether currently owned, leased, occupied, managed, controlled or licensed, or owned, leased, occupied, managed, controlled or licensed at any time prior to the date hereof), or at, on or beneath any other land or in connection with any waste or contamination migration to or from any of the Company’s property, facilities or other assets;

(vv)

the Company and each of its Subsidiaries has complied in all material respects and will comply in all material respects with the requirements of all applicable corporate Laws (including the provisions of the Sarbanes-Oxley Act of 2002 which are applicable to it) and Securities Laws, including without limitation, the Securities Laws in relation to the distribution of its securities and in all matters relating to the Offering;

A-16

(ww)

the Company and its Subsidiaries, as applicable, have filed all federal, provincial, local and non-U.S. Tax Returns that are required to be filed, or have requested extensions thereof, and have paid all Taxes required to be paid by each of them and any other assessment, fine or penalty levied against each of them, to the extent that any of the foregoing is due and payable, except for such assessments, fines and penalties which are currently being contested in good faith and for which adequate reserves have been established in accordance with GAAP. Such Tax Returns are true, correct and complete in all material respects, and accurately reflect all material liability for Taxes of the Company and its Subsidiaries for the periods covered thereby;


(xx)	the Company and its Subsidiaries, if applicable, have established on their books and records reserves which are adequate for the payment of all Taxes not yet due and payable, and there are no Liens for Taxes on the assets of the Company except for Taxes not yet due;


(yy)	no claim has ever been made by a Governmental Entity in a jurisdiction where neither the Company nor any of its Subsidiaries files Tax Returns that the Company or any of its Subsidiaries is or may be subject to Tax by, or may be required to file any Tax Returns in, that jurisdiction that has not been resolved;

(zz)

other than as disclosed by the Company in writing to the Subscriber, there are no pending audits or examinations against the Company or any of its Subsidiaries by any Governmental Entity with respect to Taxes, and there are no claims that have been asserted against the Company or any of its Subsidiaries which, if determined adversely, would result in the assertion by a Governmental Entity of any deficiency that have had or would reasonably be expected to have an adverse effect on the Tax liabilities of the Company or any of its Subsidiaries;


(aaa)	neither the Company nor any of its Subsidiaries was a passive foreign investment company within the meaning of Section 1297 of the Code in respect of the taxation year ended December 31, 2016;

(bbb)

the corporate records and minute books of the Company contain copies of all material proceedings of the shareholders, the Company Board and all committees of the Company Board and there have been no other meetings, resolutions or proceedings of the shareholders, the Company Board or any committees of the Company Board not reflected in such minute books and other records. The corporate records and minute books of the Company have been maintained in accordance with all applicable Laws and are complete and accurate in all material respects, except where such incompleteness or inaccuracy would not reasonably be expected to have a Material Adverse Effect on the Company. Financial books and records and accounts of the Company: (i) have been maintained in accordance with good business practices on a basis consistent with prior years and past practice; (ii) stated in reasonable detail end accurately and fairly reflect in all material respects the Offering; and (iii) accurately and fairly reflect in all material respects the basis for the consolidated financial statements of the Company;


(ccc)	the Company and each of its Subsidiaries has conducted and is conducting its business in compliance with all, and is not in violation of any, applicable Laws of each jurisdiction in which it carries on business or holds assets, other than such non-compliance or violations that would not, individually or in the aggregate, be reasonably expected to have a Material Adverse Effect on the Company;


(ddd)	the Company is not registered or required to be registered as an "investment company" under the U.S. Investment Company Act of 1940, as amended;

(eee)

the Company has filed all reports required to be filed by it under the U.S. Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the twelve months preceding the date hereof (the foregoing materials (together with any materials filed by the Company under the U.S. Exchange Act, whether or not required), collectively referred to herein as the SEC Reports) and the SEC Reports did not contain any untrue statement of a material fact or omit to state any material fact required to be stated there in or necessary in order to make the statements made therein, in light of the circumstances in which they were made, not misleading;


(fff)	neither the Company or any of its affiliates, nor any person acting on its or their behalf has engaged or will engage in any form of “general solicitation” or “general advertising” (as such terms are defined in Rule 503(c) of Regulation D) in the United States in connection with the offer and sale of the Offered Shares;

(ggg)

the Company has not for a period of six months prior to the date hereof sold, offered for sale or solicited any offer to buy any of its securities in a manner that would be integrated with the offer and sale of the Offered Shares and would cause the exemption from registration set forth in Section 4(a) (2) of the U.S. Securities Act to become unavailable for the offer and sale of the Offered Shares pursuant hereto;

A-17


(hhh)	the Company is eligible to register the resale of the Offered Shares by the Subscriber using Form S-3 promulgated under the U.S. Securities Act, or any similar short-form registration statement that may be available at such time under the U.S. Securities Act;

(iii)

with respect to each “employee benefit plan” (as defined in Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (ERISA)), whether or not subject to ERISA, maintained or contributed to by the Company or its Subsidiaries or pursuant to which the Company or any such Subsidiary or any organization (an ERISA Affiliate) which, together with the Company and/or any such Subsidiary, would be treated as a “single employer” within the meaning of the Code, may have a liability (each, an Employee Benefit Plan), (i) each Employee Benefit Plan has been established and maintained in compliance with its terms and the requirements of all applicable Laws (including, without limitation, ERISA and the Code), except for any noncompliance that does not and would not result, individually or in the aggregate, in a material liability of the Company or its Subsidiaries, and all contributions and payments required to be made under any Employee Plan or related agreement have been made in a timely fashion or has been reflected on the most recent balance sheet filed prior to the date hereof or accrued in the accounting records of the Company and its Subsidiaries; (ii) there are no unfunded obligations of the Company or any of its Subsidiaries under any Employee Benefit Plan; and (iii) each Employee Benefit Plan which is intended to be “qualified” within the meaning of Section 401(a) of the Code has received a favorable determination letter from the Internal Revenue Service covering all tax law changes or is comprised of a master or prototype plan that has received a favorable opinion letter from the Internal Revenue Service, and, to the Company’s knowledge, no event has occurred and no condition exists which could reasonably be expected to result in the revocation of any such determination letter or opinion letter. None of the Company, any Subsidiary of the Company or any ERISA Affiliate currently maintains or contributes to, or has at any time maintained or contributed to or been obligated to contribute to, any plan, program or arrangement covered by Title IV of ERISA or subject to Section 412 of the Code or Section 302 of ERISA;

(jjj)

neither the Company nor any of its Subsidiaries is a party to, bound by, negotiating or required to negotiate any collective bargaining agreement or other agreement with a labor union or other labor organization. No employees of the Company or any of its Subsidiaries are represented by any labor union or other labor organization. There are no activities or proceedings of any labor union or other labor organization to organize any employees of the Company or any of its Subsidiaries and no demand for recognition or certification as the exclusive bargaining representative of any employees has been made by or on behalf of any labor union or other labor organization. There are no pending or, to the knowledge of the Company, threatened, and, in the three year period prior to the date hereof, there have been no, strikes, lockouts, union organization activities (including, but not limited to, union organization campaigns or requests for representation), pickets, slowdowns, stoppages, material grievances or collective labor disputes or similar activity in respect of the business of the Company or its Subsidiaries that may, individually or in the aggregate, interfere in any material respect with the respective business activities of the Company or any of its Subsidiaries. The Company and each of its Subsidiaries are not engaged in and, in the three year period prior to the date hereof, have not engaged in any unfair labor practice that has resulted or could reasonably be expected to result, individually or in the aggregate, in any material liability to the Company or any of its Subsidiaries;

(kkk)

the Company and each of its Subsidiaries is, and, in the three years prior to the date hereof has been, in compliance in all material respects with all applicable Laws respecting labor, employment, fair employment practices (including equal employment opportunity laws), terms and conditions of employment, classification of employees, workers’ compensation, occupational safety and health, immigration, affirmative action, employee and data privacy, plant closings, and wages and hours. There is no pending or, to the knowledge of the Company, threatened charge, complaint, arbitration, audit or investigation brought by or on behalf of, or otherwise involving, any current or former employee, any person alleged to be a current or former employee, any applicant for employment, or any class of the foregoing, or any Governmental Entity, that involve the labor or employment relations and practices of the Company or any of its Subsidiaries that could reasonably be expected to result, individually or in the aggregate, in any material liability to the Company or any of its Subsidiaries;

(lll)

neither the execution and delivery of this Subscription Agreement, shareholder (at the Company Meeting or otherwise) or other approval of this Subscription Agreement nor the consummation of the transactions contemplated hereby could, either alone or in combination with another event, (i) entitle any employee, director, officer or independent contractor of the Company or any of its Subsidiaries to severance pay or any material increase in severance pay, (ii) accelerate the time of payment or vesting, or materially increase the amount of compensation due to any such employee, director, officer or independent contractor, (iii) directly or indirectly cause the Company to transfer or set aside any assets to fund any material benefits under any Employee Benefit Plan, (iv) otherwise give rise to any material liability under any Employee Benefit Plan, (v) limit or restrict the right to merge, materially amend, terminate or transfer the assets of any Employee Benefit Plan on or following the later to occur of the Tier 1 Closing and the Tier 2 Closing, (vi) require a “gross-up,”

A-18

indemnification for, or payment to any individual for any taxes imposed under Section 409A or Section 4999 of the Code or any other tax, or (vii) result in the payment of any amount that could, individually or in combination with any other such payment, constitute an “excess parachute payment” as defined in Section 280G(b)(1) of the Code;


(mmm)	the Company is a “foreign issuer” as defined in 16 C.F.R. §801.1(e)(2)(ii); and


(nnn)	the Company and the Subsidiaries (i) do not have assets located in the United States having an aggregate total value of over $80.8 million; and (ii) did not make aggregate sales in or into the United States of over $80.8 million in their most recent fiscal year.

5.2 Covenants of the Company Relating to the Company Meeting

The Company hereby covenants and agrees with the Subscriber as follows:

(a)

the Company agrees to convene and conduct the Company Meeting for the purpose of obtaining approval of the Company Shareholder Approval and shall not, except as required for quorum purposes, as required by Securities Law, or otherwise as permitted under this Subscription Agreement, adjourn, postpone or cancel (or propose or permit the adjournment, postponement or cancellation of) the Company Meeting without the Subscriber’s prior written consent, such consent not to be unreasonably withheld or delayed;

(b)

as promptly as reasonably practicable following execution of this Subscription Agreement, the Company shall prepare the Company Circular, together with any other documents required by applicable Securities Laws, and cause it to be filed in all jurisdictions where the same is required to be filed, in each case, in accordance with all applicable Securities Laws, including, without limitation, Section 14 of the U.S. Exchange Act and Regulation 14A promulgated thereunder. To the extent the SEC reviews the Company Circular, the Company shall each use commercially reasonable efforts to respond as promptly as reasonably practicable to, and resolve all comments received from, the SEC (or its staff) concerning the Company Circular, and to have the Company Circular cleared by the SEC as promptly as reasonably practicable after such filing;

(c)

as promptly as reasonably practicable after the tenth calendar day following the Company’s filing of the preliminary Company Circular with the SEC (if the SEC does not review the Company Circular) or after the preliminary Company Circular is cleared by the SEC (if the SEC reviews the Company Circular), the Company shall cause the definitive Company Circular to be mailed or otherwise delivered to Shareholders and otherwise filed in all jurisdictions where the same is required to be filed, in each case, in accordance with all applicable Securities Laws, including, without limitation, Section 14 of the U.S. Exchange Act and Regulation 14A promulgated thereunder;

(d)

the Company shall ensure that the Company Circular complies in all material respects with all applicable Securities Laws, including, without limitation, the rules applicable to proxy statements on Schedule 14A promulgated under Regulation 14A under the U.S. Exchange Act, and without limiting the generality of the foregoing, that the Company Circular contains sufficient detail to permit the Shareholders to form a reasoned judgement concerning the matters to be placed before them at the Company Meeting. The Company shall ensure that all proxies solicited by it and any of its representatives in connection with the Company Meeting are solicited in compliance with all applicable Securities Laws, including, without limitation, Section 14 of the U.S. Exchange Act and Regulation 14A promulgated thereunder;

(e)

the Company shall give the Subscriber and its legal counsel a reasonable opportunity to review and comment on the Company Circular and, in the case of review by the SEC, responses to SEC comments. The Company Circular shall be reasonably satisfactory to the Subscriber, acting reasonably, before it is printed, or distributed to Shareholders or filed with any Governmental Entity, subject to any disclosure obligations imposed on the Company by any Governmental Entity;


(f)	the Company shall disclose in the Company Circular that the Company Board has determined, after receiving financial and legal advice, that the Offering is in the best interests of Company, and the Company Board recommends that the Shareholders vote in favour of the Company Shareholder Approval;

(g)

from the date of this Subscription Agreement until the Company Meeting, the Company shall use commercially reasonable efforts to take or otherwise cause to be taken, all actions and to do or otherwise cause to be done, all things necessary to complete as promptly as is practicable the Offering and the other transactions contemplated in this Agreement, and, without limiting the generality of the foregoing, shall publically affirm the recommendation of the Company Board that Shareholders vote in favour of the Company Shareholder Approval (by the prompt issuance of a press release, in form and content satisfactory to the Subscriber, acting reasonably, to that effect) and, when requested by the Subscriber, acting

A-19

reasonably, publically reaffirm (by the prompt issuance of a press release, in form and content satisfactory to the Subscriber, acting reasonably, to that effect) the recommendation of the Company Board that the Shareholders vote in favour of the Company Shareholder Approval;

(h)

the Company shall solicit proxies from Shareholders in favour of the Company Shareholder Approval and against any resolution submitted by any person that is inconsistent with, or which seeks to hinder or delay the Company Shareholder Approval and the completion of the transactions contemplated hereby, including, if so requested by the Purchaser, acting reasonably, using the services of dealers and proxy solicitation services, and take all other actions that are reasonably necessary or desirable to seek the approval of the Company Shareholder Approval;


(i)	the Company will advise the Subscriber from time to time as the Subscriber may reasonably request, and at least on a daily basis on each of the last ten (10) Business Days prior to the date of the Company Meeting, as to the aggregate tally of the proxies received by the Company in respect of the Company Shareholder Approval;


(j)	the Company shall keep the Subscriber informed of any material requests or comments made by any Governmental Entity to the Company in connection with the Company Circular and promptly provide the Subscriber with copies of any correspondence received by the Company from, or sent by the Company to, any Governmental Entity in connection with the Company Circular;


(k)	the Company agrees that no matters shall be brought before the Company Meeting other than the adoption of this Subscription Agreement and any related and customary procedural matters (including a proposal to adjourn the meeting to allow additional solicitation of votes);

(l)

none of the information contained or incorporated by reference in the Company Circular, as of the date it is first mailed to the Shareholders, and at the time of the Company Meeting, will contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are made, not misleading; and

(m)

if at any time any information relating to the Company, its Subsidiaries or any of its or their respective affiliates, directors or officers, is discovered or otherwise learned by the Company, which should be set forth in an amendment or supplement to the Company Circular so that the Company Circular would not include any misstatement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading, the Party which discovers such information shall promptly notify the other Party and an appropriate amendment or supplement describing such information shall be promptly filed with the SEC and any other required Governmental Entity and, to the extent required by the Securities Laws, disseminated to the Shareholders.

5.3 Covenants of the Company Relating to the Conduct of Business

The Company hereby covenants and agrees with the Subscriber that at all times from the date of this Subscription Agreement until (i) the Tier 1 Closing Date, (ii) if the Tier 1 Closing has occurred, the Company Meeting or (iii) if the MI 61-101 Resolution is passed, the Tier 2 Closing Date, unless the Subscriber shall otherwise agree in writing or as otherwise expressly (A) contemplated or permitted by this Subscription Agreement, or (B) unanimously approved by the Company Board, it shall and shall cause each of its Subsidiaries to:


(a)	conduct its business and affairs and maintain its assets, and not take any action except, in the usual, ordinary and regular course of business consistent with past practice and in compliance with applicable Laws;

(b)

use commercially reasonable efforts to preserve intact its present business organization, assets (including intellectual property) and goodwill, maintain its real property interests (including title to, and leasehold interests in respect of, any real property) in good standing, keep available the services of its directors, officers and senior employees and preserve the current material relationships with suppliers, senior employees, consultants, customers and others having business relationships with it, in each case except in accordance with the usual, ordinary course of business consistent with past practices;


(c)	duly and timely file all Tax Returns required to be filed by it or any Subsidiaries on or after the date hereof and all such Tax Returns will be true, complete and correct in all respects;


(d)	timely withhold, collect, remit and pay all Taxes which are to be withheld, collected, remitted or paid by it or any Subsidiaries to the extent due and payable; and

A-20


(e)	not:

(i)

issue, sell, pledge, lease, dispose of or encumber, or agree to issue, sell, pledge, lease, dispose of or encumber, any Common Shares, Preferred Shares or any securities convertible into Common Shares or Preferred Shares (other than in connection with the exercise, in accordance with their respective terms, of outstanding Company Options) or, except as provided for in this Subscription Agreement, amend, extend or terminate, or agree to amend, extend or terminate, any of the terms of, or agreements governing, any of the outstanding Company Options or other convertible securities;


(ii)	declare, pay or set aside any dividend or make any distribution (other than dividends or distributions by any Subsidiary to the Company or any other Subsidiary) with respect to the Company or any of its Subsidiaries;


(iii)	amend or propose to amend its articles or by-laws or other constating documents; or, split, consolidate or reclassify, or propose to split, consolidate or reclassify, any of the Common Shares or Preferred Shares, or undertake or propose to undertake any other capital reorganization or change in the capital structure of the Company or any of its Subsidiaries;


(iv)	sell, pledge, lease, dispose of, abandon, cancel or encumber any assets, rights or properties, except in the ordinary course of business consistent with past practice;

(v)

except as contemplated by this Subscription Agreement, acquire or agree to acquire (by merger, amalgamation, acquisition of shares or assets or otherwise) any company, partnership or other business organization or division, or incorporate or form, or agree to incorporate or form, any company, partnership or other business organization or make or agree to make any investment either by purchase of shares or securities, contributions of capital, property transfer or purchase of, any property or assets of any other person, company, partnership or other business organization;


(vi)	enter into or agree to the terms of any material joint venture or similar agreement, arrangement or relationship;

(vii)

incur, create, assume, modify or otherwise become liable for, any indebtedness for borrowed money or any other liability or obligation, permit any of the properties or assets of the Company or any of its Subsidiaries to be subject to any Lien or issue any debt securities or assume, guarantee, endorse or otherwise as an accommodation become responsible for the obligation of any other person or make any loans, capital contribution, investments or advances except in the ordinary course of business;

(viii)

pay, discharge or satisfy any material claims, liabilities or obligations other than the payment, discharge or satisfaction, in the ordinary course of business consistent with past practice, of liabilities incurred in the ordinary course of business consistent with past practice or of fees, expenses and other charges of the Company Board, advisors and service providers which are or become payable in connection with the Offering;

(ix)

take any action or fail to take any action which action or failure to act would result in the material loss, expiration or surrender of, or the loss of any material benefit under, or reasonably be expected to cause any Governmental Entities to institute proceedings for the suspension, revocation or limitation of rights under, any material authorizations; or fail to prosecute with commercially reasonable due diligence any pending applications to any Governmental Entities;

(x)

take any action that could reasonably be expected to interfere with or be inconsistent with the completion of the Offering or the transactions contemplated in this Subscription Agreement or which would render, or which may reasonably be expected to render, untrue or inaccurate (without giving effect to, applying or taking into consideration any materiality or Material Adverse Effect qualification already contained within such representation or warranty) in any material respect any of the representations and warranties of Company set forth in this Subscription Agreement;


(xi)	except as required by GAAP, make any change in any method of accounting or auditing practice;

(xii)

make, change or revoke any Tax election or settle and/or compromise any Tax liability; prepare any Tax Returns in a manner which is inconsistent with the past practices of the Company or any of its Subsidiaries, as applicable, with respect to the treatment of items on such Tax Returns; adopt or change any Tax accounting method or Tax accounting period; enter into, cancel or modify any agreement with a Governmental Entity with respect to Taxes; incur any material liability for Taxes other than in the ordinary course of business, or file an amended Tax Return or a claim for refund of taxes with respect to the income, operations or property of the Company or its Subsidiaries;

A-21


(xiii)	other than in the ordinary course of business or as required by Law, enter into, terminate, modify or amend in any material respect any contract or agreement that is material to the Company and/or any of its Subsidiaries; or


(xiv)	announce an intention, enter into any formal or informal agreement, or otherwise make a commitment to do any of the things prohibited by any of the foregoing subsections; and


(xv)	use commercially reasonable efforts to avoid, in respect of the taxation year ending December 31, 2017, being treated as a passive foreign investment company within the meaning of Section 1297 of the Code.

5.4 Acknowledgements and Additional Covenants of the Company

The Company hereby acknowledges, covenants and agrees with the Subscriber as follows:


(a)	the Company shall maintain its status as a “reporting issuer” in, and not in default of any requirement of the Securities Laws of, each of the Provinces of Canada until the later to occur of the Tier 1 Closing Time or, if applicable, the Tier 2 Closing Time;

(b)

until the later to occur of the Tier 1 Closing Time or, if applicable, the Tier 2 Closing Time, the Company shall remain a corporation validly subsisting under the Laws of its jurisdiction of incorporation, licensed, registered or qualified as an extra‑provincial or foreign corporation in all jurisdiction where the character of its properties owned or leased or the nature of the activities conducted by it make such licensing, registration or qualification necessary;

(c)

for a period of one year after the date of this Subscription Agreement, the Company shall file all reports required to be filed by the Company after the date hereof pursuant to the U.S. Exchange Act. During this one-year period, if the Company is not required to file reports pursuant to the U.S. Exchange Act, it will prepare and furnish to the Subscriber and make publicly available in accordance with Rule 144 under the U.S. Securities Act such information as is required for the Subscriber to sell the Securities under Rule 144 under the U.S. Securities Act;

(d)

the Company shall timely file such forms and documents as may be required to be filed by the Company under the Securities Laws, including the policies of NASDAQ relating to the Offering and will take all commercially reasonable steps to obtain the listing approval of NASDAQ to the extent required in respect of the Underlying Common Shares and will comply with all other requirements of NASDAQ and requirements of the Securities Laws applicable to the offer and sale of the Offered Shares as contemplated herein required to be taken or complied with by it; provided that the Company will discuss in good faith with the Subscriber, and agree to make, any adjustments required to the terms of the Preferred Shares that are required by NASDAQ and that are not materially adverse to the Company;


(e)	the Company shall perform and carry out all of the acts and things to be completed by it as provided in this Subscription Agreement;


(f)	the Company shall use the proceeds of this Offering to further develop and continue to advance its clinical and preclinical hepatitis B virus pipeline, and for general corporate purposes, including working capital;


(g)	the Company shall take all actions as are necessary to cause the following to be effective as of the Tier 1 Closing:


i.	the Registration Rights Agreement shall be amended by the Registration Rights Amending Agreement such that the Offered Shares and the Underlying Common Shares, will be subject to the Registration Rights Agreement on substantially the same terms as the other Common Shares subject thereto (the Registration Rights Amendment);


ii.	the Governance Agreement shall be amended by the Governance Agreement Amending Agreement to reflect, inter alia, the Subscriber Board Designation Right (the Governance Agreement Amendment); and


iii.	the execution and delivery by the Company of the Lock-Up Amending Agreement and the Standstill Amending Agreement;


(h)	the Company shall take all actions as are necessary to cause the Articles of Amendment to become effective, including taking all commercially reasonable actions as are necessary to obtain the Company Shareholder Approval so that the Subscriber can fully exercise the Subscriber Board Designation Right from and after the Tier 2 Closing; and

A-22


(i)	the Company shall not sell, offer for sale or solicit offers to buy any security (as defined in Section 2 of the U.S. Securities Act) in a manner that would be integrated with the offer or sale of the Offered Shares and cause the sale of the Offered Shares to the Subscriber to be required to be registered under the U.S. Securities Act.

5.5 Survival of Representations, Warranties and Covenants of the Company

The representations and warranties of the Company contained in this Subscription Agreement shall survive the Tier 1 Closing and, if applicable, the Tier 2 Closing, and, notwithstanding such Closing, shall continue in full force and effect for the benefit of the Subscriber for a period of two years after the later to occur of the Tier 1 Closing Time or, if applicable, the Tier 2 Closing Time. The Subscriber acknowledges that it has had the opportunity to conduct a due diligence investigation with respect to the Company, and in no event shall the Company have any liability to the Subscriber with respect to a breach of representation or warranty under this Agreement to the extent that the Subscriber knew of such breach as of the Tier 1 Closing and, if applicable, the Tier 2 Closing.

5.6 Reliance and Indemnity

The Subscriber is relying on the representations, warranties and covenants contained herein in making the decision to subscribe for the Offered Shares and make payment of consideration therefor, and the Company agrees to indemnify the Subscriber and its directors and officers against all losses, claims, costs, expenses, damages or liabilities which any of them may suffer or incur as a result of or arising from reliance thereon.

ARTICLE 6 - ACKNOWLEDGEMENTS, COVENANTS, REPRESENTATIONS AND WARRANTIES OF THE SUBSCRIBER

6.1 Representations and Warranties of the Subscriber

The Subscriber hereby represents and warrants to, and covenants with, the Company as follows, with effect as of the date hereof and as of the Tier 1 Closing Time and, if applicable and only with respect to the Fundamental Subscriber Representations and Warranties, the Tier 2 Closing, and acknowledges that the Company is relying on such representations and warranties in connection with the transactions contemplated herein:


(a)	the Subscriber certifies that it is resident in the jurisdiction set out on the face page of this Subscription Agreement. Such address was not created and is not used solely for the purpose of acquiring the Offered Shares and the Subscriber was solicited to purchase, and accepted such offer to purchase the Offered Shares, in such jurisdiction;

(b)

as of the date of execution of this Subscription Agreement and as of the Tier 1 Closing Time and, if applicable, the Tier 2 Closing Time, as the case may be, the Subscriber is an “accredited investor” as defined in Rule 501(a) of Regulation. The Subscriber agrees to furnish any additional information requested by the Company or any of its affiliates to assure compliance with applicable U.S. federal and securities laws in connection with the purchase and sale of the Offered Shares;


(c)	the current structure of this transaction and all transactions and activities contemplated hereunder is not a scheme to avoid the registration requirements of the U.S. Securities Act;

(d)

the Subscriber will not offer, sell or otherwise dispose of the Offered Shares unless such offer, sale or disposition is made in accordance with an exemption from the registration requirements of the U.S. Securities Act and the Securities Laws of all applicable states of the United States or the SEC has declared effective a registration statement in respect of such securities. The Offered Shares have not been and will not be registered under the U.S. Securities Act and may not be offered or sold unless registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available;

(e)

the execution and delivery of this Subscription Agreement, the performance and compliance with the terms hereof, the subscription for the Offered Shares and the completion of the transactions by the Subscriber described herein will not result in any material breach of, or be in conflict with or constitute a material default under, or create a state of facts which, after notice or lapse of time, or both, would constitute a material default under any term or provision of the constating documents, by-laws or resolutions of the Subscriber, the Securities Laws or any other Laws applicable to the Subscriber, any agreement to which the Subscriber is a party, or any Order, statute, rule or regulation applicable to the Subscriber;

A-23


(f)	the Subscriber is subscribing for the Offered Shares as principal for its own account, for investment purposes, and not for the benefit of any other person (within the meaning of applicable Securities Laws) and not with a view to, or for resale in connection with, any distribution of the Offered Shares;


(g)	this Subscription Agreement (and all other documentation in connection with such subscription) has been duly authorized, executed and delivered by, and constitutes a legal, valid and binding agreement of, the Subscriber, enforceable against the Subscriber in accordance with its terms, provided that enforcement thereof may be limited by Laws affecting creditors’ rights generally;


(h)	the Subscriber has the necessary legal capacity and authority to execute and deliver this Subscription Agreement and to observe and perform its covenants and obligations hereunder and has obtained all necessary approvals in respect thereof;


(i)	there is no person acting or purporting to act at the request of the Subscriber who is entitled to any brokerage or finder’s fee;

(j)

the Subscriber has not received or been provided with a prospectus, offering memorandum, within the meaning of the Securities Laws in Canada, or any sales or advertising literature in connection with the Offering and the Subscriber’s decision to subscribe for the Offered Shares was not based upon, and the Subscriber has not relied upon, any representations as to facts made by or on behalf of the Company, other than the representations and warranties of the Company under this Subscription Agreement;


(k)	no person has made any written or oral representations:


i.	that any person will resell or repurchase the Offered Shares;


ii.	that any person will refund the Tier 1 Subscription Amount or, if applicable, the Tier 2 Subscription Amount; or


iii.	as to the future price or value of the Offered Shares; and

(l)

the offering and issue of the Offered Shares has not been made or solicited through or as a result of, and the distribution of the Offered Shares is not being accompanied by any advertisement, including without limitation in printed public media, radio, television or telecommunications, including electronic display, or as part of a general solicitation or general advertising with respect to the Offering.

6.2 Acknowledgments and Covenants of the Subscriber

The Subscriber, hereby acknowledges, covenants and agrees as follows:


(a)	the Subscriber shall take all actions as are necessary to cause the following to be effective as of the Tier 1 Closing:


i.	the Registration Rights Agreement shall be amended by the Registration Rights Amending Agreement such that the Offered Shares and the Underlying Common Shares, will be subject to the Registration Rights Agreement on substantially the same terms as the other Common Shares subject thereto (the Registration Rights Amendment);


ii.	the Governance Agreement shall be amended by the Governance Agreement Amending Agreement to reflect, inter alia, the Subscriber Board Designation Right (the Governance Agreement Amendment); and


iii.	the execution and delivery by the Company of the Lock-Up Amending Agreement and the Standstill Amending Agreement;

(b)

the Subscriber, to the extent required, shall cooperate with the Company to facilitate the timely filing of such forms and documents as may be required to be filed by the Company under the Securities Laws, including the policies of NASDAQ relating to the Offering; provided that the Subscriber will discuss in good faith with the Company, and agree to make, any adjustments required to the terms of the Preferred Shares that are required by NASDAQ and that are not materially adverse to the Subscriber;


(c)	there are risks associated with the purchase of the Offered Shares, including the risks outlined in the Public Record and in this Subscription Agreement. The Subscriber has such knowledge, skill and experience in business, financial and investment matters that the undersigned is capable of evaluating the merits and risks of an investment in the Offered

A-24

Shares. The Purchaser has been afforded the opportunity to receive information from, and to ask questions of and receive answers from the management of, the Company concerning this investment so as to allow it to make an informed investment decision prior to its investment. Additionally, with the assistance of the Subscriber’s own professional advisors, to the extent that the undersigned has deemed appropriate, the undersigned has made its own legal, tax, accounting and financial evaluation of the merits and risks of an investment in the Offered Shares and the consequences of this Subscription Agreement. The Subscriber has considered the suitability of the Offered Shares as an investment in light of its own circumstances and financial condition and the undersigned is able to bear the risks associated with an investment in the Offered Shares and its authority to invest in the Offered Shares;


(d)	if required by applicable Securities Laws or the Company, the Subscriber will execute, deliver and file or assist the Company in filing such reports, undertakings and other documents with respect to the issue and/or sale of the Offered Shares as may be required by any securities commission or other regulatory authority;

(e)

there are restrictions on the Subscriber’s ability to resell the Offered Shares and it is the responsibility of the Subscriber to find out what those restrictions are and to comply with them before selling the Offered Shares. The Offered Shares will be subject to the restrictions on transfer as set forth in this Subscription Agreement and under applicable Securities Laws. The Subscriber has been advised to consult its own legal advisors with respect to trading in the Offered Shares and with respect to the resale restrictions imposed by the Securities Laws of the province or territory in which the Subscriber resides and other applicable Securities Laws, and acknowledges that no representation has been made respecting the applicable hold periods imposed by the Securities Laws or other resale restrictions applicable to such securities which restrict the ability of the Subscriber to resell such securities that the Subscriber is solely responsible to find out what these restrictions are and the Subscriber is solely responsible (and the Company is in no way responsible) for compliance with applicable resale restrictions and the Subscriber is aware that it may not be able to resell such securities except in accordance with limited exemptions under the Securities Laws and other applicable Securities Laws;

(f)

the Offered Shares will be “restricted securities” as such term is defined in Rule 144(a)(3) under the U.S. Securities Act and may not be offered, resold or otherwise transferred, directly or indirectly, except pursuant to an effective registration statement under the U.S. Securities Act or in accordance with an exemption from the registration requirements of the U.S. Securities Act and applicable Securities Laws, as described in the legend affixed to the face of the certificates (or, if applicable, notice of entry into a direct registration system) evidencing the Offered Shares and the provisions of Section 6.2 hereof. The Subscriber understands that the availability of the exemption from registration afforded by Rule 144 under the U.S. Securities Act depends upon the satisfaction of various conditions, and that Rule 144 under the U.S. Securities Act may afford the basis for sales only in limited circumstances. The Subscriber understands that as an “affiliate” of the Company, it is subject to restrictions imposed by the U.S. Securities Act on its ability to transfer the Offered Shares. The Subscriber does not have the protection of Section 11 of the U.S. Securities Act in connection with its purchase of the Offered Shares hereunder;


(g)	the certificates (or, if applicable, notice of entry into a direct registration system) representing the Offered Shares issued pursuant to the Offering will bear the following legends as required by National Instrument 45-102 - Resale of Securities and the U.S. Securities Act, and with the necessary information inserted and the Subscriber agrees to comply with the terms of such legends:

A-25

“UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE <INSERT DATE THAT IS FOUR (4) MONTHS AND ONE (1) DAY AFTER CLOSING DATE>”

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS. THE HOLDER HEREOF, BY PURCHASING SUCH SECURITIES, AGREES FOR THE BENEFIT OF THE ISSUER THAT THESE SECURITIES MAY BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, DIRECTLY OR INDIRECTLY, ONLY (A) TO THE ISSUER, (B) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, (C) OUTSIDE THE UNITED STATES PURSUANT TO REGULATION S UNDER THE SECURITIES ACT, (D) INSIDE THE UNITED STATES PURSUANT TO THE EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT PROVIDED BY RULE 144 THEREUNDER, IF AVAILABLE, OR (E) IN A TRANSACTION THAT IS OTHERWISE EXEMPT FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT, AND IN EACH CASE IN COMPLIANCE WITH APPLICABLE STATE SECURITIES LAWS AND THE APPLICABLE LAWS OF ANY OTHER JURISDICTION, PROVIDED THAT IN THE CASE OF (C), (D) OR (E) ABOVE, THE HOLDER HAS, PRIOR TO SUCH SALE, FURNISHED TO THE ISSUER A LEGAL OPINION OF COUNSEL OF RECOGNIZED STANDING, REASONABLY SATISFACTORY TO THE ISSUER. HEDGING TRANSACTIONS INVOLVING THESE SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT.”

(h)

no prospectus or registration statement has been filed by the Company with any securities regulatory authorities in connection with the issuance of the Offered Shares or the Underlying Common Shares, the sale of the Offered Shares and the issuance of the Underlying Common Shares is conditional upon such sale being exempt from the requirements to file and obtain a receipt for a prospectus, to file and make effective a registration statement or to deliver an offering memorandum with this Subscription Agreement and the requirement to be a registered dealer, and as a consequence of acquiring the Offered Shares pursuant to such exemptions:


i.	certain protections, rights and remedies provided by the Securities Laws including certain statutory rights of rescission or damages and certain statutory remedies against an issuer, underwriters, auditors, directors and officers that are available to investors who acquire securities offered by a prospectus or registration statement, may not be available to the Subscriber;


ii.	the common law may not provide investors with an adequate remedy in the event that they suffer investment losses in connection with securities acquired in a private placement;


iii.	the Subscriber may not receive certain information that would otherwise be required to be given under the Securities Laws; and


iv.	the Company is relieved from certain obligations that would otherwise apply under the Securities Laws;

(i)

the Company is collecting the Subscriber’s personal information (as that term is defined under applicable privacy legislation, including, without limitation, the Personal Information Protection and Electronic Documents Act (Canada) and any other applicable similar, replacement or supplemental provincial or federal legislation or Laws in effect from time to time), for the purpose of completing this Subscription Agreement. The Subscriber acknowledges and consents to the Company retaining such personal information for only so long as required by Law. The Subscriber further acknowledges and consents to the fact that the Company may be required by the Securities Laws to provide regulatory authorities with any personal information provided under this Subscription Agreement;


(j)	the Subscriber represents and warrants that none of the funds being used to purchase the Offered Shares are, to such Subscriber's knowledge, proceeds obtained or derived, directly or indirectly, as a result of illegal activities and that:


i.	the funds being used to purchase the Offered Shares and advanced by or on behalf of the Subscriber do not represent proceeds of crime or otherwise result in a violation of any applicable anti-money laundering Laws or regulations including, without limitation, the Proceeds of Crime (Money Laundering) and Terrorist Financing

A-26

Act (Canada) (the PCMLTFA) and the Common Sharing and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act (the Patriot Act); and


ii.	the Subscriber is not a person or entity identified on a list established under section 83.05 of the Criminal Code (Canada) (the Criminal Code); and

(k)

the Subscriber acknowledges and agrees that (i) the Company may in the future be required by law to disclose the Subscriber's name and other information relating to the Subscriber and any purchase of the Offered Shares, on a confidential basis, pursuant to the Criminal Code, PCMLTFA, the Patriot Act or as otherwise may be required by applicable Laws, regulations or rules, and (ii) the Company or their agents may in the future be required by law to disclose the Subscriber's name and other information relating to the Subscriber and any purchase of the Offered Shares, on a confidential basis, pursuant to the PCMLTFA, the Patriot Act, the Criminal Code or as otherwise may be required by applicable Laws, regulations or rules.

6.3 Survival of Representations, Warranties and Covenants of the Subscriber

The representations, warranties and covenants of the Subscriber contained in this Subscription Agreement shall survive the Tier 1 Closing and, if applicable, the Tier 2 Closing, notwithstanding such Closing or any investigation made by or on behalf of the Company with respect thereto and notwithstanding any subsequent disposition by the Subscriber of any of the Offered Shares, shall continue in full force and effect for the benefit of the Company for a period of two years following the later to occur of the Tier 1 Closing Time or, if applicable, the Tier 2 Closing Time.

6.4 Reliance and Indemnity

The Company is relying on the representations, warranties and covenants contained herein to determine the Subscriber’s eligibility to subscribe for the Offered Shares under applicable Securities Laws, and the Subscriber agrees to indemnify the Company and its directors and officers against all losses, claims, costs, expenses, damages or liabilities which any of them may suffer or incur as a result of or arising from reliance thereon.

ARTICLE 7 - FILINGS AND AUTHORIZATIONS

The Parties shall use their respective commercially reasonable efforts to obtain the authorizations, consents, waiting period expirations or terminations, Orders and approvals necessary or advisable for, and to avoid any Order which would block, their execution and delivery of, and the performance of their obligations pursuant to this Subscription Agreement. The Parties shall coordinate and cooperate with one another and shall exchange and provide information to each other, subject to entering into a reasonable joint defense and confidentiality agreement, as necessary for this Article 7. The Parties shall use commercially reasonable efforts to supply such assistance as may be reasonably requested by each another in connection with the foregoing. Subject to applicable confidentiality restrictions or restrictions required by applicable Law, the Parties will notify each other promptly upon the receipt of any request by any officials of any Governmental Entity for information or the production of any documents relating to an investigation of the transactions contemplated by this Subscription Agreement. Without limiting the generality of the foregoing, each Party shall, subject to such joint defense and confidentiality agreement, provide to the others (or the others’ respective advisors) upon request copies of all correspondence between such Party and any Governmental Entity relating to the transactions contemplated by this Subscription Agreement. In addition, to the extent reasonably practicable and acceptable to the Governmental Entity, all discussions, telephone calls, and meetings with a Governmental Entity regarding the transactions contemplated by this Subscription Agreement shall include representatives of both Parties. Subject to applicable Law, the Parties will consult and cooperate with each other in connection with any analyses, appearances, presentations, and memoranda submitted to any Governmental Entity regarding the transactions contemplated by this Subscription Agreement. Notwithstanding the foregoing, to the extent not precluded by MI 61-101, the Subscriber shall take all commercially reasonable steps to vote, or cause to be voted, the Offered Shares in favour of the special resolution approving the Articles of Amendment at the Company Meeting.

ARTICLE 8 - TERMINATION RIGHTS

8.1 Subscriber’s Termination Rights

In addition to any other remedies which may be available to the Subscriber in respect of any default, act or failure to act, or non-compliance with the terms of this Subscription Agreement by the Company, the Subscriber shall be entitled, at the Subscriber’s sole discretion, to terminate and cancel, without any liability on such Subscriber’s part, the Subscriber’s obligations to purchase the Tier 1 Preferred Shares under this Subscription Agreement if any condition set out in Section 4.2 has not be satisfied by the Company or waived by the Subscriber on or prior to 3:00 pm (EST) on October 31, 2017, unless such failure was caused by the

A-27

Subscriber’s bad faith or breach in any material respect of any provision of this Subscription Agreement, or unless such time restriction is amended by both the Company and Subscriber in writing.

8.2 Company’s Termination Rights

In addition to any other remedies which may be available to the Company in respect of any default, act or failure to act, or non-compliance with the terms of this Subscription Agreement by the Subscriber, the Company shall be entitled, at the Company’s sole discretion, to terminate and cancel, without any liability on such Company’s part, the Company’s obligations to issue the Tier 1 Preferred Shares under this Subscription Agreement if any condition set out in Section 4.3 has not be satisfied by the Subscriber or waived by the Company on or prior to 3:00 pm (EST) on October 31, 2017, unless such failure was caused by the Company’s bad faith or breach in any material respect of any provision of this Subscription Agreement, or unless such time restriction is amended by both the Subscriber and Company in writing.

8.3 Additional Termination Rights - Both Parties

In addition to any other remedies which may be available to either Party in respect of any default, act or failure to act, or non-compliance with the terms of this Subscription Agreement by the other Party, either Party shall be entitled, at such Party’s sole discretion, to terminate and cancel this Subscription Agreement at any time prior to the Tier 2 Closing Time if any order or ruling is issued by any stock exchange or market, or any other Governmental Entity in Canada, the United States, or any other applicable jurisdiction; or any law or regulation under or pursuant to any statute of Canada or of any province thereof, the United States or any other applicable jurisdiction, is promulgated or changed which moratorium, inquiry, investigation, proceeding, order, ruling, law or regulation permanently restrains, enjoins or otherwise prohibits the transactions to be consummated at the Tier 2 Closing Time, as applicable, as contemplated by this Subscription Agreement and has become final and non-appealable.

8.4 Alternative Transaction and Outside

If, despite the good faith efforts of both Parties and compliance in all materials respects with the provisions of this Subscription Agreement, the Company Shareholder Approval has not been obtained by February 28, 2018, then the Company and Subscriber shall, at the request of either Party, negotiate in good faith to determine if an alternative transaction can be undertaken between the Parties, and the manner in which the Parties would most effectively undertake such a transaction. If, despite the good faith efforts of the Parties, the Parties are not able to agree on an alternative transaction by April 30, 2018, this Subscription Agreement shall automatically terminate, without any liability on either Party, unless the failure to reach such an alternative transaction was caused by a Party’s bad faith or breach in any material respect of any provision of this Subscription Agreement.

8.5 Notice of Termination

The rights of termination contained in Sections 8.1, 8.2 and 8.3 may be exercised by the applicable Party giving written notice thereof to the other Party at any time prior to the Tier 1 Closing Time or, if applicable, Tier 2 Closing Time, and are in addition to any other rights or remedies such Party may have in respect of any default, act or failure to at or non-compliance by the other Party in respect of any of the matters contemplated by this Subscription Agreement or otherwise. In the event of any such termination, there shall be no further liability or obligation on the part of the Subscriber to the Company or on the part of the Company to the Subscriber except in respect of any liability or obligation under Sections 9.2, 9.3 and 9.5 of this Subscription Agreement, which will remain in full force and effect.

ARTICLE 9 - MISCELLANEOUS

9.1 Further Assurances

Each of the Parties, upon the request of each of the other Party hereto, whether before or after the Tier 1 Closing or the Tier 2 Closing, if applicable, shall do, execute, acknowledge and deliver or cause to be done, executed, acknowledged and delivered all such further acts, deeds, documents, assignments, transfers, conveyances, powers of attorney and assurances as may reasonably be necessary or desirable to complete the transactions contemplated herein.

9.2 Press Releases

All information with respect to this Subscription Agreement, the transactions contemplated hereby and all negotiations, discussions and actions related hereto shall be treated by the Parties as confidential information. A Party intending to make a public announcement or statement, including a news release, shall make the text of such announcement available to the other Party not

A-28

less than two (2) Business Days prior to publication and the other Party may make suggestions for changes. If the Subscriber is identified in any such public announcement or statement, the Company shall not release the public announcement or statement without the Subscriber’s consent in writing, which consent the Subscriber may withhold in its sole discretion. Notwithstanding the foregoing, nothing in this paragraph shall prevent the Company from making any public disclosure, including, without limitation, disclosure of the name of the Subscriber, if such disclosure is required by Law.

9.3 Notices


(a)	Any notice, direction or other instrument required or permitted to be given to any Party hereto shall be in writing and shall be sufficiently given if delivered personally, or transmitted by facsimile or electronic mail tested prior to transmission to such Party, as follows:


i.	in the case of the Company, to:

Arbutus Biopharma Corporation

100 - 9800 Glenlyon Parkway

Burnaby, British Columbia V5J 5J8

Attention: Bruce Cousins, Executive Vice President and Chief Financial Officer

Fax: (604) 419-3201

Email: bcousins@arbutusbio.com

with a copy to (which shall not constitute notice):

Farris, Vaughn, Wills & Murphy LLP

25th Floor, 700 W Georgia St

Vancouver, British Columbia V7Y 1B3

Attention: R. Hector MacKay-Dunn, J.D., Q.C.

Fax: (604) 661-9349

Email: hmackay-dunn@farris.com

Dorsey & Whitney LLP

Suite 1070, 1095 West Pender Street

Vancouver, British Columbia V6E 2M6

Attention: Daniel M. Miller

Fax: (604)687-8504

Email: miller.dan@dorsey.com


ii.	in the case of the Subscriber:

Roivant Sciences, Inc.

320 West 37th Street, 5th Floor

New York, New York 10018

Attention: Allen Waxman, General Counsel

Email: allen.waxman@roivant.com

with a copy to (which shall not constitute notice):

Lawson Lundell LLP

1600 - 925 West Georgia Street

Vancouver, British Columbia V6C 3L2

Attention: Valerie Mann and Crispin Arthur

Fax: (604) 641-2811

Email: vcmann@lawsonlundell.com

A-29

carthur@lawsonlundell.com

White & Case LLP

1221 Avenue of the Americas

New York, New York 10020

Attention: Chang-Do Gong

Fax: (212) 354-8113

Email: cgong@whitecase.com

(b)

Any such notice, direction or other instrument, if delivered personally, shall be deemed to have been given and received on the day on which it was delivered, provided that if such day is not a Business Day then the notice, direction or other instrument shall be deemed to have been given and received on the first Business Day next following such day and if transmitted by facsimile or electronic mail, shall be deemed to have been given and received on the day of its transmission, provided that if such day is not a Business Day or if it is transmitted or received after the end of normal business hours then the notice, direction or other instrument shall be deemed to have been given and received on the first Business Day next following the day of such transmission.


(c)	Any Party may change its address for service from time to time by notice given to the other Party in accordance with the foregoing provisions.

9.4 Time of the Essence

Time shall be of the essence of this Subscription Agreement and every part hereof.

9.5 Costs and Expenses

All costs and expenses (including, without limitation, the fees and disbursements of legal counsel) incurred in connection with this Subscription Agreement and the transactions herein contemplated shall be paid and borne by the party incurring such costs and expenses.

9.6 Applicable Law

This Subscription Agreement shall be construed and enforced in accordance with, and the rights of the Parties shall be governed by, the Laws of the Province of British Columbia and the Laws of Canada applicable therein. Any and all disputes arising under this Subscription Agreement, whether as to interpretation, performance or otherwise, shall be subject to the non-exclusive jurisdiction of the courts of the Province of British Columbia and each of the Parties hereby irrevocably attorns to the jurisdiction of the courts of such jurisdiction.

9.7 Entire Agreement

This Subscription Agreement, including the Schedules hereto, constitutes the entire agreement between the parties with respect to the transactions contemplated herein and cancels and supersedes any prior understandings, agreements, negotiations and discussions between the Parties. There are no representations, warranties, terms, conditions, undertakings or collateral agreements or understandings, express or implied, between the Parties hereto other than those expressly set forth in this Subscription Agreement or in any such agreement, certificate, affidavit, statutory declaration or other document as aforesaid. This Subscription Agreement may not be amended or modified in any respect except by written instrument executed by each of the Parties.

9.8 Counterparts

This Subscription Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original and all of which together shall constitute one and the same Subscription Agreement. Counterparts may be delivered either in original or faxed form and the Parties adopt any signature received by a receiving fax machine as original signatures of the Parties.

9.9 Assignment

This Subscription Agreement may not be assigned by either Party except with the prior written consent of the other Party.

A-30

9.10 Enurement

This Subscription Agreement shall enure to the benefit of and be binding upon the Parties hereto and their respective heirs, executors, successors (including any successor by reason of the amalgamation or merger of any party), administrators and permitted assigns.

9.11 Specific Performance

The Parties agree that irreparable damage would occur in the event that any of the provisions of this Subscription Agreement or any of the Company’s covenants, agreements and obligations under the terms of the Preferred Shares were not performed in accordance with their specific terms or were otherwise breached or threatened to be breached and that an award of money damages would be inadequate in such event. Accordingly, it is acknowledged that the Parties shall be entitled to equitable relief, without proof of actual damages, including an injunction or injunctions or orders for specific performance to prevent breaches of this Subscription Agreement or the Company’s covenants, agreements and obligations under the terms of the Preferred Shares and to enforce specifically the terms and provisions of this Subscription Agreement and the terms of the Preferred Shares in addition to any other remedy to which they are entitled at law or in equity as a remedy for any such breach or threatened breach. Each Party further agrees that the other Party shall not be required to obtain, furnish or post any bond or similar instrument in connection with or as a condition to obtaining any remedy referred to in this Section 9.11, and each Party (a) irrevocably waives any right it may have to require the obtaining, furnishing or posting of any such bond or similar instrument and (b) agrees to cooperate fully in any attempt by the other Party in obtaining such equitable relief. Each Party further agrees that the only permitted objection that it may raise in response to any action for equitable relief is that it contests the existence of a breach or threatened breach of this Subscription Agreement or the Company’s covenants, agreements and obligations under the terms of the Preferred Shares, as applicable.

The Company hereby accepts the subscription for the Offered Shares as set forth on the face page of this Subscription Agreement on the terms and conditions contained in this Subscription Agreement (including all applicable schedules) this 2nd day of October, 2017.

ARBUTUS BIOPHARMA CORPORATION

Per: /s/ Dr. Mark Murray

Authorized Signing Officer

A-31

SCHEDULE “A”

FORM OF MI 61-101 RESOLUTION

“BE IT RESOLVED THAT:

(a)

the Company is hereby authorized and directed to issue (i) the Tier 2 Preferred Shares, (ii) up to 13,025,536 Underlying Common Shares upon conversion of the Tier 2 Preferred Shares and (iii) such additional Common Shares as may become issuable upon conversion of the Tier 2 Common Shares pursuant to the rights attached thereto, all as more particularly described in the Company Circular, and such resolution is hereby confirmed, approved and adopted in all respects;


(b)	the Articles of the Company be amended to authorize the Subscriber Board Designation Right, as more particularly described in the Company Circular, and the Company be and is hereby authorized to make such conforming amendments to its corporate documents as may be necessary or advisable to give effect to the foregoing resolution;

(c)


(d)	these approvals are given for all purposes under the NASDAQ rules and under Multilateral Instrument 61-101.”

A-32

SCHEDULE “B”

PREFERRED SHARE RIGHTS AND RESTRICTIONS

A-33

TERMS OF

SERIES A PARTICIPATING CONVERTIBLE PREFERRED STOCK

ARBUTUS BIOPHARMA CORPORATION

WHEREAS, the board of Arbutus Biopharma Corporation (the “Company”) desires to designate a new series of preferred shares, no par value per share (the “Preferred Shares”), set the number of shares constituting such series, and the special rights and restrictions thereof;

RESOLVED that pursuant to Article 26 of the Articles of the Company:


(a)	there be created a Series A of Preferred shares of the Company;


(b)	the identifying name of the Series A Preferred shares of the Company be “Series A Participating Convertible Preferred Shares” (the “Series A Preferred Shares”);


(c)	the maximum number of Series A Preferred Shares which the Company is authorized to issue is 1,164,000 no par value shares;


(d)	there be created and attached to the Series A Preferred Shares the special rights and restrictions set out in Part 27 of the Articles of the Company, as adopted by paragraph (f) below;


(e)	the Notice of Articles of the Company be altered accordingly;


(f)	the Articles of the Company be altered by the addition of Part 27 thereof in the form of Part 27 set out in Schedule A to these resolutions, such alteration to the Articles not to take effect until the Notice of Articles of the Company is altered to reflect such alteration to the Articles;


(g)	the Company hereby appoints Farris Vaughan Wills and Murphy LLP to act as its agent for filing the Notice of Alteration to the Notice of Articles as set out above; and


(h)	any director of the Company be and is hereby authorized to do, sign and execute all things, instruments, deeds and documents as such director may deem necessary or desirable to carry out the foregoing resolutions.

A-34

Schedule A - Special Rights and Restrictions of the Preferred Shares - Series A Participating Convertible Preferred Shares:

ARTICLE 27. SPECIAL RIGHTS AND RESTRICTIONS ATTACHED TO PREFERRED SHARES, SERIES A

The rights, privileges, restrictions and conditions attaching to the Series A Preferred Shares are as set forth below.

27.1. Interpretation. In this Part 27, unless the context otherwise requires the following terms have the following meanings:

(a) “affiliate” means as to any Person, any other Person that, directly or indirectly, is in control of, is controlled by, or is under common control with, such entity.

(b) “Conversion Price” means initially $7.13, as adjusted from time to time as provided in Article 27.6(f).

(c) “Daily VWAP” means the volume-weighted average price per share of Common Shares (or per minimum denomination or unit size in the case of any security other than Common Shares) as displayed under the heading “Bloomberg VWAP” on the Bloomberg page for the “<equity> AQR” page corresponding to the “ticker” for such Common Share or unit (or its equivalent successor if such page is not available) in respect of the period from the scheduled open of trading until the scheduled close of trading of the primary trading session on such Trading Day (or if such volume-weighted average price is unavailable, the market value of one Common Share (or per minimum denomination or unit size in the case of any security other than Common Shares) on such Trading Day. The “volume weighted average price” shall be determined without regard to after-hours trading or any other trading outside of the regular trading session trading hours.

(d) “Dividend” means, as the context requires, Participating Dividend and Participating Penalty Dividends.

(e) “Exchange” means the NASDAQ Global Select Market, the NASDAQ Global Market, the NASDAQ Capital Market The New York Stock Exchange, the Toronto Stock Exchange or any of their respective successors.

(f) “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

(g) “Ex-Date” means the first date on which the Common Shares trade on the applicable Exchange or in the applicable market, regular way, without the right to receive the issuance, dividend or distribution in question from the Company or, if applicable, from the seller of the Common Shares on such Exchange or market (in the form of due bills or otherwise) as determined by such Exchange or market.

(h) “Fundamental Change” means (i) a Transaction; (ii) any transaction or series of related transactions, after giving effect to which in excess of fifty percent (50%) of the Company’s voting power is owned directly, or indirectly through one or more entities, by any “Person” (as that term is used in Section 13(d)(3) of the Exchange Act); provided, however, that Roivant Sciences Ltd. and and anyone else with whom Roivant Sciences Ltd. is acting jointly or concert in connection with the acquisition of the Company’s voting power (within the meaning of British Columbia securities law) shall

A-35

not constitute a Person for the purpose of this subclause (ii); (iii) any sale, lease or other transfer in one transaction or a series of transactions of all or substantially all of the consolidated assets of the Company and its subsidiaries taken as a whole, to any Person other than one of the Company’s wholly-owned subsidiaries; (iv) shareholders approve any plan or proposal for the liquidation or dissolution of the Company; and (v) the Common Shares (or Reference Property, to the extent applicable) ceases to be listed or quoted on any Exchange.

(i) “Liquidation Event” means (i) approval by shareholders of the voluntary liquidation, dissolution or winding-up of the Company, (ii) the involuntary liquidation, dissolution or winding-up of the Company, (iii) the commencement by the Company of any case under applicable bankruptcy, insolvency or other similar laws now or hereafter in effect, including pursuant to Chapter 11 of the U.S. Bankruptcy Code or the Bankruptcy and Insolvency Act (Canada), (iv) the consent to entry of an order for relief in an involuntary case under applicable bankruptcy, insolvency or other similar laws now or hereafter in effect, and (v) the consent to the appointment of or taking possession by a receiver, liquidator, assignee, custodian, trustee or similar official of the Company, or any general assignment for the benefit of creditors.

(k) “Mandatory Conversion Date” mean the date that is four years after the Tier 1 Closing Date (as such term is defined in the Subscription Agreement); provided that if the Mandatory Conversion Date is not a business day, the Mandatory Conversion Date shall be postponed to the next following business day.

(l) “Market Disruption Event” means the occurrence or existence for more than one half hour period in the aggregate on any scheduled Trading Day for the Common Shares (or Reference Property, to the extent applicable) of any suspension or limitation imposed on trading (by reason of movements in price exceeding limits permitted by the applicable Exchange or otherwise) in the Common Shares (or Reference Property, to the extent applicable) or in any options, contracts or future contracts relating to the Common Shares (or Reference Property, to the extent applicable), and such suspension or limitation occurs or exists at any time before 4:00 p.m. (New York City time) on such day.

(m) “Person” means any individual, corporation, limited liability company, limited or general partnership, joint venture, association, joint-stock company, trust, unincorporated organization, government, any agency or political subdivisions thereof or other “Person” as contemplated by Section 13(d) of the Exchange Act.

(n) “Purchase Price” means $100.00 per Series A Preferred Share, as the same may be increased pursuant to Article 27.3.

(o) “Shareholder Approval Date” means the date on which the Company Shareholder Approval (as such term is defined in the Subscription Agreement) is obtained.

(p) “Total Current Voting Power” means, with respect to any Person, at the time of determination of Total Current Voting Power, the total number of votes which may be cast in the general election of directors of such Person (or, in the event the Person is not a corporation, the governing members, board or other similar body of such Person).

(q) “Trading Day” means any day on which (i) there is no Market Disruption Event and (ii) NASDAQ or, if the Common Shares (or Reference Property, to the extent applicable) is not listed on NASDAQ, the principal national securities exchange on which the Common Shares (or Reference Property, to the extent applicable) is listed and is open for trading or, if the Common Shares (or Reference Property, to the extent applicable) is not so listed, admitted for trading or

A-36

quoted, any business day. A Trading Day only includes those days that have a scheduled closing time of 4:00 p.m. (New York City time) or the then standard closing time for regular trading on the relevant Exchange or trading system.

(r) Each of the following terms is defined in the Article set forth opposite such term:



Term	Article
Common Dividend	27.3(b)
Company	Recitals
Conversion Date	27.6(d)
In-Kind Common Dividend	27.3(c)
Junior Securities	27.2(b)(i)
Liquidation Preference Optional Conversion Date	27.6(c)(i) 27.6(a)
Parity Securities	27.2(b)(ii)
Participating Cash Dividend	27.3(b)
Participating Cash Penalty Dividends	27.3(b)
Participating Dividends Participating In-Kind Dividend Participating In-Kind Penalty Dividends	27.3(c) 27.3(c) 27.3(c)
Participating Penalty Dividends	27.3(c)
Preferred Shares	Recitals
Reference Property	27.6(f)(iii)
Senior Securities	27.2(b)(iii)
Series A Preferred Shares Shareholder Rights Plan	27.2(a) 27.3(c)
Transaction	27.6(f)(iii)

(s) Unless otherwise provided for herein, all monetary values stated herein are expressed in United States currency and all references to “dollars” or “$” will be deemed references to the lawful currency of the United States.

27.2 Number; Designation; Rank.

(a) This series of convertible participating Preferred Shares is designated as the “Series A Participating Convertible Preferred Shares” (the “Series A Preferred Shares”).

(b) The Series A Preferred Shares rank, with respect to the payment of dividends, redemption payments, rights (including as to the distribution of assets upon liquidation, dissolution or winding-up of the Company) or otherwise:

(i) senior in preference and priority to the Common Shares and each other class or series of the shares, except for any class or series of shares hereafter issued in compliance with the terms hereof and the terms of which expressly provide that it will rank senior to or on parity, without preference or priority, with the Series A Preferred Shares with respect to the payment of dividends, redemption payments, rights (including as to the distribution of assets) upon liquidation, dissolution or winding-up of the Company, or otherwise (collectively with the Common Shares, the “Junior Securities”)

(ii) on parity, without preference and priority, with each other class or series of shares hereafter issued in compliance with the terms hereof and the terms of which expressly provide that it will rank on parity, without

A-37

preference or priority, with the Series A Preferred Shares with respect to the payment of dividends, redemption payments, rights (including as to the distribution of assets) upon liquidation, dissolution or winding-up of the Company, or otherwise (collectively, the “Parity Securities”); and

(iii) junior in preference and priority to each other class or series of Preferred Shares or any other shares hereafter issued in compliance with the terms hereof and the terms of which expressly provide that it will rank senior in preference or priority to the Series A Preferred Shares with respect to the payment of dividends, redemption payments, rights (including as to the distribution of assets) upon liquidation, dissolution or winding-up of the Company or otherwise (collectively, “Senior Securities”).

27.3 Dividends.

(a) Dividends. No dividends shall accrue or be payable to holders of the Series A Preferred Shares except as set forth in Articles 27.3(b) and (c).

(b) Participating Cash Dividends. If the Company declares, makes or pays any cash dividend or distribution in respect of all or substantially all holders of Common Shares (a “Common Dividend”), each shareholder holding Series A Preferred Shares shall receive a dividend (a “Participating Cash Dividend”) in the same amount in respect of each Preferred Share held thereby, at the same time as holders of Common Shares, as such holders of Series A Preferred Shares would have received if, immediately prior to the record date of such Common Dividend, they had held the number of Common Shares issuable upon the Mandatory Conversion Date. If and to the extent that the Company does not for any reason pay the entire Participating Cash Dividend when the Common Dividend is paid to the holders of Common Shares, during the period in which such Participating Cash Dividend remains unpaid, an additional dividend (the “Participating Cash Penalty Dividends”) shall be payable at an annual rate equal to 8.75% compounded annually on the amount of the unpaid Participating Cash Dividend through the daily addition of such Participating Cash Penalty Dividends to the Purchase Price (whether or not such Participating Cash Penalty Dividends are declared by the board).

(c) Participating In-Kind Dividends. If the Company distributes shares, evidences of its indebtedness or other assets, securities or property, including rights to acquire assets, securities or property, to all or substantially all holders of Common Shares (an “In-Kind Common Dividend”), including without limitation any spin-off of one or more subsidiaries or businesses of the Company but excluding: (I) dividends or distributions referred to in Article 27.6(f)(i); and (II) cash dividends with respect to which holders of Series A Preferred Shares are entitled to Participating Cash Dividends, then such shareholders shall receive in such distribution or other transaction, at the same time and in the same manner as holders of Common Shares, the same type and amount of consideration (the “Participating In-Kind Dividend” and, together with the Participating Cash Dividend, the “Participating Dividends”) as holders of Series A Preferred Shares would have received if, immediately prior to the record date of such In-Kind Common Dividend, they had held the number of Common Shares issuable upon the Mandatory Conversion Date. To the extent that the Company establishes or adopts a shareholder rights plan or agreement (i.e., a “poison pill”) (each, a “Shareholder Rights Plan”), the Company shall ensure that such shareholders will receive, as a Participating In-Kind Dividend, rights under the Shareholder Rights Plan with respect to any Common Shares that at the time of such distribution would be issuable upon conversion of the Preferred Shares. If and to the extent that the Company does not for any reason pay the entire Participating In-Kind Dividend when the In-Kind Common Dividend is paid to the holders of Common Shares, during the period in which such Participating In-Kind Dividend remains unpaid, an additional dividend (the

A-38

“Participating In-Kind Penalty Dividends” and, together with Participating Cash Penalty Dividends, the “Participating Penalty Dividends”) shall be payable at an annual rate equal to 8.75% on the amount of the unpaid Participating In-Kind Dividend through the daily addition of such Participating In-Kind Penalty Dividends to the Purchase Price (whether or not such Participating In-Kind Penalty Dividends are declared by the board).

27.4 Liquidation Preference.

(a) Upon any Liquidation Event, each Series A Preferred Share entitles the holders thereof to receive and to be paid out of the assets of the Company legally available for distribution to the Company’s shareholders, before any distribution or payment may be made to a holder of any Junior Securities, an amount in cash per share equal to an amount the holders of such share would have received upon such Liquidation Event had such shareholder converted such Series A Preferred Share into Common Shares (or Reference Property, to the extent applicable) upon the Mandatory Conversion Date.

(b) If upon any such Liquidation Event, the assets of the Company legally available for distribution to all shareholders of the Company are insufficient to pay the holders of Series A Preferred Shares the full Liquidation Preference and the holders of all Parity Securities the full liquidation preferences to which they are entitled, the shareholders of the Series A Preferred Shares and the holders of such Parity Securities will share ratably in any such distribution of the assets of the Company in proportion to the full respective amounts to which they are entitled.

(c) After payment to the holders of the Series A Preferred Shares of the full Liquidation Preference to which they are entitled, such shareholders, as such, will have no right or claim to any of the assets of the Company.

(d) The value of any property not consisting of cash that is distributed by the Company to the holders of the Series A Preferred Shares will equal the fair market value thereof (as determined in good faith by the board) on the date of distribution.

(e) No holder of Junior Securities shall receive any cash upon a Liquidation Event unless the entire Liquidation Preference in respect of the Series A Preferred Shares has been paid in cash. To the extent that there is insufficient cash available to pay the entire Liquidation Preference in respect of the Series A Preferred Shares and any liquidation preference in respect of Parity Securities in full in cash upon a Liquidation Event, the holders of the Series A Preferred Shares and the holders of such Parity Securities will share ratably in any cash available for distribution in proportion to the full respective amounts to which they are entitled upon such Liquidation Event.

(f) For the avoidance of doubt, a Transaction or Fundamental Change shall not be treated as a Liquidation Event for the purpose of this Article 27.4 (unless in connection therewith, the liquidation, dissolution or winding up of the Company is specifically approved), but shall be treated as provided for in Article 27.6(c) hereof.

27.5. Voting Rights. The Series A Preferred Shares shall not have the right to vote on any matters except as required by law, including under the British Columbia Business Corporations Act. Where such vote is required by law, as of any record date or other determination date, each shareholder holding Series A Preferred Shares shall be entitled to the number of votes such shareholder would have had if all Series A Preferred Shares held by such shareholder on such date would be converted into Common Shares on the Mandatory Conversion Date.

A-39

27.6. Conversion. Each Series A Preferred Share is convertible into Common Shares (or Reference Property, to the extent applicable) as provided in this Article 27.6.

(a) Conversion at the Option of Holders of Series A Preferred Shares. Subject to Article 27.6(b) hereof, each holder of Series A Preferred Shares is entitled to convert any or all outstanding Series A Preferred Shares held by such shareholder and receive therefor the property described in Article 27.6(c) upon such conversion in the event of (A) a transaction that involves a fundamental transfer of value to the Common Shares by means of a distribution, event or other transaction in which the Preferred Shares do not have the right to pursuant to Articles 27.3(b) or (c), or (B) a Fundamental Change. In order to convert Series A Preferred Shares into Common Shares (or Reference Property, to the extent applicable), the holder of the Series A Preferred Shares must surrender the certificates representing such Series A Preferred Shares at the office of the Company’s transfer agent for the Series A Preferred Shares (or at the registered and records office of the Company, if the Company serves as its own transfer agent), together with (x) written notice that such shareholder elects to convert all or part of the Series A Preferred Shares represented by such certificates as specified therein, (y) a written instrument or instructions of transfer or other documents and endorsements reasonably acceptable to the transfer agent or the Company, as applicable (if reasonably required by the transfer agent or the Company, as applicable), and (z) funds for any stock transfer, documentary, stamp or similar taxes, if payable by the shareholder pursuant to Article 27.6(e)(i). Except as provided in Article 27.6(b), the date the transfer agent or the Company, as applicable, receives such certificates, together with such notice and any other documents and amounts required to be paid by the holders of Series A Preferred Shares pursuant to this Article 27.6(a), will be the date of conversion (the “Optional Conversion Date”).

(b) Mandatory Conversion. In the event that any holder of Series A Preferred Shares has not elected to convert the Series A Preferred Shares held by such holder pursuant to Article 27.6(a) on or before the Mandatory Conversion Date, then such shareholder’s Series A Preferred Shares shall be automatically converted (without any further action by the shareholder and whether or not the certificates representing the Series A Preferred Shares are surrendered), in whole and not in part, into the property described in Article 27.6(c), effective as of the Mandatory Conversion Date. As promptly as practicable (but in no event more than five (5) business days) following the Mandatory Conversion Date, the Company shall deliver a notice to any shareholder whose Series A Preferred Shares have been converted pursuant to this Article 27.6(b), informing such shareholder of the number of Common Shares into which such Series A Preferred Shares have been converted, together with certificates evidencing such Common Shares. Notwithstanding the foregoing, any notice delivered by the Company in compliance with this Article 27.6(b) shall be conclusively presumed to have been duly given, whether or not such holder of Series A Preferred Shares actually receives such notice, and neither the failure of a shareholder to actually receive such notice given as aforesaid nor any immaterial defect in such notice shall affect the validity of the proceedings for the conversion of the Series A Preferred Shares as set forth in this Article 27.6(b).

(c) Amounts Received Upon Conversion. Upon a conversion of Series A Preferred Shares pursuant to Articles 27.6(a) or 27.6 (b), the holder of such converted Series A Preferred Shares shall, subject to the limitations and adjustments pursuant to the first paragraph of Article 27.6, receive in respect of each Series A Preferred Share:

A-40

as if the Mandatory Conversion Date had occurred irrespective of the timing of such conversion (the “Liquidation Preference”) by (B) the Conversion Price in effect at the time of conversion;

(ii) cash in an amount equal to the amount of any accrued but unpaid Participating Cash Dividends (to the extent not included in the Purchase Price) on the Series A Preferred Shares being converted; provided that, to the extent the Company is prohibited by law or by contract from paying such amount, then the Company shall provide written notice to the applicable holder of such inability to pay, and at the written election of the shareholder (which written election shall be delivered to the Company within five (5) business days of receipt of such written notice from the Company), the Company shall either pay such amount as soon as payment is no longer so prohibited or issue Common Shares (or Reference Property, to the extent applicable) in the manner specified in Article 27.6(c)(i) as if the amount of such accrued but unpaid Participating Cash Dividends were added to the Purchase Price; and

(iii) any accrued and unpaid Participating In-Kind Dividends.

(d) Fractional Shares. No fractional shares of Common Shares (or fractional shares in respect of Reference Property, to the extent applicable) will be issued upon conversion of the Series A Preferred Shares. In lieu of fractional shares, the Company shall pay cash in respect of each fractional share equal to such fractional amount multiplied by the Daily VWAP of the Common Shares over the thirty (30) consecutive Trading Day period ending on the Trading Day immediately preceding the Optional Conversion Date or the Mandatory Conversion Date, as the case may be (each, a “Conversion Date”). If more than one Series A Preferred Share is being converted at one time by the same holder thereof, then the number of full shares issuable upon conversion will be calculated on the basis of the aggregate number of Series A Preferred Shares converted by such shareholder at such time.

(e) Mechanics of Conversion.

(i) As soon as reasonably practicable after the Conversion Date (and in any event within four (4) Trading Days after either such date), the Company shall issue and deliver to such shareholder one or more certificates for the number of Common Shares (or Reference Property, to the extent applicable) to which such holder of Series A Preferred Shares is entitled, together with, at the option of the shareholder, a certified cheque or wire transfer of immediately available funds for payment of fractional shares and any payment required by Article 27.6(c)(ii) in exchange for the certificates representing the converted Series A Preferred Shares. Such conversion will be deemed to have been made on the Conversion Date, and the Person entitled to receive the Common Shares (or Reference Property, to the extent applicable) issuable upon such conversion shall be treated for all purposes as the record holder of such Common Shares (or Reference Property, to the extent applicable) on such date. The delivery of Common Shares upon conversion of Series A Preferred Shares shall be made, at the option of the applicable shareholder, in certificated form or by book-entry. Any such certificate or certificates shall be delivered by the Company to the appropriate shareholder on a book-entry basis or by mailing certificates evidencing the shares to the holders of the Series A Preferred Shares at their respective addresses as set forth in the conversion notice. In cases where fewer than all the Series A Preferred Shares represented by any such certificate are to be converted, a new certificate shall be issued representing the unconverted Series A Preferred Shares. The Company shall pay any documentary, stamp or similar issue or transfer tax due on the issue of Common Shares (or Reference Property, to the extent applicable) upon conversion or due upon the issuance of a new certificate for any Series A Preferred Shares not converted to the converting shareholder; provided that the Company shall not be required to pay any such amounts, and any such amounts shall be paid by the

A-41

converting shareholder, in the event that such Common Shares or Series A Preferred Shares are issued in a name other than the name of the converting shareholder.

(ii) For the purpose of effecting the conversion of Series A Preferred Shares, the Company shall: (A) at all times reserve and keep available, free from any preemptive rights, out of its treasury or authorized but unissued Common Shares (or Reference Property, to the extent applicable) the full number of Common Shares (or Reference Property, to the extent applicable) deliverable upon the conversion of all outstanding Series A Preferred Shares after taking into account any adjustments to the Conversion Price from time to time pursuant to the terms of this Article 27.6 and any increases to the Purchase Price from time to time and assuming for the purposes of this calculation that all outstanding Series A Preferred Shares are held by one holder) and (B) without prejudice to any other remedy at law or in equity any holder of Series A Preferred Shares may have as a result of such default, take all actions reasonably required to amend its Notice of Articles or Articles, as expeditiously as reasonably practicable, to increase the authorized and available amount of Common Shares (or Reference Property, to the extent applicable) if at any time such amendment is necessary in order for the Company to be able to satisfy its obligations under this Article 27.6.

(iii) From and after the Conversion Date, the Series A Preferred Shares converted on such date, will no longer be deemed to be outstanding and all rights of the holder thereof including the right to receive Dividends, but excluding the right to receive from the Company the Common Shares (or Reference Property, to the extent applicable) or any cash payment upon conversion, and except for any rights of shareholders holding Series A Preferred Shares (including any voting rights) pursuant to this Article 27.6 which by their express terms continue following conversion or, for the avoidance of doubt, rights which by their express terms continue following conversion pursuant to the Subscription Agreement, shall immediately and automatically cease and terminate with respect to such Series A Preferred Shares; provided that, in the event that a Series A Preferred Share is not converted due to a default by the Company or because the Company is otherwise unable to issue the requisite Common Shares (or Reference Property, to the extent applicable), such Series A Preferred Share will, without prejudice to any other remedy at law or in equity any shareholder holding Series A Preferred Shares may have as a result of such default, remain outstanding and will continue be entitled to all of the rights attendant to such Series A Preferred Share as provided herein.

(v) The Company shall comply with all federal, provincial and state laws, rules and regulations and applicable rules and regulations of the Exchange on which Common Shares (or Reference Property, to the extent applicable) are then listed. If any Common Shares (or Reference Property, to the extent applicable) to be reserved for the purpose of conversion of Series A Preferred Shares require registration with or approval of any Person or group (as such term is defined in Section 13(d)(3) of the Exchange Act) under any federal or state law or the rules and regulations of the Exchange on which Common Shares (or Reference Property, to the extent applicable) are then listed before such shares may be validly issued or delivered upon conversion, then the Company will, as expeditiously as reasonably practicable, use commercially reasonable efforts to secure such registration or approval, as the case may be. So long as any Common Shares (or Reference Property, to the extent applicable) into which the Series A Preferred Shares are then convertible is then listed on an Exchange, the Company will list and keep listed on any such Exchange, upon official notice of issuance, all Common Shares (or Reference Property, to the extent applicable) issuable upon conversion.

(vi) All Common Shares (or Reference Property, to the extent applicable) issued upon conversion of the Series A Preferred Shares will, upon issuance by the Company, be duly and validly issued, fully paid and

A-42

nonassessable, not issued in violation of any preemptive or similar rights arising under law or contract and free from all taxes, liens and charges with respect to the issuance thereof, and the Company shall take no action which will cause a contrary result.

(f) Adjustments to Conversion Price.

(i) Common Stock Dividends, Splits and Combinations. The Conversion Price shall be adjusted if the Company issues Common Shares as a dividend or distribution on its Common Shares, or if the Company effects a share split or share combination with respect to Common Shares, the Conversion Price based on the following formula:

where,

CP₀ = the Conversion Price in effect immediately prior to the open of business on the Ex-Date for such dividend or distribution, or the open of business on the effective date of such share split or share combination, as the case may be;

CP₁ = the Conversion Price in effect immediately after the open of business on the Ex-Date for such dividend or distribution, or the open of business on the effective date of such share split or share combination, as the case may be;

OS₀ = the number of Common Shares outstanding immediately prior to the open of business on the Ex-Date for such dividend or distribution, or the open of business on the effective date of such share split or share combination, as the case may be; and

OS₁ = the number of Common Shares outstanding immediately after such dividend or distribution, or such share split or share combination, as the case may be.

Any adjustment made under this Article 27.6(f)(i) shall become effective immediately after the open of business on the Ex-Date for such dividend or distribution, or immediately after the open of business on the effective date for such share split or share combination, as the case may be. If any dividend or distribution of the type described in this Article 27.6(f)(i) is declared but not so paid or made, or any share split or combination of the type described in this Article 27.6(f)(i) is announced but the outstanding Common Shares are not split or combined, as the case may be, the Conversion Price shall be immediately readjusted, effective as of the date the board determines not to pay such dividend or distribution, or not to split or combine the outstanding Common Shares, as the case may be, to the Conversion Price that would then be in effect if such dividend, distribution, share split or share combination had not been declared or announced.

(ii) Impact of Conversion. Notwithstanding anything in this Article 27.6(f) to the contrary, if a Conversion Price adjustment becomes effective pursuant to Article 27.6(f)(i) on any Ex-Date as described above, and a shareholder holding Series A Preferred Shares that converts its Series A Preferred Shares on or after such Ex-Date and on or prior to the related record date would be treated as the record holder of Common Shares as of the related Conversion Date based on an adjusted Conversion Price for such Ex-Date and participate on an adjusted basis in the related dividend or other event giving rise to such adjustment, then, notwithstanding the foregoing Conversion Price adjustment provisions, the Conversion Price adjustment relating to such Ex-Date will not be made for such converting shareholder. Instead, such

A-43

shareholder will be treated as if such shareholder were the record owner of the Common Shares on an un-adjusted basis and participate in the related dividend, distribution or other event giving rise to such adjustment.

(iii) Reference Property. In the case of any recapitalization, reclassification or change of the Common Shares (other than changes resulting from a subdivision or combination described in Article 27.6(f)(i)), a consolidation, merger or combination involving the Company, a sale, lease or other transfer to a third party of all or substantially all of the assets of the Company (or the Company and its subsidiaries on a consolidated basis), or any statutory share exchange, in each case as a result of which the Common Shares would be converted into, or exchanged for, stock, other securities, other property or assets (including cash or any combination thereof) (any of the foregoing, a “Transaction”), then, at the effective time of the Transaction, the right to convert each Series A Preferred Share will be changed into a right to convert such Series A Preferred Share into the kind and amount of shares of stock, other securities, other property or assets (including cash or any combination thereof) (the “Reference Property”) that a holder of Series A Preferred Shares would have received in respect of the Common Shares issuable upon conversion of such Series A Preferred Shares immediately prior to such Transaction. In the event that holders of Common Shares have the opportunity to elect the form of consideration to be received in the Transaction, the Company shall make adequate provision whereby the holders of Series A Preferred Shares shall have a reasonable opportunity to determine the form of consideration into which Series A Preferred Shares shall be convertible from and after the effective date of the Transaction. Any such determination by the holders of Series A Preferred Shares shall be subject to any limitations to which all holders of Common Shares are subject, such as pro rata reductions applicable to any portion of the consideration payable in the Transaction, and shall be conducted in such a manner as to be completed at approximately the same time as the time elections are made by holders of Common Shares. The provisions of this Article 27.6(f)(iii) and any equivalent thereof in any such securities similarly shall apply to successive Transactions. The Company shall not become a party to any Transaction unless its terms are in compliance with the foregoing.

(iv) Rules of Calculation; Treasury Shares. All calculations will be made to the nearest one-hundredth of a cent or to the nearest one-ten thousandth of a share. Except as explicitly provided herein, the number of Common Shares (or Reference Property, to the extent applicable) outstanding will be calculated on the basis of the number of issued and outstanding Common Shares (or Reference Property, to the extent applicable), not including shares held in the treasury of the Company. The Company shall not pay any dividend on or make any distribution to Common Shares (or Reference Property, to the extent applicable) held in treasury.

(v) Notice of Record Date. In the event of:

(A) any event described in Article 27.6(f)(i);

(B) any Transaction to which Article 27.6(f)(iii) applies; or

then the Company shall mail to the holders of the Series A Preferred Shares at their last addresses as shown on the records of the Company, at least twenty (20) days prior to the record date specified in (A) below or twenty (20) days prior to the date specified in (B) below, as applicable, a notice stating:

A-44

(A) the record date for the dividend, other distribution, stock split or combination or, if a record is not to be taken, the date as of which the holders of record of Common Shares to be entitled to such dividend, other distribution, stock split or combination; or

(B) the date on which such reclassification, change, dissolution, liquidation, winding-up or other event constituting a Transaction, is reasonably anticipated to become effective or otherwise occur, and the date as of which it is expected that holders of Common Shares of record will be entitled to exchange their Common Shares for Reference Property, other securities or other property deliverable upon such reclassification, change, liquidation, dissolution, winding-up or a Transaction is reasonably anticipated to occur.

(vi) Certificate of Adjustments. Upon the occurrence of each adjustment or readjustment of the Conversion Price pursuant to this Article 27.6, the Company at its expense shall as promptly as reasonably practicable compute such adjustment or readjustment in accordance with the terms hereof and furnish to each holder of Series A Preferred Shares a certificate, signed by an officer of the Company (in his or her capacity as such and not in an individual capacity), setting forth (A) the calculation of such adjustments and readjustments in reasonable detail, (B) the facts upon which such adjustment or readjustment is based, (C) the Conversion Price then in effect, and (D) the number of Common Shares (or Reference Property, to the extent applicable) and the amount, if any, of the shares, other securities or other property (including but not limited to cash and evidences of indebtedness) which then would be received upon the conversion of a Series A Preferred Share.

(vii) No Impairment. The Company will not, except with any approval required by Article 27.5 hereof and applicable law, by amendment of the Articles of the Company or through any reorganization, recapitalization, transfer of assets, merger, consolidation, dissolution, issue or sale of shares or other securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder by the Company but will at all times in good faith assist in the carrying out of all the provisions of this Article 27.6 and in the taking of all such actions as may be necessary or appropriate in order to protect the conversion rights of the holders of the Series A Preferred Shares against impairment; provided, however, that nothing in this Article 27.6 shall serve to limit or otherwise affect the right of the Company to enter into a Transaction or effect a Fundamental Change.

(f) No Other Conversion Rights. The holders of Series A Preferred Shares shall have no rights of conversion other than as specifically set forth herein.

A-45

SCHEDULE “C”

OPINIONS OF COMPANY’S COUNSEL


1.	The incorporation and valid existence of the Company and the Subsidiaries.


2.	That the Company has the corporate power and capacity to carry on its business as now carried on by it and to own its assets and to amend the Articles to designate and issue the Offered Shares having such rights, privileges and obligations as described in Schedule B of the Subscription Agreement.


3.	The authorized share capital of the Company. The rights of the Offered Shares are as set forth in the Articles.


4.	That the Subscription Agreement has been duly authorized, executed and delivered by the Company and constitutes a valid and binding obligation of the Company enforceable against the Company in accordance with its terms.

That the execution and delivery of the Subscription Agreement, the performance of the obligations of the Company thereunder, the compliance by the Company with the terms and conditions thereof and the issue and sale of the Offered Shares (including the terms of the Offered Shares) do not constitute and will not constitute, with notice or lapse of time or with both notice and lapse of time, a breach of, or default under the articles of the Company or any statute or regulation of the Province of British Columbia or any federal statute or regulation of Canada having the force of law binding upon the Company and do not and will not conflict with the articles or notice of articles of the Company.


6.	That the Tier 1 Preferred Shares and, if applicable, the Tier 2 Preferred Shares have been duly authorized, allotted and validly issued, and that the Underlying Common Shares, have been reserved for issuance.

That no prospectus, offering memorandum or other document is required under the Securities Laws of British Columbia, and except as have been obtained or completed, no proceeding is required to be taken and no approval, consent or authorization of or filing with any securities regulatory authority in the such jurisdiction is required in order to permit the issuance of the Offered Shares, subject to certain specified conditions and exceptions.

That no prospectus, offering memorandum or other document is required to be filed, no proceeding required to be taken and no approval, permit, consent or authorization is required to be obtained under the Securities Laws of British Columbia in connection with the first trade of the Tier 1 Preferred Shares or and, if applicable, the Tier 2 Preferred Shares in the such jurisdiction through persons registered in a category permitting them to trade such securities under such Securities Laws, provided that:


(a)	the Company is and has been a reporting issuer in a jurisdiction of Canada for the four-month period immediately preceding the trade;


(b)	a four-month period has elapsed from the date of issue of the Offered Shares;


(c)	the trade is not a “control distribution” as defined in National Instrument 45‑102;


(d)	no unusual effort is made to prepare the market or create a demand for such securities;


(e)	no extraordinary commission or other consideration is paid in respect of such trade;


(f)	if the seller is an insider or officer of the Company, the seller has no reasonable grounds to believe that the Company is in default of securities legislation; and


(g)	the certificates representing the Tier 1 Preferred Shares and, if applicable, the Tier 2 Preferred Shares, as the case may be, carried the appropriate legend provided under National Instrument 45‑102 and Securities Laws.

Additionally, the Company shall cause to be delivered to the Subscriber an opinion from U.S. counsel in form and content customary for transactions of this nature, including, without limitation, with respect to no order or consent required, no investment company, no registration, no violation of laws, no order or consent required, no investment company, no registration and no violation of laws.

A-46

SCHEDULE “D”

GOVERNANCE AGREEMENT AMENDING AGREEMENT

A-47

AMENDED AND RESTATED GOVERNANCE AGREEMENT

THIS AGREEMENT is made as of this ___ day of October, 2017.

BETWEEN:

Arbutus Biopharma Corporation, a corporation incorporated under the laws of British Columbia previously known as Tekmira Pharmaceuticals Corporation

(the “Company”)

- and -

Roivant Sciences Ltd., a Bermuda exempted limited company

(the “Shareholder”)

WHEREAS:


A.	The parties entered into a governance agreement dated as of January 11, 2015 (the “Original Governance Agreement”), in connection with a merger agreement entered into between the Company and OnCore Biopharma, Inc., as a result of which the Shareholder received Common Shares of the Company;


B.	The parties entered into a subscription agreement dated as of October 1, 2017 (the “Subscription Agreement”), providing for the purchase by the Shareholder of 1,164,000 Class A Preferred Shares (the “Preferred Shares”) of the Company, issuable in two tranches;

As a condition to the “Tier 1 Closing” (as defined in the Subscription Agreement), the parties agreed to amend and restate the Original Governance Agreement as provided for herein and to use commercially reasonable efforts to cause, by the "Tier 2 Closing" (as defined in the Subscription Agreement), the existing articles of the Company to be amended, which amendment (the “Amendment”) is attached as Schedule 1 to this Agreement.

NOW THEREFORE in consideration of the mutual covenants and agreements contained in this Agreement and other good and valuable consideration (the receipt and sufficiency of which are hereby acknowledged), the Parties agree as follows:

ARTICLE 1

INTERPRETATION AND GENERAL MATTERS

1.1 Definitions

In this Agreement, including the recitals, unless otherwise stated, capitalized terms used will have the meanings specified below:

“Affiliate” means with respect to any Person, any other Person that, directly or indirectly: (i) Controls, (ii) is Controlled by or (iii) is under common Control with, such Person;

“Agreement” means this document, together with any schedules attached hereto and made a part hereof, all as amended, supplemented or modified from time to time in accordance with the provisions hereof;

“Amendment” has the meaning ascribed thereto in Recital C;

“Articles” means the articles of the Company as amended by the Amendment;

“Board” means the board of directors of the Company;

“Business Day” means any day other than (i) a Saturday or a Sunday or (ii) a day on which commercial banking institutions are authorized or required by applicable law to be closed in California, New York or British Columbia;

“Common Shares” means the common shares in the capital of the Company;

A-48

“Company” has the meaning given to it in the Preamble;

“Control” means, (i) when applied to the relationship between any Person(s) and a corporation, the beneficial ownership by such Person(s) at the relevant time of shares of that corporation carrying the lesser of (A) a majority of the voting rights ordinarily exercisable at meetings of shareholders of that corporation and (B) the percentage of voting rights ordinarily exercisable at meetings of shareholders of that corporation that are sufficient to elect a majority of the directors, (ii) when applied to the relationship between any Person(s) and a limited liability company, partnership, trust or joint venture, means the beneficial ownership by such Person(s) at the relevant time of more than 50% of the ownership interests of the limited liability company, partnership, trust or joint venture or the contractual right to direct the affairs of the limited liability company, partnership, trust or joint venture, and (iii) when applied to the relationship between any Person and a limited partnership, means that such Person is the general partner of the limited partnership; and the words “Controlled by”, “Controlling” and similar words have corresponding meanings; provided that any Person(s) who Controls a corporation, limited liability company, partnership, limited partnership, trust or joint venture will be deemed to Control a corporation, limited liability company, partnership, limited partnership, trust or joint venture that is Controlled by such corporation, limited liability company, partnership, limited partnership, trust or joint venture, and so on;

“Partially Diluted Basis” means the sum of (i) the total number of Common Shares beneficially owned by the Shareholder and (ii) the total number of Common Shares into which the Preferred Shares beneficially owned by the Shareholder are convertible as of the Mandatory Conversion Date (as defined in the Company's Articles), and outstanding Common Shares shall be determined based on the sum of (x) the number of outstanding Common Shares as of the date of determination and (y) the number of Common Shares issuable on conversion of the Preferred Shares as of the Mandatory Conversion Date;

“Parties” means the Company, the Shareholder and their respective successors and permitted assigns, and “Party” means any one of them;

“Person” includes an individual, a limited liability company, a partnership, a limited partnership, a corporation with or without share capital, a trust, a joint venture, a syndicate, an unincorporated organization, a union, a government or any department or agency thereof and the heirs, executors, administrators or other legal representatives of an individual;

“Preferred Shares” has the meaning given to it in Recital B;

“Shareholder” has the meaning given to it in the Preamble;

“Shareholder Designees” has the meaning given to it in Section 2.1(a);

“Subscription Agreement” has the meaning given to it in Recital B;

“Tier 1 Closing” has the meaning given such term in Recital C; and

“Tier 2 Closing” has the meaning given such term in Recital C.

1.2 Effectiveness

Notwithstanding any other provision contained herein or in any other agreement between the Parties, this Agreement will come into full force and effect, upon completion of the Tier 1 Closing in accordance with the terms of the Subscription Agreement and terminating upon the earlier of (i) forty-eight (48) months following the Tier 1 Closing and (ii) when Shareholder no longer has a right to nominate one or more directors under the Amendment. For greater certainty, this Agreement will not be effective, and the provisions hereof will have no force or effect, if the Tier 1 Closing is not completed.

1.3 References, Headings and Schedule

The references “hereunder”, “herein” and “hereof” refer to the provisions of this Agreement, and references to Articles and Sections herein refer to articles, sections, or subsections of this Agreement. The headings of the Articles and Sections and any other headings, captions or indices herein are inserted for convenience of reference only and shall not be used in any way in construing or interpreting any provision hereof. Schedule 1 - Amendment to Articles attached hereto forms a part of this Agreement.

A-49

1.4 Singular/Plural; Derivatives

Whenever the singular or masculine or neuter is used in this Agreement, it shall be interpreted as meaning the plural or feminine or body politic or corporate, and vice versa, as the context requires. Where a term is defined herein, a capitalized derivative of such term shall have a corresponding meaning unless the context otherwise requires.

1.5 Statutory References

Unless stated otherwise, any reference to a statute shall include and shall be deemed to be a reference to such statute and to the regulations made pursuant thereto, and all amendments made thereto and enforced from time to time, and to any statute or regulation that may be passed which has the effect of supplementing the statute so referred to or the regulations made pursuant thereto.

1.6 Business Days

Whenever any action to be taken pursuant to this Agreement would otherwise be required to be taken or made on a day that is not a Business Day, such action shall be taken on the first Business Day following such day.

1.7 Calculation of Equity Interests

The Company shall be entitled to rely on the public filings of the Shareholder and its Affiliates with respect to the number of shares of the Company held by them unless and until such time as the Shareholder provides evidence satisfactory to the Company, acting reasonably, as to the number of shares held by them. Any calculation of Shareholder's equity interests will be based on the determination of such equity interests on a Partially Diluted Basis at the relevant time.

ARTICLE 2

GOVERNANCE MATTERS

2.1 Board

2.1.1

The Company will cause that number of individuals designated by the Shareholder set out in the Articles (the “Shareholder Designees”) to be appointed to the Board in accordance with the Articles either concurrently with the Tier 2 Closing or, if for any reason such Tier 2 Closing does not occur, then otherwise by resolution of the Board to add a director as provided for, and otherwise in accordance with, the Articles; provided that, in such circumstance, the Company agrees that it will, at the next annual general or special meeting held following the effective date hereof at which directors of the Company are to be elected, put before the shareholders of the Company an amendment to the Articles of the Company substantially in the form of Amendment to provide for the appointment of Shareholder Designees as set out therein. The Company and the Shareholder agree that, if required by applicable laws, any additional Shareholder Designees in addition to the two Shareholder Designees as are currently appointed pursuant to the Original Governance Agreement, will be independent director(s) for the purposes of applicable laws.

2.1.2

At each annual general or special meeting of the Company’s shareholders held following the effective date hereof at which directors of the Company are to be elected, the Company will put forward for nomination for election to the Board those Shareholder Designees that the Shareholder is entitled to nominate pursuant to the Articles (who need not be the same individuals as the Shareholder Designees appointed to the Board pursuant to Section 2.1(a) but shall be those individuals set out as RS Nominated Directors pursuant to a Nomination Notice as those terms are defined in the Articles), and shall use commercially reasonable efforts to obtain shareholder approval for the election of the Shareholder Designees at such meetings (including by soliciting proxies in favour of the Shareholder Designees) and to that end will support the Shareholder Designees for election in a manner no less rigorous or favourable than the manner in which the Company supports any of its other nominees.


2.1.3	The Company shall provide advance notice to the Shareholder of any upcoming shareholders’ meetings in accordance with Part 28 of the Articles.

2.1.4

In the event that any Shareholder Designee resigns, dies, becomes incapacitated or otherwise ceases to be a director prior to the expiration of his or her term as a director, such vacancy shall be filled in accordance with the provisions of section 5 of Part 28 of the Articles. The Company shall use all commercially reasonable steps, promptly upon receipt by it of a written notice from the Shareholder identifying a Shareholder Designee to fill such vacancy and in any event no later than five (5) business days following receipt of such written notice, as are necessary to call a meeting of the board of directors to vote on the appointment of such Shareholder Designee

A-50

to fill such vacancy (or to obtain a vote of the directors by way of unanimous written resolution) and take all such other steps as are required by the Articles and the Act with respect to such appointment.

2.2 Voting

Unless and until the Shareholder no longer has the right to appoint a Shareholder Designee pursuant to the Articles and provided that the Company is in material compliance with the terms of this Agreement and the Articles, the Shareholder will vote, and will cause its Affiliates to vote, all of the shares of the Company then owned by the Shareholder and its Affiliates:


2.2.1	in favour of:


(a)	the election of any person or persons nominated for election to the Board by the Board from time to time in accordance with the Articles, and


2.2.2	against:


(b)	the election of any person nominated by anyone other than the Board.

ARTICLE 3

REPRESENTATIONS

Each Party represents and warrants to the other Party that it has all requisite corporate power and authority to enter into this Agreement and the execution and delivery of, and the performance of, and compliance with, the terms of this Agreement does not and will not result in any breach of, or constitute a default under, and do not and will not create a state of facts which, after notice or lapse of time or both, would result in a breach of or constitute a default under any term or provision of the articles, or resolutions of that Party, any applicable laws, mortgage, note, contract, agreement (written or oral), instrument, lease or other document to which that Party is bound, or any judgment, decree, order, statute, rule or regulation applicable to that Party.

ARTICLE 4

INFORMATION RIGHTS

4.1 Shareholder Requirements

If the Shareholder (i) notifies the Company that it is actively engaging in the preparation of a registration statement to be filed under the Securities Act of 1933, as amended, for an initial public offering of its securities or (ii) has a class of securities registered under Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and, in each case, the Shareholder is required to either account for its investment in the Company under the equity method of accounting or include separate financial statements of the Company in any filing with the Securities Exchange Commission by the Shareholder, then the Company agrees to timely provide such information that the Shareholder reasonably requests in connection the Shareholder's preparation and filing of any registration statement or other filing with Securities and Exchange Commission, or as is otherwise reasonably necessary for Shareholder to comply with obligations imposed on it under applicable securities laws or any stock exchange.

4.2 Confidentiality

The Shareholder agrees that, unless the written consent of the Company is obtained, the Shareholder will not at any time use, disclose or make available, to any Person, any information (herein “Confidential Information”) concerning the business or affairs of the Company acquired pursuant to the provisions of Section 4.1 and Section 5.2 of this Agreement; provided, however, that notwithstanding the foregoing, the Shareholder may make use of, reveal or disclose Confidential Information:


4.2.1	as may be expressly permitted by this Agreement;


4.2.2	where it is already in the public domain when disclosed to the Shareholder or becomes, after having been disclosed to the Shareholder, generally available to the public through publication or otherwise unless the publication or other disclosure was made directly or indirectly by the Shareholder in breach of this Agreement;


4.2.3	as required in order to comply with applicable laws, the orders or directions of any governmental authority, the requirements of any stock exchange or clearing house, or the requirements of any other regulatory authority having jurisdiction; and


4.2.4	to Affiliates of the Shareholder, provided such Persons have agreed to maintain such Confidential Information in confidence on terms substantially similar to those in this Section 4.2.

A-51

ARTICLE 5

TAX MATTERS

5.1 PFIC Status

For so long as the Shareholder owns stock of the Company, the Company will use its reasonable efforts to avoid, in respect of any taxable year, being treated as a passive foreign investment company (“PFIC”) within the meaning of Section 1297 of the Code, including, but not limited to, causing a Subsidiary to file an election pursuant to Treasury Regulation Section 301.7701-3. No later than 75 days after the end of each taxable year, the Company shall deliver to the Shareholder an analysis as to whether the Company believes that it will be treated as a PFIC in respect of such taxable year. Such analysis may be prepared by the Company, but in preparing such analysis the Company shall consult with its internationally recognized tax advisors.

5.2 QEF Information

The Company shall use its commercially reasonable efforts to provide, and shall cause each of its subsidiaries to use its commercially reasonable efforts to provide, to the Shareholder all information that may be necessary to allow the Shareholder, and direct or indirect owners of the Shareholder, to evaluate the analysis referenced in Section 5.1 and to fulfill their U.S. tax filing and reporting obligations. The Company shall provide, and shall cause each of its subsidiaries to provide, such information to the Shareholder as direct and indirect owners of the Shareholder may reasonably require to timely file and maintain a “qualified electing fund” election (as defined in Section 1295(a) of the Code) with respect to any such entity.

ARTICLE 6

MISCELLANEOUS PROVISIONS

6.1 Waiver Must be in Writing

No waiver by any Party of any breach (whether actual or anticipated) of any of the terms, conditions, representations or warranties contained herein shall take effect or be binding upon that Party unless the waiver is expressed in writing under the authority of that Party. Any waiver so given shall extend only to the particular breach so waived and shall not limit or affect any rights with respect to any other or future breach.

6.2 No Amendment Except in Writing

This Agreement may be amended only by written instrument executed by the Company and the Shareholder.

6.3 Service of Notice

Notwithstanding anything to the contrary contained herein, any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon delivery, when sent by facsimile (if facsimile numbers are provided in Section 6.4) or electronic mail (provided that confirmation of transmission is generated and kept on file by the sending party); or (iii) one (1) Business Day after deposit with an overnight courier service with next day delivery specified, in each case, properly addressed to the party to receive the same.

6.4 Addresses for Notice

The address for service of notices hereunder of each of the Parties shall be as follows:

To the Company:

Arbutus Biopharma Corporation

100-8900 Glenlyon Parkway

Burnaby, British Columbia

Canada V5J 5J8

Attention:

Facsimile:

Email:

With a copy sent concurrently to:

A-52

Farris, Vaughan, Wills & Murphy LLP

700 West Georgia St., 25^th Floor

Vancouver, British Columbia V7Y 1B3

Tel: (604) 661-9307

Attention: R. Hector MacKay-Dunn, Q.C.

E-mail: hmackay-dunn@farris.com

and

Dorsey & Whitney LLP

Pacific Centre

1070, 1095 West Pender Street

Vancouver V6E 2M6 Canada

Tel: (604) 687-5151

Attention: Daniel Miller

Email: miller.dan@dorsey.com

To the Shareholder:

Roivant Sciences Ltd.

Clarendon House

2 Church Street

Hamilton HM11

Bermuda

Attention: Corporate Secretary

Email: info@roivant.com

and

Roivant Sciences, Inc.

1441 Broadway, 3^rd Floor

New York, NY 10018

Attention: Allen Waxman, General Counsel

Email: allen.waxman@roivant.com

With a copy sent concurrently to:

White & Case LLP

1221 Avenue of the Americas

New York, New York 10020

Attention: Sang I. Ji and Chang-Do Gong

Facsimile: (212) 354-8113

E-mail: sji@whitecase.com; cgong@whitecase.com

and

Lawson Lundell LLP

Suite 1600 - 925 West Georgia St.

Vancouver, BC V6C 3L2

Attention: Valerie Mann and Crispin Arthur

Facsimile: (604) 641-2811

Email: vcmann@lawsonlundell.com

carthur@lawsonlundell.com

A Party may change its address for service by notice to the other Party, and such changed address for service thereafter shall be effective for all purposes of this Agreement.

A-53

6.5 Further Assurances

Each Party shall provide such further documents or instruments required by any other Party as may be reasonably necessary or desirable to effect the purpose of this Agreement and carry out its provisions.

6.6 Governing Law

This Agreement shall be governed by and construed in accordance with the laws of the Province of British Columbia and the laws of Canada applicable therein. Each of the Company and the Shareholder hereby attorn to the exclusive jurisdiction of the courts of competent jurisdiction in the Province of British Columbia located in Vancouver, British Columbia.

6.7 Time

Time shall be of the essence in this Agreement.

6.8 Entire Agreement

This Agreement and any agreement or document delivered pursuant to this Agreement constitute the entire agreement between the Company and the Shareholder relating to the subject matter hereof and thereof. There are no collateral or other statements, understandings, covenants, agreements, representations or warranties, written or oral, relating to the subject matter hereof. This Agreement supersedes all prior agreements, understandings, negotiations and discussions, whether oral or written, between the Parties or their predecessors relating to the subject matter of this Agreement.

6.9 Assignment and Enurement

Neither this Agreement nor any benefits or obligations accruing under this Agreement shall be assignable by any Party other than by the Shareholder to an Affiliate with the prior written consent of the Company not to be unreasonably withheld. Subject to the foregoing, this Agreement shall enure to the benefit of and be binding upon the Parties and their respective successors and permitted assigns.

6.10 Counterpart Execution

A Party will be entitled to rely on delivery by facsimile or by e-mail in PDF format of an executed copy of this Agreement by the other Party, including the completed attachments hereto, and acceptance by the receiving party of such facsimile or PDF copy will be legally effective to create a valid and binding agreement between the Company and the Shareholder in accordance with the terms hereof. This Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which shall constitute one and the same document.

[The remainder of this page is left blank intentionally]

A-54

IN WITNESS WHEREOF the Parties have duly executed this Agreement as of the date first written above.

ARBUTUS BIOPHARMA CORPORATION

Per: ___________________________________

Name:

Title:

ROIVANT SCIENCES LTD.

Per: ___________________________________

Name:

Title:

[Signature Page to Governance Agreement]

A-55

Schedule 1

AMENDMENT TO ARTICLES OF INCORPORATION OF

ARBUTUS BIOPHARMA CORPORATION

Part 27 - Transitional Governance Matters

Notwithstanding any other provision of these Articles, until the earlier of (i) forty-eight (48) months following the first issuance of Series A Preferred Shares, and (ii) the date RS no longer has a right to nominate one or more directors under Section 1 of Part 28, the following provisions shall apply:

Supermajority Matters


1.	Any one of the following matters shall require the approval of at least seventy percent (70%) of the number of directors then in office, whether such approval is given by way of a vote at a meeting of directors or by written consent:


(a)	the removal or replacement of the chair of the board of directors of the Company;


(b)	the removal or replacement of the chief executive officer of the Company,


(c)	subject to Part 28, the nomination of a director to the board for election to the board of directors of the Company;


(d)	subject to Part 28, the appointment of a director to the board of directors of the Company to fill a vacancy created by resignation or death of a director;


(e)	subject to Part 28, the appointment of an additional director to the board of directors of the Company;


(f)	any take-over bid, issuer bid, amalgamation, plan of arrangement, business combination, merger, tender offer, exchange offer, consolidation, recapitalization, reorganization, liquidation, dissolution or winding-up in respect of, or involving, the Company or any subsidiary of the Company;

(g)

any sale or issuance of shares of the Company or other equity interests in the Company (or rights, interests or securities convertible into or exercisable for such shares or other equity interests), in one or more connected transactions, which would be greater than 5% of the outstanding shares of stock of the company, other than the grant or issuance of such equity interests in connection with any stock-based compensation plan or plans approved by the board of directors of the Company;


(h)	any sale of assets (or any strategic alliance, joint venture, license or other arrangement having the same economic effect as a sale) of the Company or any subsidiary of the Company representing a transaction value and/or payments greater than $10 million;


(i)	ceasing or abandoning any research, development or commercialization efforts that were publicly disclosed by the Company as having been underway as at the effective date of the Merger, or declining to advance the development or commercialization of such programs, whether by failing to continue to fund such programs or otherwise;


(j)	incurring any indebtedness or third party guarantees in excess of $5,000,000 individually or $10,000,000 in the aggregate; or


(k)	any amendment or proposed amendment to the Articles or Notice of Articles of the Company,

(collectively referred to as “Supermajority Matters”).

Inconsistencies


2.	In the event of an inconsistency between a provision of this Part 27 and any other provision of these Articles, the provision of this Part 27 shall prevail.

Alterations of Part 27 and Section 18.2


3.	This Part 27 and Section 18.2 may only be amended by special resolution.

A-56

Part 28 - Director Election Matters

Definitions


1.	In this Part, the following terms shall have the meanings assigned to them below:

“Company Shares” means the common shares in the capital of the Company as constituted on the date hereof;

“Independence Standards” means the standards set forth in NASDAQ Marketplace Rule 4200(a)(15) or any successor rule thereto, but not including the requirements for audit committee members set forth in NASDAQ Marketplace Rule 4350(d);

“Partially Diluted Basis” means the sum of (i) the total number of Company Shares beneficially owned by RS and (ii) the total number of Company Shares into which the Series A Preferred Shares beneficially owned by RS would be converted, assuming all Preferred Shares held by RS on any applicable date were converted into Company Shares as of the Mandatory Conversion Date, and outstanding Company Shares shall be determined based on the sum of (x) the number of outstanding Company Shares as of the date of determination and (y) the number of Company Shares that would be issued on conversion of the Series A Preferred Shares, assuming all Preferred Shares held by RS on any applicable date were converted into Company Shares as of the Mandatory Conversion Date.

“Record Date Notice” means the date of the letter filed on SEDAR by the Company’s registrar and transfer agent giving notice of the record date for determination of the shareholders entitled to notice of and to vote at any Shareholder Meeting; and

“Shareholder Meeting” means an annual general meeting of shareholders or special meeting of shareholders of the Company called for the purpose of electing directors to the board of directors of the Company.

Election of Directors

2. For so long as Roivant Sciences Ltd. (the "Nominating Shareholder" or “RS”) has “beneficial ownership” (as defined pursuant Rule 13d-3 under the United States, Securities Exchange Act of 1934, as amended) (“Beneficial Ownership”) or exercises control or direction over not less than:

(a) thirty- percent (30%) of the issued and outstanding Company Shares calculated on a Partially Diluted Basis as at the Record Date Notice, RS has the right to nominate three (3) individuals for election to the board of directors of the Company at each Shareholder Meeting, one (1) of whom must satisfy the Independence Standards; and

(b) twenty- percent (20%) of the issued and outstanding Company Shares calculated on a Partially Diluted Basis as at the Record Date Notice, RS has the right to nominate two (2) individuals for election to the board of directors of the Company at each Shareholder Meeting; and

(c) ten percent (10%) of the issued and outstanding Company Shares calculated on a Partially Diluted Basis as at the Record Date Notice, RS has the right to nominate one (1) individual for election to the board of directors of the Company at each Shareholder Meeting,

(where such designee directors are referred to as the "RS Nominated Directors").

3. Upon the Nominating Shareholder having Beneficial Ownership or exercising control or direction over less than ten percent (10%) of the outstanding Company Shares calculated on a Partially Diluted Basis as at the Record Date Notice, the nomination rights provided under Section 2 will be of no further force and effect.

Number of Directors

4. For so long as the Nominating Shareholder has a right to nominate one or more directors under Section 2 of this Part 28, the number of directors of the Company shall not exceed seven (7) directors, at least a majority of whom must satisfy the Independence Standards, without the prior written consent of the Nominating Shareholder.

Nomination Procedure

5.For so long as the Nominating Shareholder has a right to nominate one or more directors under Section 1 of this Part 28:

A-57


(a)	No earlier than ninety (90) days and no later than sixty (60) days prior to the date of each Shareholder Meeting, the Company shall notify RS in writing of the date of the Shareholder Meeting (the “Company Notice”). The Company Notice shall specify the total number of Company Shares issued and outstanding calculated on a Partially Diluted Basis as at the Record Date Notice.

(b)

RS shall have the right and option, exercisable within fifteen (15) days from receipt of the Company Notice (the “Nomination Right Notice Period”) by written notice to the Company (the “Nomination Notice”) to exercise the Nomination Right. If RS wishes to exercise the Nomination Right, RS must specify in the Nomination Notice (i) the number of Company Shares beneficially owned by the Nominating Shareholder as at the date of the Nomination Notice, (ii) the name of the individual(s) RS wishes to nominate for election to the board of directors of the Company, and (iii) confirm that the nominee(s) are eligible to act as director(s) under the Act or, if the Company is otherwise governed by another statue or regime, that the nominee(s) are eligible to act as a director under such statute or regime. As soon as reasonably possible after the request by the Company, duly completed forms and any other information in respect of the RS Nominated Directors, as required by the relevant stock exchange, shall be provided by the RS Nominated Directors.

(c)

If RS fails to deliver a Nomination Notice in response to a Company Notice within the Nomination Right Notice Period, then the Company will not be required to nominate individuals identified by RS for election to the board of directors of the Company at the Shareholder Meeting with respect to which RS failed to deliver the Nomination Notice, and RS shall have the right to nominate person(s) for election to the board of directors of the Company at the next Shareholder Meeting in accordance with this Part 28.

(d)

If RS delivers a Nomination Notice in response to a Company Notice within the Nomination Right Notice Period then, subject only to the nominee(s) identified in the Nomination Notice being eligible to act as director(s) of the Company, the Company shall (i) nominate the RS nominee(s) to stand for election to the board of directors of the Company at the Shareholder Meeting, and (ii) solicit proxies from the holders of Company Shares in respect thereof which will be satisfied by delivery of a form of proxy to the holders of Company Shares following standard procedures consistent with past practice. For greater certainty, the Company (x) shall not be required to retain a third party solicitation agent, and (y) shall include the name of the RS nominee(s) to stand for election to the board of directors of the Company in the proxy to be delivered to each holder of Company Shares in respect of the Shareholder Meeting. The Nominating Shareholder shall also provide to the Company such other information regarding the RS nominee(s) as may be reasonably requested by the Company so as to comply with applicable proxy disclosure requirements under applicable securities laws, together with such other information, including a biography of the RS Nominated Directors, that is consistent with the information the Company intends to publish about management nominees as directors of the Company in the information circular to be prepared by the Company in connection with the election of directors at a Shareholder Meeting.

Casual Vacancies

6. In the event that an RS Nominated Director resigns, dies, becomes incapacitated or otherwise ceases to be a director prior to the expiration of his or her term as a director, such vacancy on the board of directors shall be filled by the remaining directors with the nominee identified by RS promptly. The Company shall use all commercially reasonable steps, promptly upon receipt by it of a written notice from RS to fill such vacancy, as are necessary to call (no later than five (5) days following notice of such identified nominee by RS) a meeting of the board of directors to vote on the appointment of such Shareholder Designee to fill such vacancy (or to obtain a vote of the directors by way of unanimous written resolution) and take all such other steps as are required by the Act with respect to such appointment.

Transitional Period

7.This Part 28 shall remain in effect until the date that is the earlier of (i) forty-eight (48) months following the first issuance of Series A Preferred Shares and (ii) the date RS no longer has a right to nominate one or more directors under Section 1 of this Part 28.

Inconsistencies

8.In the event of an inconsistency between a provision of this Part 28 and any other provision of these Articles, the provision of this Part 28 shall prevail.

A-58

SCHEDULE “E”

LOCK-UP AMENDING AGREEMENT

A-59

AMENDED AND RESTATED LOCK-UP AGREEMENT

This Amended and Restated Lock-Up Agreement (this “Agreement”) is made as of [•], 2017 by and between Arbutus Biopharma Corporation, a British Columbia corporation (the “Company”), and Roivant Sciences Ltd., a Bermuda exempted limited company (the “Shareholder”).

WHEREAS, on January 11, 2015, the Company and the Shareholder entered into that certain Lock-Up Agreement (the “Original Agreement”) with respect to the shares of voting common stock of the Company (the “Common Shares”) acquired by the Shareholder in connection with a merger agreement entered into between the Company and OnCore Biopharma, Inc. (the “Existing Common Shares”);

WHEREAS, on October 2, 2017, the Company entered into that certain Subscription Agreement by and between the Shareholder and the Company (the “Subscription Agreement”);

WHEREAS, pursuant to the Subscription Agreement, the Shareholder will purchase shares of Series A Participating Convertible Preferred Stock of the Company, which are convertible into Common Shares (the “Series A Preferred Shares”);

WHEREAS, as an inducement for the Company to enter into the Subscription Agreement and consummate the subscription, and for the Company to enter into an amended and restated governance agreement dated as of the date hereof with the Shareholder (the “Governance Agreement”), the Shareholder has agreed to execute and deliver this Agreement; and

WHEREAS, the parties hereto desire to amend and restate the Original Agreement in its entirety.

NOW, THEREFORE, in consideration of the mutual promises and covenants contained in this Agreement, and for other good and valuable consideration that the parties hereby acknowledge, the parties hereby amend and restate the Original Agreement in its entirety as follows:

The Shareholder irrevocably agrees that for the Lock-Up Period (as defined below) and solely with respect to the applicable amount of the Lock-Up Securities (as defined below) as specified herein, other than as set forth below or with the prior written consent of the Company, the Shareholder will not, directly or indirectly by itself or through others: (1) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, the Existing Common Shares (including, but not limited to, Existing Common Shares which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission) or the Series A Preferred Shares; or (2) enter into, sell or otherwise dispose of any swap, option, future, forward or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of such Existing Common Shares, the Series A Preferred Shares or the Common Shares issuable upon conversion of the Series A Preferred Shares (the “Underlying Common Shares” and, together with such Existing Common Shares and the Series A Preferred Shares, the “Lock-Up Securities”), whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Series A Preferred Shares, Common Shares or other securities, in cash or otherwise.

For the purpose of this Agreement, the “Lock-Up Period” shall mean such period commencing on the date hereof and ending on the earlier of (i) the fourth anniversary of the date hereof, and (ii) the occurrence of any of the events set forth in the Amended and Restated Standstill Agreement that results in the restrictions set forth in Section 3 thereof not applying.

The restrictions contained in this Agreement shall not apply to the following:


(a)	transfers of Common Shares as a bona fide gift or charitable contribution;


(b)	transfers by distribution of Preferred Shares, Common Shares or other securities to affiliates, partners, members, stockholders or holders of similar equity interests of the Shareholder;


(c)	transfers pursuant to any tender offer, takeover bid, merger, consolidation, acquisition of the Company or its voting securities or other similar transaction relating to the Company or its voting securities that occurs after the date hereof and that is approved by the Board of Directors of the Company;


(d)	granting of a security interest in (whether by way of pledge or otherwise) Common Shares by the Shareholder in connection with a loan made with a financial institution in good faith on bona fide, arm’s length terms, and any

A-60

subsequent transfer of such securities to such lender or collateral agent in connection with the exercise of remedies in connection with such loan in the event of default;


(e)	issuances of Common Shares upon conversion of the Series A Preferred Shares; and


(f)	any transfer or issuance of securities of the Shareholder, or any affiliate thereof that indirectly holds the Lock-Up Securities through the Shareholder, in a bona fide transaction; provided, however, that any such transfer or issuance shall not affect any of the Shareholder’s obligations hereunder.

provided however, that in the case of any transfer or distribution pursuant to clause (a) or (b) hereunder, such transfer shall not involve a disposition for value and provided further, (i) in the case of any transfer or distribution pursuant to clause (a) or (b) hereunder, that each transferee or donee or distributee shall execute and deliver to the Company a lock-up agreement substantially in the form of this Agreement; (ii) in the case of any transfer pursuant to clause (d) hereunder, a permitted security interest shall not include any pledge in connection with a hedging or similar transaction or a financing transaction that has substantially the same effect as a hedging or sale transaction; and (iii) that no filing by any party (donor, donee, transferor, transferee, pledger, pledgee, borrower or otherwise) under the Exchange Act, or other public announcement shall be made (including voluntarily) in connection with such transfer, disposition, distribution, pledge or loan, except as otherwise compelled to do so or is required to do so to comply with applicable law or legal process or any request by or from a governmental authority or the rules of any securities exchange or the rules and regulations of any “self regulatory organization” as defined in Section 3(a)(26) of the Securities Exchange Act of 1934, as amended, or any other United States or foreign securities exchange, futures exchange, commodities exchange or contract market.

The Shareholder represents and warrants that it is not a party to any agreement or understanding that would cause a breach of this Agreement if it were entered into during the period in which the restrictions set forth herein are effective.

The Shareholder acknowledges that the execution, delivery and performance of this Agreement is a material inducement to the Company to enter into the Subscription Agreement, and the Company shall be entitled to specific performance of the Shareholder’s obligations hereunder. The parties agree that any breach or threatened breach of this Agreement by the Shareholder may cause immediate and irreparable harm to the Company for which monetary damages will not be adequate and that, in the event of a breach or threatened breach of this Agreement, the Company shall be entitled to seek and obtain immediate injunctive and other equitable relief without proof of actual damages in addition to any other remedies as may be available at law or in equity. The Shareholder further agrees to waive any requirement for the securing or posting of any bond in connection with such remedy. All rights under this Agreement are cumulative, not exclusive, and will be in addition to all rights and remedies available to the Company at law or in equity.

The Shareholder and the Company agree that this Agreement shall automatically terminate and be of no further force or effect if (a) the Company is in material breach of its obligations under Articles 2 or 4 of the Governance Agreement or Part 27 or Part 28 of the Company’s Articles and (b) such breach remains uncured for at least thirty (30) days after notice to the Company thereof.

The Shareholder agrees and consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar against the transfer of the Lock-Up Securities except in compliance with the foregoing restrictions. In furtherance of the foregoing, the Company and any duly appointed transfer agent for the registration or transfer of the securities described herein are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Agreement.

The Shareholder hereby represents and warrants that the Shareholder has full power and authority to execute, deliver and perform this Agreement. All authority herein conferred or agreed to be conferred and any obligations of the Shareholder shall be binding upon the successors, assigns, heirs or personal representatives of the Shareholder. This Agreement may not be amended or otherwise modified in any respect without the written consent of the Company and the Shareholder.

This Agreement shall become effective only upon the Tier 1 Closing Date.

THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE PROVINCE OF BRITISH COLUMBIA AND THE LAWS OF CANADA APPLICABLE THEREIN, WITHOUT REGARD TO THE CONFLICT OF LAWS PRINCIPLES THEREOF.

A-61

Any and all disputes arising under this Agreement, whether as to interpretation, performance or otherwise, shall be subject to the non-exclusive jurisdiction of the courts of the Province of British Columbia and each of the Parties hereby irrevocably attorns to the jurisdiction of the courts of such jurisdiction.

[Signature page follows]

A-62

IN WITNESS THEREOF, the parties hereto have executed this Agreement on the date first written above.



	COMPANY:

	ARBUTUS BIOPHARMA CORPORATION

	By:
		Name:
		Title:
		Date:


	SHAREHOLDER:

	ROIVANT SCIENCES LTD.

	By:
		Name:
		Title:
		Date:

A-63

SCHEDULE “F”

REGISTRATION RIGHTS AMENDING AGREEMENT

A-64

AMENDING AGREEMENT

THIS AMENDMENT (this “Amendment”) is executed as of [•], 2017, by and among Arbutus Biopharma Corporation (f/k/a Tekmira Pharmaceuticals Corporation) (the “Company”), a British Columbia corporation, Roivant Sciences Ltd., a Bermuda exempted limited company (“RSL”), Patrick T. Higgins, Michael J. McElhaugh, Michael J. Sofia and Bryce A. Roberts (such parties other than the Company being collectively referred to as the “OnCore Holders”).

RECITALS

WHEREAS, the parties hereto entered into a Registration Rights Agreement, dated January 11, 2015, as amended on November 2, 2015 (the “Registration Rights Agreement”), pursuant to which the Company agreed in certain circumstances to register for resale under the Securities Act of 1933, as amended, certain common shares in the Company held by the OnCore Holders;

WHEREAS, the Company and RSL entered into a Subscription Agreement, dated October 2, 2017, pursuant to which the Company agreed to issue to RSL, and RSL agreed to subscribe for, a certain number of Series A Preferred Shares (as defined below); and

WHEREAS, the parties hereto now wish to amend the terms of the Registration Rights Agreement in order to have the Registration Rights Agreement cover the shares of Common Stock issuable upon conversion of the Preferred Shares.

NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein, the parties do hereby agree as follows:

1.Defined Terms. All capitalized terms used and not otherwise defined herein shall have the meaning ascribed thereto in the Registration Rights Agreement.

2.Amendment.

(a)Section 1.1(m) of the Registration Rights Agreement is deleted in its entirety and replaced with the following:

“The term “Registrable Securities” means (A) the shares of Common Stock issued to the OnCore Holders pursuant to the Merger Agreement and any assignee or transferee thereof in accordance with Section 1.12 hereof, (B) any and all shares of Common Stock issuable or issued upon conversion of the Series A Preferred Shares, and (C) any shares of Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right or other security that is issued as) a dividend or other distribution with respect to, or in exchange for, or in replacement of, the shares referenced in clauses (A) and (B) above or the Series A Preferred Shares. Notwithstanding the foregoing, Registrable Securities shall not include any securities (x) sold by a person to the public pursuant to a registration statement (on Form S-8 or otherwise) or pursuant to Rule 144, (y) sold in a private transaction in which the transferor’s rights under Section 1 of this Agreement are not assigned or (z) held by a Holder (together with its affiliates and other Holders that share a common investment advisor with such Holder) if such Holder (together with its affiliates and other Holders that share a common investment advisor with such Holder) beneficially owns less than 3% of the Company’s outstanding shares of Common Stock, if such securities may then be sold pursuant to Rule 144(b)(1).”

(b)Section 1.1 of the Registration Rights Agreement is amended by adding the following subsection (q):

“(q) The term “Series A Preferred Shares” means the shares of the series of convertible participating preferred shares of the Company designated as “Series A Participating Convertible Preferred Shares” and convertible into shares of Common Stock in accordance with the terms set forth in that certain Terms of Series A Participating Convertible Preferred Shares of the Company, authorized by the Board on [•], 2017.

A-65

3.Entire Agreement; Ratification. This Amendment constitutes the entire agreement among the parties with respect to the subject matter hereof. Except as expressly amended hereby, the terms of the Registration Rights Agreement are each hereby confirmed and ratified in all respects by the parties hereto and remain in full force and effect.

4.Binding Effect. This Agreement shall be binding upon and inure to the benefit of the parties hereto, and any of their respective subsidiaries, affiliates, insurers, predecessors, successors, officers, directors, managers, employees, stockholders, members, agents, attorneys or assigns.

5.Governing Law. This Amendment shall be governed by and construed under the laws of the State of New York as applied to agreements among New York residents entered into and to be performed entirely within New York without giving effect to principles of conflicts of laws.

6.Counterparts. This Amendment may be signed in counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same agreement.

7.Necessary Action. Each party shall perform any further acts and execute and deliver any documents that may be reasonably necessary to carry out the provisions of this Amendment.

[Signature pages to follow]

A-66

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first above written.

ARBUTUS BIOPHARMA CORPORATION

By: _______________________________

Name: _____________________________

Title: ______________________________

Address: ___________________________

A-67

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first above written.

ROIVANT SCIENCES LTD.

By: _______________________________

Name: _____________________________

Title: ______________________________

Address: ___________________________

A-68

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first above written.

By: _______________________________

Patrick T. Higgins

Address: ___________________________

A-69

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first above written.

By: _______________________________

Michael J. McElhaugh

Address: ___________________________

A-70

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first above written.

By: _______________________________

Michael J. Sofia

Address: ___________________________

A-71

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first above written.

By: _______________________________

Bryce A. Roberts

Address: ___________________________

A-72

SCHEDULE “G”

STANDSTILL AMENDING AGREEMENT

A-73

AMENDED AND RESTATED STANDSTILL AGREEMENT

This Amended and Restated Standstill Agreement (this “Agreement”) is made as of [•], 2017 by and between Arbutus Biopharma Corporation, a British Columbia corporation (“Arbutus” or the “Company”), and Roivant Sciences Ltd., a Bermuda exempted limited company, for and on behalf of itself and entities and accounts that it controls directly or indirectly, or with respect to which it exercises voting discretion, whether such entities or accounts now exist or are organized in the future (collectively, the “Shareholder”).

WHEREAS, on January 11, 2015 the Company and the Shareholder entered into that certain Standstill Agreement (the “Original Agreement”);

WHEREAS, on the October 2, 2017, the Company entered into a Subscription Agreement by and among the Shareholder and the Company (the “Subscription Agreement”);

WHEREAS, pursuant to the Subscription Agreement, the Shareholder will purchase shares of Series A Participating Convertible Preferred Stock of the Company which are convertible into Common Stock (the “Preferred Shares”);

WHEREAS, the parties hereto desire to amend and restate the Original Agreement in its entirety.



1.	Definitions. In this Agreement, the following terms shall have the meaning assigned to them below. Capitalized terms used but not defined herein shall have the meanings ascribed thereto in the Subscription Agreement.

“Common Stock” means the shares of voting common stock of the Company.

“Lock-up Agreement” means the amended and restated Lock-Up Agreement dated as of the date hereof between the Company and the Shareholder.

“Shareholder Maximum Ownership Percentage” means 49.99% of the outstanding Common Stock, including shares of Common Stock the Shareholder would be entitled to acquire, assuming all Preferred Shares held by the Shareholder on any applicable date were converted into Common Stock as of the Mandatory Conversion Date (as such term is defined in the rights and restrictions attached to the Preferred Shares).



2.	Original Agreement. The Original Agreement is hereby amended and restated in its entirety by this Agreement.



3.	Standstill. For a period commencing on the date hereof and ending on the earlier of (i) forty-eight (48) months following the Tier 1 Closing and (ii) the date upon which the Shareholder no longer has the right to nominate at least one (1) director to the Company’s board of directors (the “Board”) pursuant to the Governance Agreement and/or Part 28 of the Company’s Articles, the Shareholder shall not, without the prior written consent of the Company, directly or indirectly:

A-74



a.	acquire, offer to acquire, or agree to acquire ownership (including, but not limited to, beneficial ownership as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended (“Exchange Act”)), by purchase or otherwise, any additional shares of Common Stock, or any rights or options to acquire any such securities or any securities convertible into such securities; provided that, in the event that at any time, whether due to an increase in the total outstanding shares of Common Stock , a sale of shares of Common Stock or Preferred Shares by the Shareholder (made in compliance with the provisions of the Lock-Up Agreement) or otherwise, the Shareholder beneficially owns, directly or indirectly, Common Stock representing less than the Shareholder Maximum Ownership Percentage, the Shareholder may acquire additional shares of Common Stock or rights or options to acquire any such securities or any securities convertible into such securities; provided, further, that the Shareholder’s ownership percentage will not exceed the Shareholder Maximum Ownership Percentage;



b.	call or seek to call any meeting of the stockholders of the Company;



c.	submit, or participate with others that submit, any stockholder proposals for the vote or consent (collectively, “vote”) of stockholders (whether pursuant to Rule 14a-8 under the Exchange Act, or otherwise) of the Company or any proposal for consideration by the Board;



d.	solicit “proxies” or make, participate in or encourage any “solicitation” (as such terms are used in the proxy rules of the Securities Exchange Commission) for proxies for any stockholder proposals of the Company or nominations of candidates for election as directors or trustees of the Company;



e.	form or join in a partnership, syndicate or other group, including, without limitations, a “group” as defined under Section 13(d) of the Exchange Act, with respect to the Common Shares, or deposit any Common Shares in a voting trust, arrangement or agreement, except for such actions that may be permitted under the Lock-Up Agreement;



f.	publicly or privately: (i) encourage, recommend, advise, finance or urge others to put forward stockholder proposals of the Company or nominations with respect to directors/trustees of the Company or enter into any arrangements with any other person in connection with any of the foregoing as they relate to the Company; (ii) indicate support or approval for any stockholder proposals or nominations relating to the Company that are not otherwise approved by the Board in accordance with the Articles; (iii) solicit or encourage others to vote against any matter recommended by the Board in accordance with the Articles; or (iv) act alone or in concert with others to seek control of, or otherwise effect a change to, the management or policies of the Company, unless otherwise approved by the Board in accordance with the Articles; or



g.	take or seek to take, or cause or seek to cause or solicit others to take any action inconsistent with any of the foregoing as they relate to the Company.

For the avoidance of doubt, this Agreement will not be construed to preclude, prohibit, restrict or otherwise prevent the Shareholder from taking any actions that are permitted or contemplated by the Governance Agreement or the Company’s Articles.

Notwithstanding anything contained in this Agreement to the contrary, the Shareholder shall not be required to dispose of any of its holdings of Preferred Shares or Common Shares if (i) the number of shares of Common Stock is reduced or if the aggregate ownership of the Shareholder is increased solely as a result of a recapitalization or other transaction of the Company and as a result of such transaction, the Shareholder’s ownership exceeds the Shareholder Maximum Ownership Percentage or (ii) a majority of the members of the Board of the Company (other than the Shareholder nominees) approve a transaction pursuant to which the Shareholder’s ownership exceeds the Shareholder Maximum Ownership Percentage.

A-75

The restrictions set forth in this Section 3 shall not apply if any of the following occurs:


a.	in the event that the Company enters into a definitive agreement for a merger, consolidation or other business combination transaction as a result of which the stockholders of the Company would own (including, but not limited to, beneficial ownership) voting securities of the resulting corporation having 50% or less of the total voting power of the outstanding voting securities;


b.	in the event that a bona fide tender offer or exchange offer for at least a majority of the outstanding voting securities of the Company is commenced by a third person (not involving any breach of this Section 3 by the Shareholder); or

the Company solicits from one or more persons or enters into discussions with one or more persons regarding, a proposal with respect to a merger of, or a business combination transaction involving, the Company, in each case without similarly soliciting a proposal from the Shareholder, or the Company makes a public announcement that it is seeking to sell itself and/or explore strategic alternatives which could lead to a sale, restructuring, business combination, merger or other similar transaction and, in such event, such announcement is made with the approval of the Board.

Nothing in this Section 3 shall restrict the Shareholder from (i) making any proposal directly to the Board on a confidential basis; or (ii) voting its Common Stock in any manner the Shareholder determines in its sole discretion; provided that, the Shareholder complies with any voting requirements applicable to the Shareholder set forth in the Governance Agreement and/or the Company’s Articles.



4.	Termination. The Shareholder may terminate this Agreement if the Company is in material breach of Articles 2 or 4.2 of the Governance Agreement or Part 27 or Part 28 of the Company’s Articles and such breach remains uncured for at least fifteen (15) days after notice to the Company thereof.



5.	Remedies. The parties agree that any breach or threatened breach of this Agreement may cause immediate and irreparable harm to the Company for which monetary damages will not be adequate and that, in the event of a breach or threatened breach of this Agreement, the Company shall be entitled to seek and obtain immediate injunctive and other equitable relief without proof of actual damages in addition to any other remedies as may be available at law or in equity. The Shareholder further agrees to waive any requirement for the securing or posting of any bond in connection with such remedy. All rights under this Agreement are cumulative, not exclusive, and will be in addition to all rights and remedies available to the Company at law or in equity.



6.	No Assignment. This Agreement shall be binding upon and inure to the benefit of the parties and their respective agents, executors, heirs, successors and permitted assigns. Neither this Agreement nor any of the benefits of this Agreement shall be assigned by a party without prior written consent of the other parties hereto. No person not a party to this Agreement shall have rights, benefits, or obligations hereunder.



7.	Amendments. No amendments, changes, or modifications may be made to this Agreement without the express prior written consent of each of the parties hereto.



8.	Notices. All notices or communications hereunder shall be in writing, addressed as follows:

A-76

To the Company:

Arbutus Biopharma Corporation

100-8900 Glenlyon Parkway

Burnaby, British Columbia

Canada V5J 5J8

Attention: Bruce Cousins, Executive Vice President and Chief Financial Officer

Facsimile: (604) 419-3201

Email: bcousins@arbutusbio.com

With a copy sent concurrently to:

Farris, Vaughan, Wills & Murphy LLP

700 West Georgia St., 25th Floor

Vancouver, British Columbia V7Y 1B3

Tel: (604) 661-9307

Attention: R. Hector MacKay-Dunn, Q.C.

E-mail: hmackay-dunn@farris.com

and

Dorsey & Whitney LLP

Suite 1070, 1095 West Pender Street

Vancouver, British Columbia V6E 2M6

Tel: (604) 687-5151

Attention: Daniel Miller

Email: miller.dan@dorsey.com

To the Shareholder:

Roivant Sciences Ltd.

Clarendon House

2 Church Street

Hamilton HM11

Bermuda

Attention: Corporate Secretary

Facsimile: +1 (441) 292 4720

Email: info@roivant.com

and

Roivant Sciences, Inc.

320 West 37th Street, 5th Floor

New York, New York 10018

Attention: Allen Waxman, General Counsel

Email: allen.waxman@roivant.com

With a copy sent concurrently to:

White & Case LLP

1221 Avenue of the Americas

New York, New York 10020

Attention: Sang I. Ji and Chang-Do Gong

Facsimile: (212) 354-8113

A-77

E-mail: sji@whitecase.com;

cgong@whitecase.com

Lawson Lundell LLP

1600 - 925 West Georgia Street

Vancouver, British Columbia V6C 3L2

Attention: Valerie Mann and Crispin Arthur

Fax: (604) 641-2811

Email: vcmann@lawsonlundell.com

carthur@lawsonlundell.com

Any such notice or communication shall be delivered by hand or by courier or sent certified or registered mail, return receipt requested, postage prepaid, addressed as above (or to such other address as such party may designate in a notice duly delivered as described above), and the third business day after the actual date of mailing shall constitute the time at which notice was given.



9.	Invalidity. If any term or provision of this Agreement is held by a court of competent jurisdiction to be invalid, void or unenforceable, the remainder of the terms and provisions of this Agreement shall remain in full force and effect and shall in no way be affected, impaired or invalidated.



10.	No Waiver. No failure or delay by a party in exercising any right hereunder or any partial exercise thereof shall operate as a waiver thereof or preclude any other or further exercise of any right hereunder. No waiver, express or implied, by any party of any breach of default by any other party in the performance by the other party of its obligations under this Agreement shall be deemed or construed to be a waiver of any other breach or default, whether prior, subsequent, or contemporaneous, under this Agreement. Any waiver must be in writing and executed by the party against whom the waiver is sought to be charged.



11.	Counterparts. This Agreement may be executed in two counterparts, which may be delivered by facsimile or by portable document format (PDF) attachment to email transmission, each of which shall be deemed an original, and when taken together all such counterparts shall be deemed to constitute one and the same document.



12.	Applicable Law This Agreement shall be construed, interpreted and governed in accordance with the laws of the Province of British Columbia and the laws of Canada, without reference to rules relating to conflicts of law.



13.	Entire Agreement. This Agreement contains the entire understanding between the parties and is intended to be the complete and exclusive statement of the terms and conditions of the agreement between the parties and supersedes in all respects any prior agreement or understanding between the Company and the Shareholder.

{REMAINDER INTENTIONALLY LEFT BLANK}

A-78

IN WITNESS THEREOF, the parties hereto have executed this Agreement on the date first written above.



	COMPANY:

	ARBUTUS BIOPHARMA CORPORATION

	By:
		Name:
		Title:
		Date:


	SHAREHOLDER:

	ROIVANT SCIENCES LTD.

	By:
		Name:
		Title:
		Date:

[Signature Page to Amended and Restated Standstill Agreement]

A-79

Exhibit B

AMENDMENT TO ARTICLES OF INCORPORATION OF

ARBUTUS BIOPHARMA CORPORATION

Part 27 - Transitional Governance Matters

Supermajority Matters

1. Any one of the following matters shall require the approval of at least seventy percent (70%) of the number of directors then in office, whether such approval is given by way of a vote at a meeting of directors or by written consent:

(a) the removal or replacement of the chair of the board of directors of the Company;

(b) the removal or replacement of the chief executive officer of the Company,

(d) subject to Part 28, the appointment of a director to the board of directors of the Company to fill a vacancy created by the resignation or death of a director;

(e) subject to Part 28, the appointment of an additional director to the board of directors of the Company;

(f) any take-over bid, issuer bid, amalgamation, plan of arrangement, business combination, merger, tender offer, exchange offer, consolidation, recapitalization, reorganization, liquidation, dissolution or winding-up in respect of, or involving, the Company or any subsidiary of the Company;

(g) any sale or issuance of shares of the Company or other equity interests in the Company (or rights, interests or securities convertible into or exercisable for such shares or other equity interests), in one or more connected transactions, which would be greater than 5% of the outstanding shares of stock of the company, other than the grant or issuance of such equity interests in connection with any stock-based compensation plan or plans approved by the board of directors of the Company;

(h) any sale of assets (or any strategic alliance, joint venture, license or other arrangement having the same economic effect as a sale) of the Company or any subsidiary of the Company representing a transaction value and/or payments greater than $10 million;

(i) ceasing or abandoning any research, development or commercialization efforts that were publicly disclosed by the Company as having been underway as at the effective date of the Merger, or declining to advance the development or commercialization of such programs, whether by failing to continue to fund such programs or otherwise;

(j) incurring any indebtedness or third party guarantees in excess of $5,000,000 individually or $10,000,000 in the aggregate; or

(k) any amendment or proposed amendment to the Articles or Notice of Articles of the Company,

(collectively referred to as “Supermajority Matters”).

Inconsistencies

2. In the event of an inconsistency between a provision of this Part 27 and any other provision of these Articles, the provision of this Part 27 shall prevail.

B-1

Alterations of Part 27 and Section 18.2

3. This Part 27 and Section 18.2 may only be amended by special resolution.

Part 28 - Director Election Matters

Definitions

1. In this Part, the following terms shall have the meanings assigned to them below:

(a) “Company Shares” means the common shares in the capital of the Company as constituted on the date hereof;

(b) “Independence Standards” means the standards set forth in NASDAQ Marketplace Rule 5605(a)(2) or any successor rule thereto, but not including the requirements for audit committee members set forth in NASDAQ Marketplace Rule 5605(c);

(c) “Partially Diluted Basis” means the sum of (i) the total number of Company Shares beneficially owned by RS and (ii) the total number of Company Shares into which the Series A Preferred Shares beneficially owned by RS would be converted, assuming all Preferred Shares held by RS on any applicable date were converted into Company Shares as of the Mandatory Conversion Date, and outstanding Company Shares shall be determined based on the sum of (x) the number of outstanding Company Shares as of the date of determination and (y) the number of Company Shares that would be issued on conversion of the Series A Preferred Shares, assuming all Preferred Shares held by RS on any applicable date were converted into Company Shares as of the Mandatory Conversion Date.

(d) “Record Date Notice” means the date of the letter filed on SEDAR by the Company’s registrar and transfer agent giving notice of the record date for determination of the shareholders entitled to notice of and to vote at any Shareholder Meeting; and

(e) “Shareholder Meeting” means an annual general meeting of shareholders or special meeting of shareholders of the Company called for the purpose of electing directors to the board of directors of the Company.

Election of Directors

B-2

(where such designee directors are referred to as the "RS Nominated Directors").

Number of Directors

Nomination Procedure

5. For so long as the Nominating Shareholder has a right to nominate one or more directors under Section 1 of this Part 28:

(a) No earlier than ninety (90) days and no later than sixty (60) days prior to the date of each Shareholder Meeting, the Company shall notify RS in writing of the date of the Shareholder Meeting (the “Company Notice”). The Company Notice shall specify the total number of Company Shares issued and outstanding calculated on a Partially Diluted Basis as at the Record Date Notice.

(b) RS shall have the right and option, exercisable within fifteen (15) days from receipt of the Company Notice (the “Nomination Right Notice Period”) by written notice to the Company (the “Nomination Notice”) to exercise the Nomination Right. If RS wishes to exercise the Nomination Right, RS must specify in the Nomination Notice (i) the number of Company Shares beneficially owned by the Nominating Shareholder as at the date of the Nomination Notice, (ii) the name of the individual(s) RS wishes to nominate for election to the board of directors of the Company, and (iii) confirm that the nominee(s) are eligible to act as director(s) under the Act or, if the Company is otherwise governed by another statue or regime, that the nominee(s) are eligible to act as a director under such statute or regime. As soon as reasonably possible after the request by the Company, duly completed forms and any other information in respect of the RS Nominated Directors, as required by the relevant stock exchange, shall be provided by the RS Nominated Directors.

(c) If RS fails to deliver a Nomination Notice in response to a Company Notice within the Nomination Right Notice Period, then the Company will not be required to nominate individuals identified by RS for election to the board of directors of the Company at the Shareholder Meeting with respect to which RS failed to deliver the Nomination Notice, and RS shall have the right to nominate person(s) for election to the board of directors of the Company at the next Shareholder Meeting in accordance with this Part 28.

(d) If RS delivers a Nomination Notice in response to a Company Notice within the Nomination Right Notice Period then, subject only to the nominee(s) identified in the Nomination Notice being eligible to act as director(s) of the Company, the Company shall (i) nominate the RS nominee(s) to stand for election to the board of directors of the Company at the Shareholder Meeting, and (ii) solicit proxies from the holders of Company Shares in respect thereof which will be satisfied by delivery of a form of proxy to the holders of Company Shares following standard procedures consistent with past practice. For greater certainty, the Company (x) shall not be required to retain a third party solicitation agent, and (y) shall include the name of the RS nominee(s) to stand for election to the board of directors of the Company in the proxy to be delivered to each holder of Company Shares in respect of the

B-3

Shareholder Meeting. The Nominating Shareholder shall also provide to the Company such other information regarding the RS nominee(s) as may be reasonably requested by the Company so as to comply with applicable proxy disclosure requirements under applicable securities laws, together with such other information, including a biography of the RS Nominated Directors, that is consistent with the information the Company intends to publish about management nominees as directors of the Company in the information circular to be prepared by the Company in connection with the election of directors at a Shareholder Meeting.

Casual Vacancies

Transitional Period

7. This Part 28 shall remain in effect until the date that is the earlier of (i) forty-eight (48) months following the first issuance of Series A Preferred Shares and (ii) the date RS no longer has a right to nominate one or more directors under Section 1 of this Part 28.

Inconsistencies

8. In the event of an inconsistency between a provision of this Part 28 and any other provision of these Articles, the provision of this Part 28 shall prevail.

B-4

EXHIBIT C

AMENDED AND RESTATED GOVERNANCE AGREEMENT

THIS AGREEMENT is made as of this 16^th day of October, 2017.

BETWEEN:

Arbutus Biopharma Corporation, a corporation incorporated under the laws of British Columbia previously known as Tekmira Pharmaceuticals Corporation

(the “Company”)

- and -

Roivant Sciences Ltd., a Bermuda exempted limited company

(the “Shareholder”)

WHEREAS:


A.	The parties entered into a governance agreement dated as of January 11, 2015 (the “Original Governance Agreement”), in connection with a merger agreement entered into between the Company and OnCore Biopharma, Inc., as a result of which the Shareholder received Common Shares of the Company;


B.	The parties entered into a subscription agreement dated as of October 1, 2017 (the “Subscription Agreement”), providing for the purchase by the Shareholder of 1,164,000 Class A Preferred Shares (the “Preferred Shares”) of the Company, issuable in two tranches;

ARTICLE 1

INTERPRETATION AND GENERAL MATTERS

1.1 Definitions

In this Agreement, including the recitals, unless otherwise stated, capitalized terms used will have the meanings specified below:

“Affiliate” means with respect to any Person, any other Person that, directly or indirectly: (i) Controls, (ii) is Controlled by or (iii) is under common Control with, such Person;

C-1

“Amendment” has the meaning ascribed thereto in Recital C;

“Articles” means the articles of the Company as amended by the Amendment;

“Board” means the board of directors of the Company;

“Common Shares” means the common shares in the capital of the Company;

“Company” has the meaning given to it in the Preamble;

“Parties” means the Company, the Shareholder and their respective successors and permitted assigns, and “Party” means any one of them;

“Preferred Shares” has the meaning given to it in Recital B;

“Shareholder” has the meaning given to it in the Preamble;

“Shareholder Designees” has the meaning given to it in Section 2.1(a);

C-2

“Subscription Agreement” has the meaning given to it in Recital B;

“Tier 1 Closing” has the meaning given such term in Recital C; and

“Tier 2 Closing” has the meaning given such term in Recital C.

1.2 Effectiveness

1.3 References, Headings and Schedule

1.4 Singular/Plural; Derivatives

1.5 Statutory References

1.6 Business Days

1.7 Calculation of Equity Interests

C-3

ARTICLE 2

GOVERNANCE MATTERS

2.1 Board

(a)

(b)


(c)	The Company shall provide advance notice to the Shareholder of any upcoming shareholders’ meetings in accordance with Part 28 of the Articles.

(d)

2.2 Voting

C-4

Articles, the Shareholder will vote, and will cause its Affiliates to vote, all of the shares of the Company then owned by the Shareholder and its Affiliates:


(a)	in favour of:


(i)	the election of any person or persons nominated for election to the Board by the Board from time to time in accordance with the Articles, and


(b)	against:


(i)	the election of any person nominated by anyone other than the Board.

ARTICLE 3

REPRESENTATIONS

ARTICLE 4

INFORMATION RIGHTS

4.1 Shareholder Requirements

4.2 Confidentiality


(a)	as may be expressly permitted by this Agreement;


(b)	where it is already in the public domain when disclosed to the Shareholder or becomes, after having been disclosed to the Shareholder, generally available to the public through publication

C-5

or otherwise unless the publication or other disclosure was made directly or indirectly by the Shareholder in breach of this Agreement;


(c)	as required in order to comply with applicable laws, the orders or directions of any governmental authority, the requirements of any stock exchange or clearing house, or the requirements of any other regulatory authority having jurisdiction; and


(d)	to Affiliates of the Shareholder, provided such Persons have agreed to maintain such Confidential Information in confidence on terms substantially similar to those in this Section 4.2.

ARTICLE 5

TAX MATTERS

5.1 PFIC Status

5.2 QEF Information

ARTICLE 6

MISCELLANEOUS PROVISIONS

6.1 Waiver Must be in Writing

6.2 No Amendment Except in Writing

This Agreement may be amended only by written instrument executed by the Company and the Shareholder.

6.3 Service of Notice

C-6

will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon delivery, when sent by facsimile (if facsimile numbers are provided in Section 6.4) or electronic mail (provided that confirmation of transmission is generated and kept on file by the sending party); or (iii) one (1) Business Day after deposit with an overnight courier service with next day delivery specified, in each case, properly addressed to the party to receive the same.

6.4 Addresses for Notice

The address for service of notices hereunder of each of the Parties shall be as follows:

To the Company:

Arbutus Biopharma Corporation

100-8900 Glenlyon Parkway

Burnaby, British Columbia

Canada V5J 5J8

Attention:

Facsimile:

Email:

With a copy sent concurrently to:

Farris, Vaughan, Wills & Murphy LLP

700 West Georgia St., 25^th Floor

Vancouver, British Columbia V7Y 1B3

Tel: (604) 661-9307

Attention: R. Hector MacKay-Dunn, Q.C.

E-mail: hmackay-dunn@farris.com

and

Dorsey & Whitney LLP

Pacific Centre

1070, 1095 West Pender Street

Vancouver V6E 2M6 Canada

Tel: (604) 687-5151

Attention: Daniel Miller

Email: miller.dan@dorsey.com

To the Shareholder:

Roivant Sciences Ltd.

Clarendon House

2 Church Street

Hamilton HM11

Bermuda

Attention: Corporate Secretary

Email: info@roivant.com

C-7

and

Roivant Sciences, Inc.

1441 Broadway, 3^rd Floor

New York, NY 10018

Attention: Allen Waxman, General Counsel

Email: allen.waxman@roivant.com

With a copy sent concurrently to:

White & Case LLP

1221 Avenue of the Americas

New York, New York 10020

Attention: Sang I. Ji and Chang-Do Gong

Facsimile: (212) 354-8113

E-mail: sji@whitecase.com; cgong@whitecase.com

and

Lawson Lundell LLP

Suite 1600 - 925 West Georgia St.

Vancouver, BC V6C 3L2

Attention: Valerie Mann and Crispin Arthur

Facsimile: (604) 641-2811

Email: vcmann@lawsonlundell.com

carthur@lawsonlundell.com

A Party may change its address for service by notice to the other Party, and such changed address for service thereafter shall be effective for all purposes of this Agreement.

6.5 Further Assurances

6.6 Governing Law

6.7 Time

Time shall be of the essence in this Agreement.

6.8 Entire Agreement

C-8

written or oral, relating to the subject matter hereof. This Agreement supersedes all prior agreements, understandings, negotiations and discussions, whether oral or written, between the Parties or their predecessors relating to the subject matter of this Agreement.

6.9 Assignment and Enurement

6.10 Counterpart Execution

[The remainder of this page is left blank intentionally]

IN WITNESS WHEREOF the Parties have duly executed this Agreement as of the date first written above.

ARBUTUS BIOPHARMA CORPORATION

Per:/s/ Mark J Murray

Name: Mark J Murray

Title: President and CEO

ROIVANT SCIENCES LTD.

Per:/s/ Marianne L. Romeo

Name: Marianne L. Romeo

Title: Authorized Signatory

[Signature Page to Governance Agreement]

C-9

Schedule 1

C-10

AMENDMENT TO ARTICLES OF INCORPORATION

Part 27 - Transitional Governance Matters

Supermajority Matters

(a) the removal or replacement of the chair of the board of directors of the Company;

(b) the removal or replacement of the chief executive officer of the Company,

(d) subject to Part 28, the appointment of a director to the board of directors of the Company to fill a vacancy created by the resignation or death of a director;

(e) subject to Part 28, the appointment of an additional director to the board of directors of the Company;

(j) incurring any indebtedness or third party guarantees in excess of $5,000,000 individually or $10,000,000 in the aggregate; or

(k) any amendment or proposed amendment to the Articles or Notice of Articles of the Company,

(collectively referred to as “Supermajority Matters”).

C-11

Inconsistencies

2. In the event of an inconsistency between a provision of this Part 27 and any other provision of these Articles, the provision of this Part 27 shall prevail.

Alterations of Part 27 and Section 18.2

3. This Part 27 and Section 18.2 may only be amended by special resolution.

Part 28 - Director Election Matters

Definitions

1. In this Part, the following terms shall have the meanings assigned to them below:

(a) “Company Shares” means the common shares in the capital of the Company as constituted on the date hereof;

(b) “Independence Standards” means the standards set forth in NASDAQ Marketplace Rule 4200(a)(15) or any successor rule thereto, but not including the requirements for audit committee members set forth in NASDAQ Marketplace Rule 4350(d);

Election of Directors

C-12

(where such designee directors are referred to as the "RS Nominated Directors").

Number of Directors

Nomination Procedure

5. For so long as the Nominating Shareholder has a right to nominate one or more directors under Section 1 of this Part 28:

(d) If RS delivers a Nomination Notice in response to a Company Notice within the Nomination Right Notice Period then, subject only to the nominee(s) identified in the Nomination Notice being

C-13

eligible to act as director(s) of the Company, the Company shall (i) nominate the RS nominee(s) to stand for election to the board of directors of the Company at the Shareholder Meeting, and (ii) solicit proxies from the holders of Company Shares in respect thereof which will be satisfied by delivery of a form of proxy to the holders of Company Shares following standard procedures consistent with past practice. For greater certainty, the Company (x) shall not be required to retain a third party solicitation agent, and (y) shall include the name of the RS nominee(s) to stand for election to the board of directors of the Company in the proxy to be delivered to each holder of Company Shares in respect of the Shareholder Meeting. The Nominating Shareholder shall also provide to the Company such other information regarding the RS nominee(s) as may be reasonably requested by the Company so as to comply with applicable proxy disclosure requirements under applicable securities laws, together with such other information, including a biography of the RS Nominated Directors, that is consistent with the information the Company intends to publish about management nominees as directors of the Company in the information circular to be prepared by the Company in connection with the election of directors at a Shareholder Meeting.

Casual Vacancies

Transitional Period

7. This Part 28 shall remain in effect until the date that is the earlier of (i) forty-eight (48) months following the first issuance of Series A Preferred Shares and (ii) the date RS no longer has a right to nominate one or more directors under Section 1 of this Part 28.

Inconsistencies

8. In the event of an inconsistency between a provision of this Part 28 and any other provision of these Articles, the provision of this Part 28 shall prevail.

C-14

EXHIBIT D

AMENDED AND RESTATED LOCK-UP AGREEMENT

This Amended and Restated Lock-Up Agreement (this “Agreement”) is made as of October 16^th, 2017 by and between Arbutus Biopharma Corporation, a British Columbia corporation (the “Company”), and Roivant Sciences Ltd., a Bermuda exempted limited company (the “Shareholder”).

WHEREAS, on October 2, 2017, the Company entered into that certain Subscription Agreement by and between the Shareholder and the Company (the “Subscription Agreement”);

WHEREAS, the parties hereto desire to amend and restate the Original Agreement in its entirety.

NOW, THEREFORE, in consideration of the mutual promises and covenants contained in this Agreement, and for

other good and valuable consideration that the parties hereby acknowledge, the parties hereby amend and restate the Original Agreement in its entirety as follows:

The restrictions contained in this Agreement shall not apply to the following:


(a)	transfers of Common Shares as a bona fide gift or charitable contribution;

transfers by distribution of Preferred Shares, Common Shares or other securities to affiliates, partners, members, stockholders or holders of similar equity interests of the Shareholder;- 2 -


(b)	transfers pursuant to any tender offer, takeover bid, merger, consolidation, acquisition of the Company or its voting securities or other similar transaction relating to the Company or its voting securities that occurs after the date hereof and that is approved by the Board of Directors of the Company;

D-1


(c)	granting of a security interest in (whether by way of pledge or otherwise) Common Shares by the Shareholder in connection with a loan made with a financial institution in good faith on bona fide, arm’s length terms, and any subsequent transfer of such securities to such lender or collateral agent in connection with the exercise of remedies in connection with such loan in the event of default;


(d)	issuances of Common Shares upon conversion of the Series A Preferred Shares; and


(e)	any transfer or issuance of securities of the Shareholder, or any affiliate thereof that indirectly holds the Lock-Up Securities through the Shareholder, in a bona fide transaction; provided, however, that any such transfer or issuance shall not affect any of the Shareholder’s obligations hereunder.

This Agreement shall become effective only upon the Tier 1 Closing Date.

THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE

D-2

PROVINCE OF BRITISH COLUMBIA AND THE LAWS OF CANADA APPLICABLE THEREIN, WITHOUT REGARD TO THE CONFLICT OF LAWS PRINCIPLES THEREOF.

[Signature page follows]

IN WITNESS THEREOF, the parties hereto have executed this Agreement on the date first written above.



COMPANY:

ARBUTUS BIOPHARMA CORPORATION

By:		/s/ Mark J Murray
	Name:	Mark J Murray
	Title:	President and CEO
	Date:	October 16, 2017


SHAREHOLDER:

ROIVANT SCIENCES LTD.

By:		/s/ Marianne L. Romeo
	Name:	Marianne L. Romeo
	Title:	Authorized Signatory
	Date:	October 16, 2017

D-3

EXHIBIT E

AMENDING AGREEMENT

THIS AMENDMENT (this “Amendment”) is executed as of October 16^th, 2017, by and among Arbutus Biopharma Corporation (f/k/a Tekmira Pharmaceuticals Corporation) (the “Company”), a British Columbia corporation, and Roivant Sciences Ltd., a Bermuda exempted limited company (“RSL”).

RECITALS

WHEREAS, the Company, RSL, Patrick T. Higgins, Michael J. McElhaugh, Michael J. Sofia and Bryce A. Roberts (such parties other than the Company being collectively referred to as the “OnCore Holders”) entered into a Registration Rights Agreement, dated January 11, 2015, as amended on November 2, 2015 (the “Registration Rights Agreement”), pursuant to which the Company agreed in certain circumstances to register for resale under the Securities Act of 1933, as amended, certain common shares in the Company held by the OnCore Holders;

WHEREAS, as of the date hereof, RSL holds 16,013,540 shares of Common Stock of the Company, constituting a majority of the outstanding Registrable Securities under the Registration Rights Agreement, and accordingly may, pursuant to Section 2.7 thereof, together with the Company amend the Registration Rights Agreement;

NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein, the parties do hereby agree as follows:

1.Defined Terms. All capitalized terms used and not otherwise defined herein shall have the meaning ascribed thereto in the Registration Rights Agreement.

2.Amendment.

(a)Section 1.1(m) of the Registration Rights Agreement is deleted in its entirety and replaced with the following:

“The term “Registrable Securities” means (A) the shares of Common Stock issued to the OnCore Holders pursuant to the Merger Agreement and any assignee or transferee thereof in accordance with Section 1.12 hereof, (B) any and all shares of Common Stock issuable or issued upon conversion of the Series A Preferred Shares, and (C) any shares of Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right or other security that is issued as) a dividend or other distribution with respect to, or in exchange for, or in replacement of, the shares referenced in clause (A) and (B) above or the Series A Preferred Shares. Notwithstanding the foregoing, Registrable Securities shall not include any securities (x) sold by a person to the public pursuant to a registration statement (on Form S-8 or otherwise) or pursuant to Rule 144, (y) sold in a private transaction in which the transferor’s rights under Section 1 of this Agreement are not assigned or (z) held by a Holder (together with its affiliates and other

E-1

Holders that share a common investment advisor with such Holder) if such Holder (together with its affiliates and other Holders that share a common investment advisor with such Holder) beneficially owns less than 3% of the Company’s outstanding shares of Common Stock, if such securities may then be sold pursuant to Rule 144(b)(1).”

3.Section 1.1 of the Registration Rights Agreement is amended by adding the following subsection (q):

4.Entire Agreement; Ratification. This Amendment constitutes the entire agreement among the parties with respect to the subject matter hereof. Except as expressly amended hereby, the terms of the Registration Rights Agreement are each hereby confirmed and ratified in all respects by the parties hereto and remain in full force and effect.

5.Binding Effect. This Agreement shall be binding upon and inure to the benefit of the parties hereto, and any of their respective subsidiaries, affiliates, insurers, predecessors, successors, officers, directors, managers, employees, stockholders, members, agents, attorneys or assigns.

6.Governing Law. This Amendment shall be governed by and construed under the laws of the State of New York as applied to agreements among New York residents entered into and to be performed entirely within New York without giving effect to principles of conflicts of laws.

7.Counterparts. This Amendment may be signed in counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same agreement.

8.Necessary Action. Each party shall perform any further acts and execute and deliver any documents that may be reasonably necessary to carry out the provisions of this Amendment.

[Signature pages to follow]

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first above written.

ARBUTUS BIOPHARMA CORPORATION

By: /s/ Dr. Mark J. Murray

Name: Mark J Murray

Title: President and CEO


Address: 100-8900 Glenlyon Parkway	Burnaby, BC Canada V5J 5J8

E-2

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first above written.

ROIVANT SCIENCES LTD.

By: /s/ Marianne L. Romeo

Name: Marianne L. Romeo

Title: Authorized Signatory


Address: Clarendon House - 2 Church St.	Hamilton Hill, Bermuda

E-3

Exhibit F

AMENDED AND RESTATED STANDSTILL AGREEMENT

This Amended and Restated Standstill Agreement (this “Agreement”) is made as of October 16^th, 2017 by and between Arbutus Biopharma Corporation, a British Columbia corporation (“Arbutus” or the “Company”), and Roivant Sciences Ltd., a Bermuda exempted limited company, for and on behalf of itself and entities and accounts that it controls directly or indirectly, or with respect to which it exercises voting discretion, whether such entities or accounts now exist or are organized in the future (collectively, the “Shareholder”).

WHEREAS, on January 11, 2015 the Company and the Shareholder entered into that certain Standstill Agreement (the “Original Agreement”);

WHEREAS, on the October 2, 2017, the Company entered into a Subscription Agreement by and among the Shareholder and the Company (the “Subscription Agreement”);

WHEREAS, the parties hereto desire to amend and restate the Original Agreement in its entirety.



1.	Definitions. In this Agreement, the following terms shall have the meaning assigned to them below. Capitalized terms used but not defined herein shall have the meanings ascribed thereto in the Subscription Agreement.

“Common Stock” means the shares of voting common stock of the Company.

“Lock-up Agreement” means the amended and restated Lock-Up Agreement dated as of the date hereof between the Company and the Shareholder.



2.	Original Agreement. The Original Agreement is hereby amended and restated in its entirety by this Agreement.



3.	Standstill. For a period commencing on the date hereof and ending on the earlier of (i) forty-eight (48) months following the Tier 1 Closing and (ii) the date upon which the Shareholder no longer has the right to nominate at least one (1) director to the Company’s board of directors (the “Board”) pursuant to the Governance Agreement and/or Part 28 of the Company’s Articles, the Shareholder shall not, without the prior written consent of the Company, directly or indirectly:

F-1



a.	acquire, offer to acquire, or agree to acquire ownership (including, but not limited to, beneficial ownership as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended (“Exchange Act”)), by purchase or otherwise, any additional shares of Common Stock, or any rights or options to acquire any such securities or any securities convertible into such securities; provided that, in the event that at any time, whether due to an increase in the total outstanding shares of Common Stock , a sale of shares of Common Stock or Preferred Shares by the Shareholder (made in compliance with the provisions of the Lock-Up Agreement) or otherwise, the Shareholder beneficially owns, directly or indirectly, Common Stock representing less than the Shareholder Maximum Ownership Percentage, the Shareholder may acquire additional shares of Common Stock or rights or options to acquire any such securities or any securities convertible into such securities; provided, further, that the Shareholder’s ownership percentage will not exceed the Shareholder Maximum Ownership Percentage;



b.	call or seek to call any meeting of the stockholders of the Company;



c.	submit, or participate with others that submit, any stockholder proposals for the vote or consent (collectively, “vote”) of stockholders (whether pursuant to Rule 14a-8 under the Exchange Act, or otherwise) of the Company or any proposal for consideration by the Board;



d.	solicit “proxies” or make, participate in or encourage any “solicitation” (as such terms are used in the proxy rules of the Securities Exchange Commission) for proxies for any stockholder proposals of the Company or nominations of candidates for election as directors or trustees of the Company;



e.	form or join in a partnership, syndicate or other group, including, without limitations, a “group” as defined under Section 13(d) of the Exchange Act, with respect to the Common Shares, or deposit any Common Shares in a voting trust, arrangement or agreement, except for such actions that may be permitted under the Lock-Up Agreement;



f.	publicly or privately: (i) encourage, recommend, advise, finance or urge others to put forward stockholder proposals of the Company or nominations with respect to directors/trustees of the Company or enter into any arrangements with any other person in connection with any of the foregoing as they relate to the Company; (ii) indicate support or approval for any stockholder proposals or nominations relating to the Company that are not otherwise approved by the Board in accordance with the Articles; (iii) solicit or encourage others to vote against any matter recommended by the Board in accordance with the Articles; or (iv) act alone or in concert with others to seek control of, or otherwise effect a change to, the management or policies of the Company, unless otherwise approved by the Board in accordance with the Articles; or



g.	take or seek to take, or cause or seek to cause or solicit others to take any action inconsistent with any of the foregoing as they relate to the Company.

F-2

The restrictions set forth in this Section 3 shall not apply if any of the following occurs:


a.	in the event that the Company enters into a definitive agreement for a merger, consolidation or other business combination transaction as a result of which the stockholders of the Company would own (including, but not limited to, beneficial ownership) voting securities of the resulting corporation having 50% or less of the total voting power of the outstanding voting securities;


b.	in the event that a bona fide tender offer or exchange offer for at least a majority of the outstanding voting securities of the Company is commenced by a third person (not involving any breach of this Section 3 by the Shareholder); or



4.	Termination. The Shareholder may terminate this Agreement if the Company is in material breach of Articles 2 or 4.2 of the Governance Agreement or Part 27 or Part 28 of the Company’s Articles and such breach remains uncured for at least fifteen (15) days after notice to the Company thereof.



5.	Remedies. The parties agree that any breach or threatened breach of this Agreement may cause immediate and irreparable harm to the Company for which monetary damages will not be adequate and that, in the event of a breach or threatened breach of this Agreement, the Company shall be entitled to seek and obtain immediate injunctive and other equitable relief without proof of actual damages in addition to any other remedies as may be available at law or in equity. The Shareholder further agrees to waive any requirement for the securing or posting of any bond in connection with such remedy. All rights under this Agreement are cumulative, not exclusive, and will be in addition to all rights and remedies available to the Company at law or in equity.



6.	No Assignment. This Agreement shall be binding upon and inure to the benefit of the parties and their respective agents, executors, heirs, successors and permitted assigns. Neither this Agreement nor any of the benefits of this Agreement shall be assigned by a party without prior written consent of the other parties hereto. No person not a party to this Agreement shall have rights, benefits, or obligations hereunder.



7.	Amendments. No amendments, changes, or modifications may be made to this Agreement without the express prior written consent of each of the parties hereto.



8.	Notices. All notices or communications hereunder shall be in writing, addressed as follows:

F-3

To the Company:

Arbutus Biopharma Corporation

100-8900 Glenlyon Parkway

Burnaby, British Columbia

Canada V5J 5J8

Attention: Bruce Cousins, Executive Vice President and Chief Financial Officer

Facsimile: (604) 419-3201

Email: bcousins@arbutusbio.com

With a copy sent concurrently to:

Farris, Vaughan, Wills & Murphy LLP

700 West Georgia St., 25th Floor

Vancouver, British Columbia V7Y 1B3

Tel: (604) 661-9307

Attention: R. Hector MacKay-Dunn, Q.C.

E-mail: hmackay-dunn@farris.com

and

Dorsey & Whitney LLP

Suite 1070, 1095 West Pender Street

Vancouver, British Columbia V6E 2M6

Tel: (604) 687-5151

Attention: Daniel Miller

Email: miller.dan@dorsey.com

To the Shareholder:

Roivant Sciences Ltd.

Clarendon House

2 Church Street

Hamilton HM11

Bermuda

Attention: Corporate Secretary

Facsimile: +1 (441) 292 4720

Email: info@roivant.com

and

Roivant Sciences, Inc.

320 West 37th Street, 5th Floor

New York, New York 10018

Attention: Allen Waxman, General Counsel

Email: allen.waxman@roivant.com

With a copy sent concurrently to:

White & Case LLP

1221 Avenue of the Americas

New York, New York 10020

Attention: Sang I. Ji and Chang-Do Gong

Facsimile: (212) 354-8113

E-mail: sji@whitecase.com;

cgong@whitecase.com

F-4

Lawson Lundell LLP

1600 - 925 West Georgia Street

Vancouver, British Columbia V6C 3L2

Attention: Valerie Mann and Crispin Arthur

Fax: (604) 641-2811

Email: vcmann@lawsonlundell.com

carthur@lawsonlundell.com



9.	Invalidity. If any term or provision of this Agreement is held by a court of competent jurisdiction to be invalid, void or unenforceable, the remainder of the terms and provisions of this Agreement shall remain in full force and effect and shall in no way be affected, impaired or invalidated.



10.	No Waiver. No failure or delay by a party in exercising any right hereunder or any partial exercise thereof shall operate as a waiver thereof or preclude any other or further exercise of any right hereunder. No waiver, express or implied, by any party of any breach of default by any other party in the performance by the other party of its obligations under this Agreement shall be deemed or construed to be a waiver of any other breach or default, whether prior, subsequent, or contemporaneous, under this Agreement. Any waiver must be in writing and executed by the party against whom the waiver is sought to be charged.



11.	Counterparts. This Agreement may be executed in two counterparts, which may be delivered by facsimile or by portable document format (PDF) attachment to email transmission, each of which shall be deemed an original, and when taken together all such counterparts shall be deemed to constitute one and the same document.



12.	Applicable Law This Agreement shall be construed, interpreted and governed in accordance with the laws of the Province of British Columbia and the laws of Canada, without reference to rules relating to conflicts of law.



13.	Entire Agreement. This Agreement contains the entire understanding between the parties and is intended to be the complete and exclusive statement of the terms and conditions of the agreement between the parties and supersedes in all respects any prior agreement or understanding between the Company and the Shareholder.

{REMAINDER INTENTIONALLY LEFT BLANK}

F-5

IN WITNESS THEREOF, the parties hereto have executed this Agreement on the date first written above.



COMPANY:

ARBUTUS BIOPHARMA CORPORATION

By:		/s/ Mark J Murray
	Name:	Mark J Murray
	Title:	President and CEO
	Date:	October 16, 2017


SHAREHOLDER:

ROIVANT SCIENCES LTD.

By:		/s/ Marianne L. Romeo
	Name:	Marianne L. Romeo
	Title:	Authorized Signatory
	Date:	October 16, 2017

[Signature Page to Amended and Restated Standstill Agreement]

F-6

F-7

EXHIBIT G

RECORD RECEIVED FOR DEPOSIT AND DEEMED TO BE IN EFFECT ON OCTOBER 16, 2017

Arbutus Biopharma Corporation

(the "Company")

EXTRACT OF RESOLUTIONS CONSENTED TO IN WRITING BY

ALL THE DIRECTORS OF THE Company

ON October 2, 2017

“BE IT RESOLVED THAT:

.........

Designation of Preferred Shares


8.	Pursuant to Article 26.1 of the Articles, the following series of Preferred Shares be designated with the identifying name and the maximum number of shares of each series set out below:

Identifying Name of Series Number of Preferred Shares of Series

Series A Participating

Convertible Preferred Shares 1,164,000

There be created and attached to the Preferred Shares, Series A (the “Preferred Shares”) the special rights and restrictions in the form attached hereto as Schedule “A” (the “Preferred Share Rights”) and the Articles be altered by adding as Part 26A the wording set out in Schedule “A”, with such additions, omissions or revisions thereto, if any, as any director or officer of the Company (other than an Interested Director) may determine.


9.	The Notice of Articles be altered to reflect the alterations authorized by these resolutions.


10.	Pursuant to section 259 of the BCBCA, the alteration of the authorized share structure of the Company and the alteration of the Articles shall not take effect until these resolutions are received for deposit at the Company’s records office and a Notice of Alteration to Notice of Articles identifying the date of these resolutions has been filed with the Registrar of Companies.


11.	Farris, Vaughan, Wills & Murphy LLP to act as its agent to attend to the electronic filing of the Notice of Alteration to Notice of Articles with the Registrar of Companies.”

[Remainder of page intentionally left blank - signature page follows]

G-1

Certified as of the 16^th day of October, 2017.



		/s/ Bruce G. Cousins
		Bruce G. Cousins, Chief Financial Officer

G-2

SCHEDULE “A”

Series A Participating Convertible Preferred Shares

Special Rights and Restrictions

G-3


26A	SPECIAL RIGHTS AND RESTRICTIONS ATTACHED TO PREFERRED SHARES, SERIES A

The rights, privileges, restrictions and conditions attaching to the Series A Preferred Shares are as set forth below.

Interpretation


26A.1	In this Part 26A, unless the context otherwise requires the following terms have the following meanings:

(a)“Conversion Price” means initially $7.13, as adjusted from time to time as provided in Article 26A.6(f).

(b)“Daily VWAP” means the volume-weighted average price per share of Common Shares (or per minimum denomination or unit size in the case of any security other than Common Shares) as displayed under the heading “Bloomberg VWAP” on the Bloomberg page for the “<equity> AQR” page corresponding to the “ticker” for such Common Share or unit (or its equivalent successor if such page is not available) in respect of the period from the scheduled open of trading until the scheduled close of trading of the primary trading session on such Trading Day (or if such volume-weighted average price is unavailable, the market value of one Common Share (or per minimum denomination or unit size in the case of any security other than Common Shares) on such Trading Day. The “volume weighted average price” shall be determined without regard to after-hours trading or any other trading outside of the regular trading session trading hours.

(c)“Dividend” means, as the context requires, Participating Dividend and Participating Penalty Dividends.

(d)“Exchange” means the NASDAQ Global Select Market, the NASDAQ Global Market, the NASDAQ Capital Market The New York Stock Exchange, the Toronto Stock Exchange or any of their respective successors.

(e)“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

(f)“Ex-Date” means the first date on which the Common Shares trade on the applicable Exchange or in the applicable market, regular way, without the right to receive the issuance, dividend or distribution in question from the Company or, if applicable, from the seller of the Common Shares on such Exchange or market (in the form of due bills or otherwise) as determined by such Exchange or market.

(g)“Fundamental Change” means (i) a Transaction; (ii) any transaction or series of related transactions, after giving effect to which in excess of fifty percent (50%) of the Company’s voting power is owned directly, or indirectly through one or more entities, by any “Person” (as that term is used in Section 13(d)(3) of the Exchange Act); provided, however, that Roivant Sciences Ltd. and anyone else with whom Roivant Sciences Ltd. is acting jointly or concert in connection with the acquisition of the Company’s voting power (within the meaning of British Columbia securities law) shall not constitute a Person for the purpose of this subclause (ii); (iii) any sale, lease or other transfer in one transaction or a series of transactions of all or substantially all of the consolidated assets of the Company and its subsidiaries taken as a whole, to any Person other than one of the Company’s wholly-owned subsidiaries; (iv) shareholders approve any plan or proposal for the liquidation or dissolution of the Company; and (v) the Common Shares (or Reference Property, to the extent applicable) ceases to be listed or quoted on any Exchange.

(h)“Liquidation Event” means (i) approval by shareholders of the voluntary liquidation, dissolution or winding-up of the Company, (ii) the involuntary liquidation, dissolution or winding-up of the Company, (iii) the commencement by the Company of any case under applicable bankruptcy, insolvency or other similar laws now or hereafter in effect, including pursuant to Chapter 11 of the U.S. Bankruptcy Code or the Bankruptcy and Insolvency Act (Canada), (iv) the consent to entry of an order for relief in an involuntary case under applicable bankruptcy, insolvency or other similar laws now or hereafter in effect, and (v) the consent to the appointment of or taking possession by a receiver, liquidator, assignee, custodian, trustee or similar official of the Company, or any general assignment for the benefit of creditors.

G-4

(i)“Mandatory Conversion Date” mean the date that is four years after the Tier 1 Closing Date (as such term is defined in the Subscription Agreement); provided that if the Mandatory Conversion Date is not a business day, the Mandatory Conversion Date shall be postponed to the next following business day.

(j)“Market Disruption Event” means the occurrence or existence for more than one half hour period in the aggregate on any scheduled Trading Day for the Common Shares (or Reference Property, to the extent applicable) of any suspension or limitation imposed on trading (by reason of movements in price exceeding limits permitted by the applicable Exchange or otherwise) in the Common Shares (or Reference Property, to the extent applicable) or in any options, contracts or future contracts relating to the Common Shares (or Reference Property, to the extent applicable), and such suspension or limitation occurs or exists at any time before 4:00 p.m. (New York City time) on such day.

(k)“Person” means any individual, corporation, limited liability company, limited or general partnership, joint venture, association, joint-stock company, trust, unincorporated organization, government, any agency or political subdivisions thereof or other “Person” as contemplated by Section 13(d) of the Exchange Act.

(l)“Purchase Price” means $100.00 per Series A Preferred Share, as the same may be increased pursuant to Article 26A.3.

(m)“Total Current Voting Power” means, with respect to any Person, at the time of determination of Total Current Voting Power, the total number of votes which may be cast in the general election of directors of such Person (or, in the event the Person is not a corporation, the governing members, board or other similar body of such Person).

(n)“Trading Day” means any day on which (i) there is no Market Disruption Event and (ii) NASDAQ or, if the Common Shares (or Reference Property, to the extent applicable) is not listed on NASDAQ, the principal national securities exchange on which the Common Shares (or Reference Property, to the extent applicable) is listed and is open for trading or, if the Common Shares (or Reference Property, to the extent applicable) is not so listed, admitted for trading or quoted, any business day. A Trading Day only includes those days that have a scheduled closing time of 4:00 p.m. (New York City time) or the then standard closing time for regular trading on the relevant Exchange or trading system.

(o)Each of the following terms is defined in the Article set forth opposite such term:

G-5



Term	Article
Common Dividend	26A.3(b)
Company	Recitals
Conversion Date	26A.6(d)
In-Kind Common Dividend	26A.3(c)
Junior Securities	26A.2(b)(i)
Liquidation Preference	26A.6(c)(i)
Optional Conversion Date	26A.6(a)
Parity Securities	26A.2(b)(ii)
Participating Cash Dividend	26A.3(b)
Participating Cash Penalty Dividends	26A.3(b)
Participating Dividends	26A.3(c)
Participating In-Kind Dividend	26A.3(c)
Participating In-Kind Penalty Dividends	26A.3(c)
Participating Penalty Dividends	26A.3(c)
Preferred Shares	Recitals
Reference Property	26A.6(f)(iii)
Senior Securities	26A.2(b)(iii)
Series A Preferred Shares	26A.2(a)
Shareholder Rights Plan	26A.3(c)
Transaction	26A.6(f)(iii)

(p)Unless otherwise provided for herein, all monetary values stated herein are expressed in United States currency and all references to “dollars” or “$” will be deemed references to the lawful currency of the United States.

Number; Designation; Rank

26A.2

(a)This series of convertible participating Preferred Shares is designated as the “Series A Participating Convertible Preferred Shares” (the “Series A Preferred Shares”).

(b)The Series A Preferred Shares rank, with respect to the payment of dividends, redemption payments, rights (including as to the distribution of assets upon liquidation, dissolution or winding-up of the Company) or otherwise:

i.senior in preference and priority to the Common Shares and each other class or series of the shares, except for any class or series of shares hereafter issued in compliance with the terms hereof and the terms of which expressly provide that it will rank senior to or on parity, without preference or priority, with the Series A Preferred Shares with respect to the payment of dividends, redemption payments, rights (including as to the distribution of assets) upon liquidation, dissolution or winding-up of the Company, or otherwise (collectively with the Common Shares, the “Junior Securities”);

ii.on parity, without preference and priority, with each other class or series of shares hereafter issued in compliance with the terms hereof and the terms of which expressly provide that it will rank on parity, without preference or priority, with the Series A Preferred Shares with respect to the payment of dividends, redemption payments, rights (including as to the distribution of assets) upon liquidation, dissolution or winding-up of the Company, or otherwise (collectively, the “Parity Securities”); and

iii.junior in preference and priority to each other class or series of Preferred Shares or any other shares hereafter issued in compliance with the terms hereof and the terms of which expressly provide that it will rank senior in preference or priority to the Series A Preferred Shares with respect to the payment of dividends, redemption payments, rights (including as to the distribution of assets) upon

G-6

liquidation, dissolution or winding-up of the Company or otherwise (collectively, “Senior Securities”).

Dividends

26A.3

(a)Dividends. No dividends shall accrue or be payable to holders of the Series A Preferred Shares except as set forth in Articles 26A.3(b) and (c).

(b)Participating Cash Dividends. If the Company declares, makes or pays any cash dividend or distribution in respect of all or substantially all holders of Common Shares (a “Common Dividend”), each shareholder holding Series A Preferred Shares shall receive a dividend (a “Participating Cash Dividend”) in the same amount in respect of each Preferred Share held thereby, at the same time as holders of Common Shares, as such holders of Series A Preferred Shares would have received if, immediately prior to the record date of such Common Dividend, they had held the number of Common Shares issuable upon the Mandatory Conversion Date. If and to the extent that the Company does not for any reason pay the entire Participating Cash Dividend when the Common Dividend is paid to the holders of Common Shares, during the period in which such Participating Cash Dividend remains unpaid, an additional dividend (the “Participating Cash Penalty Dividends”) shall be payable at an annual rate equal to 8.75% compounded annually on the amount of the unpaid Participating Cash Dividend through the daily addition of such Participating Cash Penalty Dividends to the Purchase Price (whether or not such Participating Cash Penalty Dividends are declared by the board).

(c)Participating In-Kind Dividends. If the Company distributes shares, evidences of its indebtedness or other assets, securities or property, including rights to acquire assets, securities or property, to all or substantially all holders of Common Shares (an “In-Kind Common Dividend”), including without limitation any spin-off of one or more subsidiaries or businesses of the Company but excluding: (I) dividends or distributions referred to in Article 26A.6(f)(i); and (II) cash dividends with respect to which holders of Series A Preferred Shares are entitled to Participating Cash Dividends, then such shareholders shall receive in such distribution or other transaction, at the same time and in the same manner as holders of Common Shares, the same type and amount of consideration (the “Participating In-Kind Dividend” and, together with the Participating Cash Dividend, the “Participating Dividends”) as holders of Series A Preferred Shares would have received if, immediately prior to the record date of such In-Kind Common Dividend, they had held the number of Common Shares issuable upon the Mandatory Conversion Date. To the extent that the Company establishes or adopts a shareholder rights plan or agreement (i.e., a “poison pill”) (each, a “Shareholder Rights Plan”), the Company shall ensure that such shareholders will receive, as a Participating In-Kind Dividend, rights under the Shareholder Rights Plan with respect to any Common Shares that at the time of such distribution would be issuable upon conversion of the Preferred Shares. If and to the extent that the Company does not for any reason pay the entire Participating In-Kind Dividend when the In-Kind Common Dividend is paid to the holders of Common Shares, during the period in which such Participating In-Kind Dividend remains unpaid, an additional dividend (the “Participating In-Kind Penalty Dividends” and, together with Participating Cash Penalty Dividends, the “Participating Penalty Dividends”) shall be payable at an annual rate equal to 8.75% on the amount of the unpaid Participating In-Kind Dividend through the daily addition of such Participating In-Kind Penalty Dividends to the Purchase Price (whether or not such Participating In-Kind Penalty Dividends are declared by the board).

Liquidation Preference

26A.4

(a)Upon any Liquidation Event, each Series A Preferred Share entitles the holders thereof to receive and to be paid out of the assets of the Company legally available for distribution to the Company’s shareholders, before any distribution or payment may be made to a holder of any Junior Securities, an amount in cash per share equal to an amount the holders of such share would have received upon such Liquidation Event had such shareholder converted such Series A Preferred Share into Common Shares (or Reference Property, to the extent applicable) upon the Mandatory Conversion Date.

G-7

(b)If upon any such Liquidation Event, the assets of the Company legally available for distribution to all shareholders of the Company are insufficient to pay the holders of Series A Preferred Shares the full Liquidation Preference and the holders of all Parity Securities the full liquidation preferences to which they are entitled, the shareholders of the Series A Preferred Shares and the holders of such Parity Securities will share ratably in any such distribution of the assets of the Company in proportion to the full respective amounts to which they are entitled.

(c)After payment to the holders of the Series A Preferred Shares of the full Liquidation Preference to which they are entitled, such shareholders, as such, will have no right or claim to any of the assets of the Company.

(d)The value of any property not consisting of cash that is distributed by the Company to the holders of the Series A Preferred Shares will equal the fair market value thereof (as determined in good faith by the board) on the date of distribution.

(e)No holder of Junior Securities shall receive any cash upon a Liquidation Event unless the entire Liquidation Preference in respect of the Series A Preferred Shares has been paid in cash. To the extent that there is insufficient cash available to pay the entire Liquidation Preference in respect of the Series A Preferred Shares and any liquidation preference in respect of Parity Securities in full in cash upon a Liquidation Event, the holders of the Series A Preferred Shares and the holders of such Parity Securities will share ratably in any cash available for distribution in proportion to the full respective amounts to which they are entitled upon such Liquidation Event.

(f)For the avoidance of doubt, a Transaction or Fundamental Change shall not be treated as a Liquidation Event for the purpose of this Article 26A.4 (unless in connection therewith, the liquidation, dissolution or winding up of the Company is specifically approved), but shall be treated as provided for in Article 26A.6(c) hereof.

Voting Rights

26A.5 The Series A Preferred Shares shall not have the right to vote on any matters except as required by law, including under the British Columbia Business Corporations Act. Where such vote is required by law, as of any record date or other determination date, each shareholder holding Series A Preferred Shares shall be entitled to the number of votes such shareholder would have had if all Series A Preferred Shares held by such shareholder on such date would be converted into Common Shares on the Mandatory Conversion Date.

Conversion

26A.6 Each Series A Preferred Share is convertible into Common Shares (or Reference Property, to the extent applicable) as provided in this Article 26A.6.

(a)Conversion at the Option of Holders of Series A Preferred Shares. Subject to Article 26A.6(b) hereof, each holder of Series A Preferred Shares is entitled to convert any or all outstanding Series A Preferred Shares held by such shareholder and receive therefor the property described in Article 26A.6(c) upon such conversion in the event of (A) a transaction that involves a fundamental transfer of value to the Common Shares by means of a distribution, event or other transaction in which the Preferred Shares do not have the right to pursuant to Articles 26A.3(b) or (c), or (B) a Fundamental Change. In order to convert Series A Preferred Shares into Common Shares (or Reference Property, to the extent applicable), the holder of the Series A Preferred Shares must surrender the certificates representing such Series A Preferred Shares at the office of the Company’s transfer agent for the Series A Preferred Shares (or at the registered and records office of the Company, if the Company serves as its own transfer agent), together with (x) written notice that such shareholder elects to convert all or part of the Series A Preferred Shares represented by such certificates as specified therein, (y) a written instrument or instructions of transfer or other documents and endorsements reasonably acceptable to the transfer agent or the Company, as applicable (if reasonably required by the transfer agent or the Company, as applicable), and (z) funds for any stock transfer, documentary, stamp or similar taxes, if payable by the shareholder pursuant to Article 26A.6(e)(i). Except as provided in Article 26A.6(b), the date the transfer agent or the Company, as applicable, receives such certificates, together with such notice and any other documents

G-8

and amounts required to be paid by the holders of Series A Preferred Shares pursuant to this Article 26A.6(a), will be the date of conversion (the “Optional Conversion Date”).

(b)Mandatory Conversion. In the event that any holder of Series A Preferred Shares has not elected to convert the Series A Preferred Shares held by such holder pursuant to Article 26A.6(a) on or before the Mandatory Conversion Date, then such shareholder’s Series A Preferred Shares shall be automatically converted (without any further action by the shareholder and whether or not the certificates representing the Series A Preferred Shares are surrendered), in whole and not in part, into the property described in Article 26A.6(c), effective as of the Mandatory Conversion Date. As promptly as practicable (but in no event more than five (5) business days) following the Mandatory Conversion Date, the Company shall deliver a notice to any shareholder whose Series A Preferred Shares have been converted pursuant to this Article 26A.6(b), informing such shareholder of the number of Common Shares into which such Series A Preferred Shares have been converted, together with certificates evidencing such Common Shares. Notwithstanding the foregoing, any notice delivered by the Company in compliance with this Article 26A.6(b) shall be conclusively presumed to have been duly given, whether or not such holder of Series A Preferred Shares actually receives such notice, and neither the failure of a shareholder to actually receive such notice given as aforesaid nor any immaterial defect in such notice shall affect the validity of the proceedings for the conversion of the Series A Preferred Shares as set forth in this Article 26A.6(b).

(c)Amounts Received Upon Conversion. Upon a conversion of Series A Preferred Shares pursuant to Articles 26A.6(a) or 26A.6 (b), the holder of such converted Series A Preferred Shares shall, subject to the limitations and adjustments pursuant to the first paragraph of Article 26A.6, receive in respect of each Series A Preferred Share:

(i)a number of Common Shares (or Reference Property, to the extent applicable) equal to the amount determined by dividing (A) the Purchase Price for the Series A Preferred Share to be converted plus an amount equal to 8.75% of the Purchase Price per annum compounded annually including, in the case of a conversion pursuant to Article 26A.6(a), as if the Mandatory Conversion Date had occurred irrespective of the timing of such conversion (the “Liquidation Preference”) by (B) the Conversion Price in effect at the time of conversion;

(ii)cash in an amount equal to the amount of any accrued but unpaid Participating Cash Dividends (to the extent not included in the Purchase Price) on the Series A Preferred Shares being converted; provided that, to the extent the Company is prohibited by law or by contract from paying such amount, then the Company shall provide written notice to the applicable holder of such inability to pay, and at the written election of the shareholder (which written election shall be delivered to the Company within five (5) business days of receipt of such written notice from the Company), the Company shall either pay such amount as soon as payment is no longer so prohibited or issue Common Shares (or Reference Property, to the extent applicable) in the manner specified in Article 26A.6(c)(i) as if the amount of such accrued but unpaid Participating Cash Dividends were added to the Purchase Price; and

(iii)any accrued and unpaid Participating In-Kind Dividends.

(d)Fractional Shares. No fractional shares of Common Shares (or fractional shares in respect of Reference Property, to the extent applicable) will be issued upon conversion of the Series A Preferred Shares. In lieu of fractional shares, the Company shall pay cash in respect of each fractional share equal to such fractional amount multiplied by the Daily VWAP of the Common Shares over the thirty (30) consecutive Trading Day period ending on the Trading Day immediately preceding the Optional Conversion Date or the Mandatory Conversion Date, as the case may be (each, a “Conversion Date”). If more than one Series A Preferred Share is being converted at one time by the same holder thereof, then the number of full shares issuable upon conversion will be calculated on the basis of the aggregate number of Series A Preferred Shares converted by such shareholder at such time.

(e)Mechanics of Conversion.

(i)As soon as reasonably practicable after the Conversion Date (and in any event within four (4) Trading Days after either such date), the Company shall issue and deliver to such shareholder one

G-9

or more certificates for the number of Common Shares (or Reference Property, to the extent applicable) to which such holder of Series A Preferred Shares is entitled, together with, at the option of the shareholder, a certified cheque or wire transfer of immediately available funds for payment of fractional shares and any payment required by Article 26A.6(c)(ii) in exchange for the certificates representing the converted Series A Preferred Shares. Such conversion will be deemed to have been made on the Conversion Date, and the Person entitled to receive the Common Shares (or Reference Property, to the extent applicable) issuable upon such conversion shall be treated for all purposes as the record holder of such Common Shares (or Reference Property, to the extent applicable) on such date. The delivery of Common Shares upon conversion of Series A Preferred Shares shall be made, at the option of the applicable shareholder, in certificated form or by book-entry. Any such certificate or certificates shall be delivered by the Company to the appropriate shareholder on a book-entry basis or by mailing certificates evidencing the shares to the holders of the Series A Preferred Shares at their respective addresses as set forth in the conversion notice. In cases where fewer than all the Series A Preferred Shares represented by any such certificate are to be converted, a new certificate shall be issued representing the unconverted Series A Preferred Shares. The Company shall pay any documentary, stamp or similar issue or transfer tax due on the issue of Common Shares (or Reference Property, to the extent applicable) upon conversion or due upon the issuance of a new certificate for any Series A Preferred Shares not converted to the converting shareholder; provided that the Company shall not be required to pay any such amounts, and any such amounts shall be paid by the converting shareholder, in the event that such Common Shares or Series A Preferred Shares are issued in a name other than the name of the converting shareholder.

(ii)For the purpose of effecting the conversion of Series A Preferred Shares, the Company shall: (A) at all times reserve and keep available, free from any pre-emptive rights, out of its treasury or authorized but unissued Common Shares (or Reference Property, to the extent applicable) the full number of Common Shares (or Reference Property, to the extent applicable) deliverable upon the conversion of all outstanding Series A Preferred Shares after taking into account any adjustments to the Conversion Price from time to time pursuant to the terms of this Article 26A.6 and any increases to the Purchase Price from time to time and assuming for the purposes of this calculation that all outstanding Series A Preferred Shares are held by one holder) and (B) without prejudice to any other remedy at law or in equity any holder of Series A Preferred Shares may have as a result of such default, take all actions reasonably required to amend its Notice of Articles or Articles, as expeditiously as reasonably practicable, to increase the authorized and available amount of Common Shares (or Reference Property, to the extent applicable) if at any time such amendment is necessary in order for the Company to be able to satisfy its obligations under this Article 26A.6.

(iii)From and after the Conversion Date, the Series A Preferred Shares converted on such date, will no longer be deemed to be outstanding and all rights of the holder thereof including the right to receive Dividends, but excluding the right to receive from the Company the Common Shares (or Reference Property, to the extent applicable) or any cash payment upon conversion, and except for any rights of shareholders holding Series A Preferred Shares (including any voting rights) pursuant to this Article 26A.6 which by their express terms continue following conversion or, for the avoidance of doubt, rights which by their express terms continue following conversion pursuant to the Subscription Agreement, shall immediately and automatically cease and terminate with respect to such Series A Preferred Shares; provided that, in the event that a Series A Preferred Share is not converted due to a default by the Company or because the Company is otherwise unable to issue the requisite Common Shares (or Reference Property, to the extent applicable), such Series A Preferred Share will, without prejudice to any other remedy at law or in equity any shareholder holding Series A Preferred Shares may have as a result of such default, remain outstanding and will continue be entitled to all of the rights attendant to such Series A Preferred Share as provided herein.

(iv)The Company shall comply with all federal, provincial and state laws, rules and regulations and applicable rules and regulations of the Exchange on which Common Shares (or Reference Property, to the extent applicable) are then listed. If any Common Shares (or Reference Property, to the extent applicable) to be reserved for the purpose of conversion of Series A Preferred Shares require registration with or approval of any Person or group (as such term is defined in Section 13(d)(3) of the Exchange Act) under any federal or state law or the rules and regulations of the Exchange on which Common Shares (or Reference Property, to the extent applicable) are then listed before such

G-10

shares may be validly issued or delivered upon conversion, then the Company will, as expeditiously as reasonably practicable, use commercially reasonable efforts to secure such registration or approval, as the case may be. So long as any Common Shares (or Reference Property, to the extent applicable) into which the Series A Preferred Shares are then convertible is then listed on an Exchange, the Company will list and keep listed on any such Exchange, upon official notice of issuance, all Common Shares (or Reference Property, to the extent applicable) issuable upon conversion.

(v)All Common Shares (or Reference Property, to the extent applicable) issued upon conversion of the Series A Preferred Shares will, upon issuance by the Company, be duly and validly issued, fully paid and non-assessable, not issued in violation of any pre-emptive or similar rights arising under law or contract and free from all taxes, liens and charges with respect to the issuance thereof, and the Company shall take no action which will cause a contrary result.

(f)Adjustments to Conversion Price.

(i)Common Stock Dividends, Splits and Combinations. The Conversion Price shall be adjusted if the Company issues Common Shares as a dividend or distribution on its Common Shares, or if the Company effects a share split or share combination with respect to Common Shares, the Conversion Price based on the following formula:

where,

OS₁ = the number of Common Shares outstanding immediately after such dividend or distribution, or such share split or share combination, as the case may be.

Any adjustment made under this Article 26A.6(f)(i) shall become effective immediately after the open of business on the Ex-Date for such dividend or distribution, or immediately after the open of business on the effective date for such share split or share combination, as the case may be. If any dividend or distribution of the type described in this Article 26A.6(f)(i) is declared but not so paid or made, or any share split or combination of the type described in this Article 26A.6(f)(i) is announced but the outstanding Common Shares are not split or combined, as the case may be, the Conversion Price shall be immediately readjusted, effective as of the date the board determines not to pay such dividend or distribution, or not to split or combine the outstanding Common Shares, as the case may be, to the Conversion Price that would then be in effect if such dividend, distribution, share split or share combination had not been declared or announced.

(ii)Impact of Conversion. Notwithstanding anything in this Article 26A.6(f) to the contrary, if a Conversion Price adjustment becomes effective pursuant to Article 26A.6(f)(i) on any Ex-Date as described above, and a shareholder holding Series A Preferred Shares that converts its Series A Preferred Shares on or after such Ex-Date and on or prior to the related record date would be treated as the record holder of Common Shares as of the related Conversion Date based on an adjusted

G-11

Conversion Price for such Ex-Date and participate on an adjusted basis in the related dividend or other event giving rise to such adjustment, then, notwithstanding the foregoing Conversion Price adjustment provisions, the Conversion Price adjustment relating to such Ex-Date will not be made for such converting shareholder. Instead, such shareholder will be treated as if such shareholder were the record owner of the Common Shares on an un-adjusted basis and participate in the related dividend, distribution or other event giving rise to such adjustment.

(iii)Reference Property. In the case of any recapitalization, reclassification or change of the Common Shares (other than changes resulting from a subdivision or combination described in Article 26A.6(f)(i)), a consolidation, merger or combination involving the Company, a sale, lease or other transfer to a third party of all or substantially all of the assets of the Company (or the Company and its subsidiaries on a consolidated basis), or any statutory share exchange, in each case as a result of which the Common Shares would be converted into, or exchanged for, stock, other securities, other property or assets (including cash or any combination thereof) (any of the foregoing, a “Transaction”), then, at the effective time of the Transaction, the right to convert each Series A Preferred Share will be changed into a right to convert such Series A Preferred Share into the kind and amount of shares of stock, other securities, other property or assets (including cash or any combination thereof) (the “Reference Property”) that a holder of Series A Preferred Shares would have received in respect of the Common Shares issuable upon conversion of such Series A Preferred Shares immediately prior to such Transaction. In the event that holders of Common Shares have the opportunity to elect the form of consideration to be received in the Transaction, the Company shall make adequate provision whereby the holders of Series A Preferred Shares shall have a reasonable opportunity to determine the form of consideration into which Series A Preferred Shares shall be convertible from and after the effective date of the Transaction. Any such determination by the holders of Series A Preferred Shares shall be subject to any limitations to which all holders of Common Shares are subject, such as pro rata reductions applicable to any portion of the consideration payable in the Transaction, and shall be conducted in such a manner as to be completed at approximately the same time as the time elections are made by holders of Common Shares. The provisions of this Article 26A.6(f)(iii) and any equivalent thereof in any such securities similarly shall apply to successive Transactions. The Company shall not become a party to any Transaction unless its terms are in compliance with the foregoing.

(iv)Rules of Calculation; Treasury Shares. All calculations will be made to the nearest one-hundredth of a cent or to the nearest one-ten thousandth of a share. Except as explicitly provided herein, the number of Common Shares (or Reference Property, to the extent applicable) outstanding will be calculated on the basis of the number of issued and outstanding Common Shares (or Reference Property, to the extent applicable), not including shares held in the treasury of the Company. The Company shall not pay any dividend on or make any distribution to Common Shares (or Reference Property, to the extent applicable) held in treasury.

(v)Notice of Record Date. In the event of:

(A)any event described in Article 26A.6(f)(i);

(B)any Transaction to which Article 26A.6(f)(iii) applies; or

(C)the dissolution, liquidation or winding-up of the Company,

(A)the record date for the dividend, other distribution, stock split or combination or, if a record is not to be taken, the date as of which the holders of record of Common Shares to be entitled to such dividend, other distribution, stock split or combination; or

(B)the date on which such reclassification, change, dissolution, liquidation, winding-up or other event constituting a Transaction, is reasonably anticipated to become effective

G-12

or otherwise occur, and the date as of which it is expected that holders of Common Shares of record will be entitled to exchange their Common Shares for Reference Property, other securities or other property deliverable upon such reclassification, change, liquidation, dissolution, winding-up or a Transaction is reasonably anticipated to occur.

(vi)Certificate of Adjustments. Upon the occurrence of each adjustment or readjustment of the Conversion Price pursuant to this Article 26A.6, the Company at its expense shall as promptly as reasonably practicable compute such adjustment or readjustment in accordance with the terms hereof and furnish to each holder of Series A Preferred Shares a certificate, signed by an officer of the Company (in his or her capacity as such and not in an individual capacity), setting forth (A) the calculation of such adjustments and readjustments in reasonable detail, (B) the facts upon which such adjustment or readjustment is based, (C) the Conversion Price then in effect, and (D) the number of Common Shares (or Reference Property, to the extent applicable) and the amount, if any, of the shares, other securities or other property (including but not limited to cash and evidences of indebtedness) which then would be received upon the conversion of a Series A Preferred Share.

(vii)No Impairment. The Company will not, except with any approval required by Article 26A.5 hereof and applicable law, by amendment of the Articles of the Company or through any reorganization, recapitalization, transfer of assets, merger, consolidation, dissolution, issue or sale of shares or other securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder by the Company but will at all times in good faith assist in the carrying out of all the provisions of this Article 26A.6 and in the taking of all such actions as may be necessary or appropriate in order to protect the conversion rights of the holders of the Series A Preferred Shares against impairment; provided, however, that nothing in this Article 26A.6 shall serve to limit or otherwise affect the right of the Company to enter into a Transaction or effect a Fundamental Change.

(g)No Other Conversion Rights. The holders of Series A Preferred Shares shall have no rights of conversion other than as specifically set forth herein.

G-13

PROXY

SPECIAL MEETING OF SHAREHOLDERS (the “Meeting”) OF ARBUTUS BIOPHARMA CORPORATION (the “Company” or “Arbutus”)

TO BE HELD AT Arbutus headquarters at 100-8900 Glenlyon Parkway, Burnaby, British Columbia on Thursday, January 11, 2018 at 2:00 pm (Pacific Time)



The undersigned shareholder of the Company hereby appoints, Dr. Mark J. Murray, President and Chief Executive Officer of the Company, or failing him, Bruce Cousins, Executive Vice President and Chief Financial Officer of the Company, or in the place of the foregoing, _____________________________ as proxyholder for and on behalf of the undersigned shareholder with the power of substitution to attend, act and vote for and on behalf of the undersigned shareholder in respect of all matters that may properly come before the Meeting and at every adjournment thereof, to the same extent and with the same powers as if the undersigned shareholder were present at the said Meeting, or any adjournment thereof. The undersigned shareholder hereby directs the proxyholder to vote the securities of the Company registered in the name of the undersigned shareholder as specified herein. In their discretion, the proxies are authorized to vote upon such business as may properly come before the Meeting or any adjournments or postponements thereof. The undersigned shareholder hereby revokes any Proxy previously given to attend and vote at said Meeting. SIGN HERE: _______________________________________ Please Print Name: _______________________________________ Date: _______________________________________ THIS PROXY IS NOT VALID UNLESS IT IS SIGNED. IF THIS PROXY IS NOT DATED, IT WILL BE DEEMED TO BE DATED SEVEN CALENDAR DAYS AFTER THE DATE ON WHICH IT WAS MAILED TO YOU, THE REGISTERED SHAREHOLDER. SEE IMPORTANT INFORMATION AND INSTRUCTIONS ON REVERSE		Resolutions (For full details of each item, please see the enclosed Notice of Special Meeting and Management Proxy Circular and Proxy Statement). Please indicate your proposal selection by placing an “X” in the appropriate space with blue or black ink only. For Against Abstain 1. To approve the issuance by the Company to _______ ________ ________ Roivant Sciences Ltd. (“Roivant”) of a second tranche of 664,000 series A participating convertible preferred shares of the Company (the “Preferred Shares”) at a price of $100 per share for gross proceeds to the Company of $66.4 million, and common shares, no par value, issuable upon conversion of the Preferred Shares, pursuant to the Subscription Agreement between the Company and Roivant dated October 2, 2017 (the “Subscription Agreement”), as part of a larger subscription by Roivant under the Subscription Agreement for an aggregate of 1,164,000 Preferred Shares for gross proceeds to the Company of $116.4 million. 2. To approve an amendment to Part 27 of Arbutus’ _______ ________ ________ Articles of Incorporation (“Articles”) to extend the period during which certain decisions of the Board require approval of at least 70% of the directors from March 4, 2018 to October 16, 2021. 3. To approve an amendment to Part 28 of Arbutus’ Articles _______ ________ ________ pursuant to which: (i) Roivant would have the right until October 16, 2021, subject to certain conditions, to nominate up to three members of the Board (at least one of whom must be "independent" within the meaning of the Articles, if Roivant has three nominees), and (ii) for so long as Roivant has such nomination rights, the total number of directors of Arbutus would not, without the prior written consent of Roivant, be permitted to exceed seven directors, the majority of whom would be required to be "independent". 4. To transact such other business as may properly come before the Meeting.

G-14

INSTRUCTIONS FOR COMPLETION OF PROXY


1.	This Proxy is solicited by the Board of Directors of the Company.


2.	If you are a registered shareholder and you wish to attend the Meeting to vote on the proposal in person, please register your attendance with the Company’s scrutineers at the Meeting.

If you cannot attend the Meeting but wish to vote on the proposal, you have the right to appoint a person or company other than the designees of management named herein, who need not be a shareholder of the Company, to vote according to your instructions. To appoint someone other than the designees of management named, please insert your appointed proxyholder’s name in the space provided, sign and date and return the Proxy. Where you do not specify a choice on a proposal shown on the Proxy, this Proxy confers discretionary authority upon your appointed proxyholder.

If you cannot attend the Meeting but wish to vote on the proposal and to appoint one of the management appointees named, please leave the wording appointing a nominee as shown, sign and date and return the Proxy. Where you do not specify a choice on a proposal shown on the Proxy, a nominee of management acting as proxyholder will vote the securities as if you had specified a vote for such proposal.

The securities represented by this Proxy will be voted or withheld from voting in accordance with your instructions on any ballot of a proposal that may be called for and, if you specify a choice with respect to any matter to be acted upon, the securities will be voted accordingly. With respect to any amendments or variations in any of the proposal shown on the Proxy, or any other matters which may properly come before the Meeting, the securities will be voted by the appointed nominee as he or she in their sole discretion sees fit.

If you vote on the proposal and return your Proxy, you may still attend the Meeting and vote in person should you later decide to do so. If you are a registered shareholder and you wish to revoke your Proxy, you may do so by depositing a letter to that effect and delivering it to AST Trust Company (Canada) PO Box 721, Agincourt, ON M1S 0A1, or by hand to 1600-1066 West Hastings St., Vancouver, BC V6E 3X1 (hand delivery), or to the address of the registered office of Arbutus at Farris, Vaughan, Wills & Murphy LLP, 25^th Floor, 700 West Georgia Street, Vancouver, British Columbia, V7Y 1B3, attention: R. Hector MacKay-Dunn, Q.C., at any time up to and including the last business day preceding the day of the Meeting, or any adjournment thereof, or to the Chairman of the Meeting on the day of the Meeting before any vote in respect of which the proxy has been taken.

In order to be entitled to vote or to have its shares voted at the Meeting, a shareholder which is a corporation (a “Corporate Shareholder”) must either (a) attach a certified copy of the directors’ resolution authorizing a representative to attend the Meeting on the Corporate Shareholder’s behalf, or (b) attach a certified copy of the directors’ resolution authorizing the completion and delivery of the Proxy.

To be represented at the Meeting, this Proxy must be received at the office of AST Trust Company (Canada): PO Box 721, Agincourt, ON M1S 0A1 (mail) or 1600-1066 West Hastings St., Vancouver, BC V6E 3X1; facsimile: 1-866-781-3111 (toll free in North America) or 1-416-368-2502; scan and email to proxy@canstockta.com; by telephone using a touch-tone phone, 1-888-489-5760 (English) (toll free in North America) or 1-888-489-7352 (Bilingual) (toll free in North America) using your 13-digit control number; by casting your vote online at cstvotemyproxy.com using your 13-digit control number, in each case, no later than forty eight (48) hours (excluding Saturdays, Sundays and holidays) prior to the time of the Meeting, or adjournment thereof. The Chairman of the Meeting may waive the proxy cut-off without notice. The mailing address of AST Trust Company (Canada) is Proxy Department, AST Trust Company (Canada): PO Box 721, Agincourt, ON M1S 0A1, or the address for delivery by hand is 1600-1066 West Hastings St., Vancouver, BC V6E 3X1.

G-15